1289294P1-1.txt

EVENTS EXTRACTED:
<EVENT end="110" id="V1304862" lisp="(ONT::EVENT ONT::V1304862 ONT::TRANSFORM :AFFECTED ONT::V1304872 :FORCE ONT::TRUE :AGENT ONT::V1304792 :TENSE W::PRES :PERF +)" paragraph="paragraph190" rule="-RULE5_1_AFFECTED_AFFECTED1-ROBUSTPRO-AFFECTED-ONLY" start="45" uttnum="217"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="110" id="V1304862" start="45"><type>ONT::TRANSFORM</type><text>relative absence of detrimental side-effects has made it a model</text></predicate><arg1 end="90" id="V1304792" role=":AGENT" start="45"><type>ONT::LACK</type><text normalization="ABSENCE">relative absence of detrimental side-effects</text></arg1><arg2 end="102" id="V1304872" role=":AFFECTED" start="99"><type>ONT::REFERENTIAL-SEM</type><text normalization="IT">it</text></arg2><text>relative absence of detrimental side-effects has made it a model</text></EVENT>
Argument:V1304792
Argument:V1304872

<EVENT end="90" id="V1304822" lisp="(ONT::EVENT ONT::V1304822 ONT::MODULATE)" paragraph="paragraph190" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="62" uttnum="217"><type>ONT::MODULATE</type><predicate end="90" id="V1304822" start="62"><type>ONT::MODULATE</type><text>of detrimental side-effects</text></predicate><text>of detrimental side-effects</text></EVENT>

<EVENT end="217" id="V1305051" lisp="(ONT::EVENT ONT::V1305051 ONT::INHIBIT :AGENT ONT::V1304962 :AFFECTED ONT::V1305086 :FORCE ONT::TRUE)" paragraph="paragraph190" rule="-RULE30_1_AGENT_AFFECTED" start="114" uttnum="217"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="217" id="V1305051" start="114"><type>ONT::INHIBIT</type><text>the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes,</text></predicate><arg1 end="177" id="V1304962" role=":AGENT" start="114"><type>ONT::GROW</type><text normalization="DEVELOPMENT">the development of an array of new therapeutic agents targeted</text></arg1><arg2 end="217" id="V1305086" role=":AFFECTED" start="188"><type>ONT::PROTEIN</type><text normalization="">signal transduction enzymes,</text></arg2><text>the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes,</text></EVENT>
Argument:V1304962
Argument:V1305086

SENTENCES EXTRACTED:
The therapeutic effectiveness of Gleevec and relative absence of detrimental side-effects has made it a model for the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes, especially protein kinases..
1289294P17.txt

EVENTS EXTRACTED:
<EVENT end="39" id="V2328136" lisp="(ONT::EVENT ONT::V2328136 ONT::ACTIVATE :EPI ONT::V2328132 :AFFECTED ONT::V2328185)" paragraph="paragraph221" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE40_2_AGENT_AFFECTED-AFFECTED" start="0" uttnum="248"><type>ONT::ACTIVATE</type><epistemic-modality id="V2328132" /><predicate end="39" id="V2328136" start="0"><type>ONT::ACTIVATE</type><text>We could detect activation of the mTOR</text></predicate><arg2 end="39" id="V2328185" role=":AFFECTED" start="27"><type>ONT::GENE-PROTEIN</type><text normalization="">of the mTOR</text></arg2><text>We could detect activation of the mTOR</text></EVENT>
Argument:V2328185

<EVENT end="97" id="V2328277" lisp="(ONT::EVENT ONT::V2328277 ONT::INCREASE :AFFECTED ONT::V2328318 :FORCE ONT::TRUE)" paragraph="paragraph221" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="66" uttnum="248"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="97" id="V2328277" start="66"><type>ONT::INCREASE</type><text>in proliferating melanoma cells</text></predicate><arg2 end="97" id="V2328318" role=":AFFECTED" start="83"><type>ONT::CELL</type><text normalization="">melanoma cells</text></arg2><text>in proliferating melanoma cells</text></EVENT>
Argument:V2328318

<EVENT end="196" id="V2328536" lisp="(ONT::EVENT ONT::V2328536 ONT::PHOSPHORYLATION :EPI ONT::V2328525 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph221" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE60_4_AGENT_AFFECTED-NONE" start="136" uttnum="248"><type>ONT::PHOSPHORYLATION</type><epistemic-modality id="V2328525" /><predicate end="196" id="V2328536" start="136"><type>ONT::PHOSPHORYLATION</type><text>detecting the phosphorylation of the mTOR substrate, 4EBP1,</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>detecting the phosphorylation of the mTOR substrate, 4EBP1,</text></EVENT>

<EVENT end="311" id="V2328833" lisp="(ONT::EVENT ONT::V2328833 ONT::PHOSPHORYLATION :AFFECTED ONT::V2328861 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph221" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="282" uttnum="248"><type>ONT::PHOSPHORYLATION</type><predicate end="311" id="V2328833" start="282"><type>ONT::PHOSPHORYLATION</type><text>The phosphorylation of 4EBP1</text></predicate><arg2 end="311" id="V2328861" role=":AFFECTED" start="302"><type>ONT::GENE-PROTEIN</type><text normalization="">of 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The phosphorylation of 4EBP1</text></EVENT>
Argument:V2328861

<EVENT end="375" id="V2328943" lisp="(ONT::EVENT ONT::V2328943 ONT::TRANSFORM :EPI ONT::V2328906 :AGENT ONT::V2328833 :FORCE ONT::TRUE)" paragraph="paragraph221" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE5_1_AGENT_AFFECTED-AGENT" start="282" uttnum="248"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><epistemic-modality id="V2328906" /><predicate end="375" id="V2328943" start="282"><type>ONT::TRANSFORM</type><text>The phosphorylation of 4EBP1 has previously been demonstrated to retard migration in SDS-PAGE</text></predicate><arg1 end="311" id="V2328833" role=":AGENT" start="282"><type>ONT::PHOSPHORYLATION</type><text normalization="">The phosphorylation of 4EBP1</text></arg1><text>The phosphorylation of 4EBP1 has previously been demonstrated to retard migration in SDS-PAGE</text></EVENT>
Argument:V2328833

<EVENT end="536" id="V2355505" lisp="(ONT::EVENT ONT::V2355505 ONT::PHOSPHORYLATION :FORCE ONT::TRUE :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph221" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="521" uttnum="248"><type>ONT::PHOSPHORYLATION</type><force>ONT::TRUE</force><predicate end="536" id="V2355505" start="521"><type>ONT::PHOSPHORYLATION</type><text>phosphorylated</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylated</text></EVENT>

SENTENCES EXTRACTED:
We could detect activation of the mTOR and ERK signaling pathways in proliferating melanoma cells.Shown in Figure 1 B is a Western blot detecting the phosphorylation of the mTOR substrate, 4EBP1, from 3 different melanoma cell lines grown in the presence of either 5% or 0.5% serum.The phosphorylation of 4EBP1 has previously been demonstrated to retard migration in SDS-PAGE  [25], seen as the upper band in the doublet in the even numbered lanes (Figure 1B) .Shown in Figure 1 C is a Western blot detecting both the dual phosphorylated (activated) form of ERK, as well as total ERK protein in three different melanoma cell lines grown in 5% or 0.5% serum.
1289294P31-2.txt

EVENTS EXTRACTED:
<EVENT end="111" id="V3460600" lisp="(ONT::EVENT ONT::V3460600 ONT::INHIBIT :AGENT ONT::V3460637 :AFFECTED ONT::V3460545 :MODALITY (ONT::CONDITIONAL W::COULD) :FORCE ONT::POSSIBLE :TENSE W::PRES :PASSIVE +)" paragraph="paragraph253" rule="-RULE30_1_AGENT_AFFECTED" start="38" uttnum="280"><type>ONT::INHIBIT</type><force>ONT::POSSIBLE</force><modality>W::COULD</modality><predicate end="111" id="V3460600" start="38"><type>ONT::INHIBIT</type><text>insulin-activated phosphorylation of 4EBP1 could be inhibited by PD098059</text></predicate><arg1 end="111" id="V3460637" role=":AGENT" start="100"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">by PD098059</text></arg1><arg2 end="81" id="V3460545" role=":AFFECTED" start="38"><type>ONT::PHOSPHORYLATION</type><text normalization="">insulin-activated phosphorylation of 4EBP1</text></arg2><text>insulin-activated phosphorylation of 4EBP1 could be inhibited by PD098059</text></EVENT>
Argument:V3460637
Argument:V3460545
NESTED EVENT!!!

<EVENT end="81" id="V3460545" lisp="(ONT::EVENT ONT::V3460545 ONT::PHOSPHORYLATION :INEVENT ONT::V3460532 :AFFECTED ONT::V3460573 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph253" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="38" uttnum="280"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V3460532" /></features><predicate end="81" id="V3460545" start="38"><type>ONT::PHOSPHORYLATION</type><text>insulin-activated phosphorylation of 4EBP1</text></predicate><arg2 end="81" id="V3460573" role=":AFFECTED" start="72"><type>ONT::GENE-PROTEIN</type><text normalization="">of 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>insulin-activated phosphorylation of 4EBP1</text></EVENT>
Argument:V3460573

<EVENT end="255" id="V3467469" lisp="(ONT::EVENT ONT::V3467469 ONT::INCREASE :EPI ONT::V3467451)" paragraph="paragraph253" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE20_1_AGENT_AFFECTED-NONE" start="207" uttnum="280"><type>ONT::INCREASE</type><epistemic-modality id="V3467451" /><predicate end="255" id="V3467469" start="207"><type>ONT::INCREASE</type><text>HEK 293 cells show increase in protein synthesis</text></predicate><text>HEK 293 cells show increase in protein synthesis</text></EVENT>

<EVENT end="306" id="V3472681" lisp="(ONT::EVENT ONT::V3472681 ONT::INHIBIT :AFFECTED ONT::V3472695)" paragraph="paragraph253" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="261" uttnum="280"><type>ONT::INHIBIT</type><predicate end="306" id="V3472681" start="261"><type>ONT::INHIBIT</type><text>simultaneous inhibition of both mTOR and ERK</text></predicate><arg2 end="306" id="V3472695" role=":AFFECTED" start="285"><type>ONT::GENE-PROTEIN</type><text normalization="">of both mTOR and ERK</text></arg2><text>simultaneous inhibition of both mTOR and ERK</text></EVENT>
Argument:V3472695

<EVENT end="354" id="V3472796" lisp="(ONT::EVENT ONT::V3472796 ONT::INHIBIT :AFFECTED ONT::V3472819 :FORCE ONT::TRUE)" paragraph="paragraph253" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="322" uttnum="280"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="354" id="V3472796" start="322"><type>ONT::INHIBIT</type><text>prevent de novo translation [39]</text></predicate><arg2 end="354" id="V3472819" role=":AFFECTED" start="330"><type>ONT::CHANGE-FORMAT</type><text normalization="TRANSLATION">de novo translation [39]</text></arg2><text>prevent de novo translation [39]</text></EVENT>
Argument:V3472819

SENTENCES EXTRACTED:
In proximal tubular epithelial cells, insulin-activated phosphorylation of 4EBP1 could be inhibited by PD098059, suggesting a requirement for MAPK [38] .Another report shows that following hypertonic stress, HEK 293 cells show increase in protein synthesis, and simultaneous inhibition of both mTOR and ERK was required to prevent de novo translation [39]..
1289294P14-1.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
Points above this line indicate antagonism, and points below the line indicate synergism..
1289294P27-1.txt

EVENTS EXTRACTED:
<EVENT end="31" id="V3151999" lisp="(ONT::EVENT ONT::V3151999 ONT::INCREASE :AFFECTED ONT::V3152088)" paragraph="paragraph244" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="271"><type>ONT::INCREASE</type><predicate end="31" id="V3151999" start="0"><type>ONT::INCREASE</type><text>Increase in cell growth (size)</text></predicate><arg2 end="31" id="V3152088" role=":AFFECTED" start="9"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">in cell growth (size)</text></arg2><text>Increase in cell growth (size)</text></EVENT>
Argument:V3152088

<EVENT end="144" id="V3152412" lisp="(ONT::EVENT ONT::V3152412 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph244" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="121" uttnum="271"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="144" id="V3152412" start="121"><type>ONT::MODULATE</type><text>to operate in parallel,</text></predicate><text>to operate in parallel,</text></EVENT>

<EVENT end="203" id="V3165612" lisp="(ONT::EVENT ONT::V3165612 ONT::INHIBIT :AFFECTED ONT::V3165631)" paragraph="paragraph244" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="166" uttnum="271"><type>ONT::INHIBIT</type><predicate end="203" id="V3165612" start="166"><type>ONT::INHIBIT</type><text>combined inhibition of these kinases</text></predicate><arg2 end="203" id="V3165631" role=":AFFECTED" start="186"><type>ONT::GENE-PROTEIN</type><text normalization="">of these kinases</text></arg2><text>combined inhibition of these kinases</text></EVENT>
Argument:V3165631

SENTENCES EXTRACTED:
Increase in cell growth (size) is a pre-requisite for cell proliferation.Because the B-Raf and mTOR pathways are thought to operate in parallel, we hypothesized that combined inhibition of these kinases would be effective in blocking cell growth and cell proliferation.Though our results with multiple melanoma cell lines support that hypothesis, they also gave some unexpected results..
1289294P34.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
The author(s) declare that they have no competing interests..
1289294P6.txt

EVENTS EXTRACTED:
<EVENT end="52" id="V1711470" lisp="(ONT::EVENT ONT::V1711470 ONT::STIMULATE :AFFECTED ONT::V1711431 :FORCE ONT::TRUE :TENSE W::PRES :PASSIVE +)" paragraph="paragraph201" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="228"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="52" id="V1711470" start="0"><type>ONT::STIMULATE</type><text>Melanoma cell proliferation is stimulated by serum..</text></predicate><arg2 end="28" id="V1711431" role=":AFFECTED" start="0"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">Melanoma cell proliferation</text></arg2><text>Melanoma cell proliferation is stimulated by serum..</text></EVENT>
Argument:V1711431

SENTENCES EXTRACTED:
Melanoma cell proliferation is stimulated by serum..
1289294P26-1.txt

EVENTS EXTRACTED:
<EVENT end="32" id="V3083936" lisp="(ONT::EVENT ONT::V3083936 ONT::INHIBIT :AGENT ONT::V3084008 :AFFECTED ONT::V3083978)" paragraph="paragraph242" rule="-RULE30_1_AGENT_AFFECTED" start="0" uttnum="269"><type>ONT::INHIBIT</type><predicate end="32" id="V3083936" start="0"><type>ONT::INHIBIT</type><text>Inhibition of mTOR by rapamycin</text></predicate><arg1 end="32" id="V3084008" role=":AGENT" start="19"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">by rapamycin</text></arg1><arg2 end="19" id="V3083978" role=":AFFECTED" start="11"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR</text></arg2><text>Inhibition of mTOR by rapamycin</text></EVENT>
Argument:V3084008
Argument:V3083978

<EVENT end="113" id="V3084056" lisp="(ONT::EVENT ONT::V3084056 ONT::MODULATE :AFFECTED ONT::V3084087)" paragraph="paragraph242" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="41" uttnum="269"><type>ONT::MODULATE</type><predicate end="113" id="V3084056" start="41"><type>ONT::MODULATE</type><text>standard treatment for immunosuppression following organ transplant [15]</text></predicate><arg2 end="113" id="V3084087" role=":AFFECTED" start="60"><type>ONT::MEDICAL-DISORDERS-AND-CONDITIONS</type><text normalization="">for immunosuppression following organ transplant [15]</text></arg2><text>standard treatment for immunosuppression following organ transplant [15]</text></EVENT>
Argument:V3084087

<EVENT end="113" id="V3084093" lisp="(ONT::EVENT ONT::V3084093 ONT::TRANSLOCATE :AGENT ONT::V3084087 :FORCE ONT::TRUE :NEUTRAL ONT::V3084112)" paragraph="paragraph242" rule="-RULE10_4_AGENT_AFFECTED-AGENT" start="60" uttnum="269"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="113" id="V3084093" start="60"><type>ONT::TRANSLOCATE</type><text>for immunosuppression following organ transplant [15]</text></predicate><arg1 end="113" id="V3084087" role=":AGENT" start="60"><type>ONT::MEDICAL-DISORDERS-AND-CONDITIONS</type><text normalization="">for immunosuppression following organ transplant [15]</text></arg1><arg2 end="113" id="V3084112" role=":NEUTRAL" start="92"><type>ONT::MEDICAL-PROCEDURE</type><text normalization="">organ transplant [15]</text></arg2><text>for immunosuppression following organ transplant [15]</text></EVENT>
Argument:V3084087
Argument:V3084112

SENTENCES EXTRACTED:
Inhibition of mTOR by rapamycin has been standard treatment for immunosuppression following organ transplant [15], and the rapamycin derivative CCI-779 is now being clinically tested as a cancer chemotherapy [18-20].Thus, B-Raf and mTOR are acknowledged targets for anti-proliferative therapy [29]..
1289294P33.txt

EVENTS EXTRACTED:
<EVENT end="169" id="V3533485" lisp="(ONT::EVENT ONT::V3533485 ONT::MODULATE :AFFECTED ONT::V3533488 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph255" rule="-RULE10_1_AGENT_AFFECTED-ROBUSTPRO-AFFECTED-ONLY" start="71" uttnum="282"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="169" id="V3533485" start="71"><type>ONT::MODULATE</type><text>which renders them sensitive to drugs that inhibit these protein targets.Under these circumstances</text></predicate><arg2 end="90" id="V3533488" role=":AFFECTED" start="85"><type>ONT::REFERENTIAL-SEM</type><text normalization="THEM">them</text></arg2><text>which renders them sensitive to drugs that inhibit these protein targets.Under these circumstances</text></EVENT>
Argument:V3533488

<EVENT end="169" id="V3533537" lisp="(ONT::EVENT ONT::V3533537 ONT::INHIBIT :AGENT ONT::V3533518 :FORCE ONT::TRUE :AFFECTED ONT::V3533589 :TENSE W::PRES)" paragraph="paragraph255" rule="-RULE30_1_AGENT_FORMAL-AGENT" start="103" uttnum="282"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="169" id="V3533537" start="103"><type>ONT::INHIBIT</type><text>drugs that inhibit these protein targets.Under these circumstances</text></predicate><arg1 end="169" id="V3533518" role=":AGENT" start="103"><type>ONT::MEDICATION</type><text normalization="">drugs that inhibit these protein targets.Under these circumstances</text></arg1><arg2 end="169" id="V3533589" role=":AFFECTED" start="150"><type>ONT::SITUATION</type><text normalization="CIRCUMSTANCE">these circumstances</text></arg2><text>drugs that inhibit these protein targets.Under these circumstances</text></EVENT>
Argument:V3533518
Argument:V3533589

<EVENT end="253" id="V3535370" lisp="(ONT::EVENT ONT::V3535370 ONT::INHIBIT :AFFECTED ONT::V3535406)" paragraph="paragraph255" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="220" uttnum="282"><type>ONT::INHIBIT</type><predicate end="253" id="V3535370" start="220"><type>ONT::INHIBIT</type><text>as Gleevec inhibition of BCR-ABL</text></predicate><arg2 end="253" id="V3535406" role=":AFFECTED" start="242"><type>ONT::GENE</type><text normalization="">of BCR-ABL</text></arg2><text>as Gleevec inhibition of BCR-ABL</text></EVENT>
Argument:V3535406

<EVENT end="328" id="V3549166" lisp="(ONT::EVENT ONT::V3549166 ONT::TRANSLOCATE :AGENT ONT::V3549161 :FORCE ONT::TRUE)" paragraph="paragraph255" rule="-RULE10_4_AGENT_AFFECTED-AGENT" start="307" uttnum="282"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="328" id="V3549166" start="307"><type>ONT::TRANSLOCATE</type><text>single drug targeted</text></predicate><arg1 end="328" id="V3549161" role=":AGENT" start="307"><type>ONT::MEDICATION</type><text normalization="">single drug targeted</text></arg1><text>single drug targeted</text></EVENT>
Argument:V3549161

<EVENT end="569" id="V3561128" lisp="(ONT::EVENT ONT::V3561128 ONT::INHIBIT :AFFECTED ONT::V3561136 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph255" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="536" uttnum="282"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="569" id="V3561128" start="536"><type>ONT::INHIBIT</type><text>that inhibits different pathways</text></predicate><arg2 end="569" id="V3561136" role=":AFFECTED" start="550"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">different pathways</text></arg2><text>that inhibits different pathways</text></EVENT>
Argument:V3561136

SENTENCES EXTRACTED:
Cancer cells may be dependent on particular oncogenes for cell growth, which renders them sensitive to drugs that inhibit these protein targets.Under these circumstances, single chemical inhibitors are efficacious, such as Gleevec inhibition of BCR-ABL in CML [2] .However, in a number of different cancers, single drug targeted therapy is only effective in about half of the patients [41] .These cancer cells utilize either alternate pathways or compensatory mechanisms to evade inhibition.Under these circumstances, combination therapy that inhibits different pathways may be especially effective.
1289294P24.txt

EVENTS EXTRACTED:
<EVENT end="90" id="V2899213" lisp="(ONT::EVENT ONT::V2899213 ONT::MODULATE :AFFECTED ONT::V2899148 :FORCE ONT::TRUE)" paragraph="paragraph237" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="9" uttnum="264"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="90" id="V2899213" start="9"><type>ONT::MODULATE</type><text>that total 4EBP1 in cells treated with a combination of rapamycin plus BAY43-9006</text></predicate><arg2 end="90" id="V2899148" role=":AFFECTED" start="0"><type>ONT::GENE-PROTEIN</type><text normalization="">We noted that total 4EBP1 in cells treated with a combination of rapamycin plus BAY43-9006</text></arg2><text>that total 4EBP1 in cells treated with a combination of rapamycin plus BAY43-9006</text></EVENT>
Argument:V2899148

<EVENT end="184" id="V2906700" lisp="(ONT::EVENT ONT::V2906700 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph237" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="154" uttnum="264"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="184" id="V2906700" start="154"><type>ONT::MODULATE</type><text>treated with either rapamycin</text></predicate><text>treated with either rapamycin</text></EVENT>

<EVENT end="269" id="V2906857" lisp="(ONT::EVENT ONT::V2906857 ONT::BIND :EPI ONT::V2906923 :AFFECTED ONT::V2906871)" paragraph="paragraph237" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE40_4_AGENT_AFFECTED-AFFECTED" start="204" uttnum="264"><type>ONT::BIND</type><epistemic-modality id="V2906923" /><predicate end="269" id="V2906857" start="204"><type>ONT::BIND</type><text>Equal recovery of other proteins from the cells was demonstrated</text></predicate><arg2 end="252" id="V2906871" role=":AFFECTED" start="219"><type>ONT::PROTEIN</type><text normalization="">of other proteins from the cells</text></arg2><text>Equal recovery of other proteins from the cells was demonstrated</text></EVENT>
Argument:V2906871

<EVENT end="336" id="V2919467" lisp="(ONT::EVENT ONT::V2919467 ONT::BIND)" paragraph="paragraph237" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="326" uttnum="264"><type>ONT::BIND</type><predicate end="336" id="V2919467" start="326"><type>ONT::BIND</type><text>a loading</text></predicate><text>a loading</text></EVENT>

<EVENT end="408" id="V2919591" lisp="(ONT::EVENT ONT::V2919591 ONT::BIND :INEVENT ONT::V2919586 :AFFECTED ONT::V2919619)" paragraph="paragraph237" rule="-INEVENT2B,-RULE40_4_AGENT_AFFECTED-AFFECTED" start="379" uttnum="264"><type>ONT::BIND</type><features><inevent id="V2919586" /></features><predicate end="408" id="V2919591" start="379"><type>ONT::BIND</type><text>the reduced recovery of 4EBP1</text></predicate><arg2 end="408" id="V2919619" role=":AFFECTED" start="400"><type>ONT::GENE-PROTEIN</type><text normalization="">of 4EBP1</text></arg2><text>the reduced recovery of 4EBP1</text></EVENT>
Argument:V2919619

<EVENT end="408" id="V2919586" lisp="(ONT::EVENT ONT::V2919586 ONT::DECREASE :AFFECTED ONT::V2919591 :FORCE ONT::TRUE)" paragraph="paragraph237" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="379" uttnum="264"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="408" id="V2919586" start="379"><type>ONT::DECREASE</type><text>the reduced recovery of 4EBP1</text></predicate><arg2 end="408" id="V2919591" role=":AFFECTED" start="379"><type>ONT::BIND</type><text normalization="">the reduced recovery of 4EBP1</text></arg2><text>the reduced recovery of 4EBP1</text></EVENT>
Argument:V2919591
NESTED EVENT!!!

<EVENT end="476" id="V2933160" lisp="(ONT::EVENT ONT::V2933160 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph237" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="447" uttnum="264"><type>ONT::PHOSPHORYLATION</type><predicate end="476" id="V2933160" start="447"><type>ONT::PHOSPHORYLATION</type><text>on the phosphorylation state</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>on the phosphorylation state</text></EVENT>

<EVENT end="500" id="V2933185" lisp="(ONT::EVENT ONT::V2933185 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph237" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="484" uttnum="264"><type>ONT::PHOSPHORYLATION</type><predicate end="500" id="V2933185" start="484"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation</text></EVENT>

<EVENT end="593" id="V2933207" lisp="(ONT::EVENT ONT::V2933207 ONT::INHIBIT :FORCE ONT::TRUE)" paragraph="paragraph237" rule="-RULE30_1_AGENT_FORMAL-NONE" start="504" uttnum="264"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="593" id="V2933207" start="504"><type>ONT::INHIBIT</type><text>blocked with the single drug treatments, without change in the level of the 4EBP1 protein</text></predicate><text>blocked with the single drug treatments, without change in the level of the 4EBP1 protein</text></EVENT>

<EVENT end="545" id="V2933238" lisp="(ONT::EVENT ONT::V2933238 ONT::MODULATE :AFFECTED ONT::V2933235)" paragraph="paragraph237" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="517" uttnum="264"><type>ONT::MODULATE</type><predicate end="545" id="V2933238" start="517"><type>ONT::MODULATE</type><text>the single drug treatments,</text></predicate><arg2 end="533" id="V2933235" role=":AFFECTED" start="517"><type>ONT::MEDICATION</type><text normalization="">the single drug</text></arg2><text>the single drug treatments,</text></EVENT>
Argument:V2933235

SENTENCES EXTRACTED:
We noted that total 4EBP1 in cells treated with a combination of rapamycin plus BAY43-9006, or with U0126, was lower relative to untreated cells or cells treated with either rapamycin or BAY43-9006 alone.Equal recovery of other proteins from the cells was demonstrated by immunoblotting both for p70S6K and for GAPDH, used as a loading control.We do not understand the basis for the reduced recovery of 4EBP1, but it did not seem to depend simply on the phosphorylation state because phosphorylation was blocked with the single drug treatments, without change in the level of the 4EBP1 protein..
1289294P21-2.txt

EVENTS EXTRACTED:
<EVENT end="90" id="V2689728" lisp="(ONT::EVENT ONT::V2689728 ONT::MODULATE :AFFECTED ONT::V2689738 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph231" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="9" uttnum="258"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="90" id="V2689728" start="9"><type>ONT::MODULATE</type><text>all melanoma cell lines tested displayed synergistic inhibition of proliferation,</text></predicate><arg2 end="90" id="V2689738" role=":AFFECTED" start="50"><type>ONT::INHIBIT</type><text normalization="">synergistic inhibition of proliferation,</text></arg2><text>all melanoma cell lines tested displayed synergistic inhibition of proliferation,</text></EVENT>
Argument:V2689738
NESTED EVENT!!!

<EVENT end="90" id="V2689738" lisp="(ONT::EVENT ONT::V2689738 ONT::INHIBIT :AFFECTED ONT::V2689752)" paragraph="paragraph231" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="50" uttnum="258"><type>ONT::INHIBIT</type><predicate end="90" id="V2689738" start="50"><type>ONT::INHIBIT</type><text>synergistic inhibition of proliferation,</text></predicate><arg2 end="89" id="V2689752" role=":AFFECTED" start="73"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">of proliferation</text></arg2><text>synergistic inhibition of proliferation,</text></EVENT>
Argument:V2689752

SENTENCES EXTRACTED:
However, all melanoma cell lines tested displayed synergistic inhibition of proliferation, indicating that these drugs were more effective in combination than alone..
1289294P16-1.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
These human melanoma cell lines proliferated even in limiting serum (0.5%).However, all showed higher rates of proliferation ~ 2-fold in the presence of 5% serum..
1289294P32.txt

EVENTS EXTRACTED:
<EVENT end="288" id="V3503376" lisp="(ONT::EVENT ONT::V3503376 ONT::INHIBIT :AFFECTED ONT::V3503397 :FORCE ONT::TRUE)" paragraph="paragraph254" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="207" uttnum="281"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="288" id="V3503376" start="207"><type>ONT::INHIBIT</type><text>of combining inhibitors of these two pathways on proliferation of melanoma cells</text></predicate><arg2 end="288" id="V3503397" role=":AFFECTED" start="231"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">of these two pathways on proliferation of melanoma cells</text></arg2><text>of combining inhibitors of these two pathways on proliferation of melanoma cells</text></EVENT>
Argument:V3503397

<EVENT end="412" id="V3514251" lisp="(ONT::EVENT ONT::V3514251 ONT::INCREASE)" paragraph="paragraph254" rule="-RULE20_1_AGENT_AFFECTED-NONE" start="345" uttnum="281"><type>ONT::INCREASE</type><predicate end="412" id="V3514251" start="345"><type>ONT::INCREASE</type><text>development for such combination therapies in human clinical trials</text></predicate><text>development for such combination therapies in human clinical trials</text></EVENT>

<EVENT end="473" id="V3520085" lisp="(ONT::EVENT ONT::V3520085 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph254" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="414" uttnum="281"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="473" id="V3520085" start="414"><type>ONT::MODULATE</type><text>sponsored by the Clinical Trials Evaluation Program (CTEP)</text></predicate><text>sponsored by the Clinical Trials Evaluation Program (CTEP)</text></EVENT>

<EVENT end="607" id="V3520399" lisp="(ONT::EVENT ONT::V3520399 ONT::INHIBIT :AFFECTED ONT::V3520415)" paragraph="paragraph254" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="515" uttnum="281"><type>ONT::INHIBIT</type><predicate end="607" id="V3520399" start="515"><type>ONT::INHIBIT</type><text>that the combination of inhibitors synergistic for inhibition of melanoma cell proliferation</text></predicate><arg2 end="589" id="V3520415" role=":AFFECTED" start="577"><type>ONT::CANCER</type><text normalization="">of melanoma</text></arg2><text>that the combination of inhibitors synergistic for inhibition of melanoma cell proliferation</text></EVENT>
Argument:V3520415

<EVENT end="550" id="V3520362" lisp="(ONT::EVENT ONT::V3520362 ONT::INHIBIT)" paragraph="paragraph254" rule="-RULE30_1_AGENT_FORMAL-NONE" start="536" uttnum="281"><type>ONT::INHIBIT</type><predicate end="550" id="V3520362" start="536"><type>ONT::INHIBIT</type><text>of inhibitors</text></predicate><text>of inhibitors</text></EVENT>

SENTENCES EXTRACTED:
Since there appears to be cross-talk between mTOR and Raf-MEK-ERK pathways, it might be expected that combination therapy with rapamycin and BAY43-9006 might simply be additive.To our knowledge, the effects of combining inhibitors of these two pathways on proliferation of melanoma cells had not previously been examined.However, studies are in development for such combination therapies in human clinical trials, sponsored by the Clinical Trials Evaluation Program (CTEP) of the NIH.In the present study, we found that the combination of inhibitors synergistic for inhibition of melanoma cell proliferation..
1289294P9-2.txt

EVENTS EXTRACTED:
<EVENT end="53" id="V1864784" lisp="(ONT::EVENT ONT::V1864784 ONT::INCREASE :FORCE ONT::TRUE)" paragraph="paragraph207" rule="-RULE20_1_AGENT_AFFECTED-NONE" start="35" uttnum="234"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="53" id="V1864784" start="35"><type>ONT::INCREASE</type><text>grown in media as</text></predicate><text>grown in media as</text></EVENT>

<EVENT end="134" id="V1865057" lisp="(ONT::EVENT ONT::V1865057 ONT::INCREASE :FORCE ONT::TRUE)" paragraph="paragraph207" rule="-RULE20_1_AGENT_AFFECTED-NONE" start="120" uttnum="234"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="134" id="V1865057" start="120"><type>ONT::INCREASE</type><text>grown in 5.0%</text></predicate><text>grown in 5.0%</text></EVENT>

<EVENT end="236" id="V1865193" lisp="(ONT::EVENT ONT::V1865193 ONT::PHOSPHORYLATION :EPI ONT::V1865228 :AFFECTED ONT::V1865206 :MODA (ONT::N-TUPLE-VAL W::DUAL) :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph207" rule="-RULE50_0_AGENT_NEUTRAL-EVENT,-RULE60_4_AGENT_AFFECTED-MODA1_1-AFFECTED" start="151" uttnum="234"><type>ONT::PHOSPHORYLATION</type><epistemic-modality id="V1865228" /><mods><mod><type>ONT::N-TUPLE-VAL</type><value>DUAL</value></mod></mods><predicate end="236" id="V1865193" start="151"><type>ONT::PHOSPHORYLATION</type><text>The dual phosphorylation of ERK was analyzed by phosophosite-specific immunoblotting</text></predicate><arg2 end="183" id="V1865206" role=":AFFECTED" start="176"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The dual phosphorylation of ERK was analyzed by phosophosite-specific immunoblotting</text></EVENT>
Argument:V1865206

<EVENT end="290" id="V1876101" lisp="(ONT::EVENT ONT::V1876101 ONT::TRANSFORM :AFFECTED ONT::V1876083 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph207" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="272" uttnum="234"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="290" id="V1876101" start="272"><type>ONT::TRANSFORM</type><text>cells cultured as</text></predicate><arg2 end="278" id="V1876083" role=":AFFECTED" start="272"><type>ONT::CELL</type><text normalization="">cells</text></arg2><text>cells cultured as</text></EVENT>
Argument:V1876083

<EVENT end="454" id="V1893104" lisp="(ONT::EVENT ONT::V1893104 ONT::PHOSPHORYLATION :AFFECTED ONT::V1893117 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph207" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="417" uttnum="234"><type>ONT::PHOSPHORYLATION</type><predicate end="454" id="V1893104" start="417"><type>ONT::PHOSPHORYLATION</type><text>.The relative phosphorylation of ERK</text></predicate><arg2 end="454" id="V1893117" role=":AFFECTED" start="447"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>.The relative phosphorylation of ERK</text></EVENT>
Argument:V1893117

SENTENCES EXTRACTED:
VMM5A, VMM18, and VMM39 cells were grown in media as indicated.C, Western blot analysis of ERK from melanoma cell lines grown in 5.0% FBS and 0.5% FBS.The dual phosphorylation of ERK was analyzed by phosophosite-specific immunoblotting in VMM5A, VMM18, and VMM39 melanoma cells cultured as described (upper panel) .The total amount of ERK protein was determined by immunoblotting with a separate antibody (lower panel) .The relative phosphorylation of ERK was quantitated by densitometry analysis using Image Quant 5.2 software and the values are given below the top panel..
1289294P28-1.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
Together, these findings argue against use of CCI-779 as a single agent, but support investigation of mTOR inhibitors as part of combination therapy for treatment of patients with malignant melanoma..
1289294P19-2.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
The mean value for triplicate samples from three independent experiments is plotted.Error bars are present at each point on the graph.The Student T test was performed and the bracket and asterisk represents a statistically significant difference between VMM39 (wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002..
1289294P16.txt

EVENTS EXTRACTED:
<EVENT end="508" id="V2289069" lisp="(ONT::EVENT ONT::V2289069 ONT::DECREASE :AFFECTED ONT::V2289084)" paragraph="paragraph219" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="461" uttnum="246"><type>ONT::DECREASE</type><predicate end="508" id="V2289069" start="461"><type>ONT::DECREASE</type><text>reduction of MTS (a novel tetrazolium compound)</text></predicate><arg2 end="508" id="V2289084" role=":AFFECTED" start="471"><type>ONT::MOLECULAR-DOMAIN</type><text normalization="">of MTS (a novel tetrazolium compound)</text></arg2><text>reduction of MTS (a novel tetrazolium compound)</text></EVENT>
Argument:V2289084

SENTENCES EXTRACTED:
We examined the serum-dependent proliferation of various human melanoma cell lines.Figure 1 A is a growth curve for the VMM18 cell line, which is representative of the growth curves generated for each of the cell lines from a collection of human melanomas (Table 1) .Cell proliferation was determined by the number of cells at 0, 4, 8, 16, 24, 48, and 72 hours, quantitated using the Cell Titer 96 Aqueous (Promega Corporation, Madison, WI) assay which measures reduction of MTS (a novel tetrazolium compound).
1289294P9-1.txt

EVENTS EXTRACTED:
<EVENT end="110" id="V1842018" lisp="(ONT::EVENT ONT::V1842018 ONT::MODULATE :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph206" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="83" uttnum="233"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="110" id="V1842018" start="83"><type>ONT::MODULATE</type><text>listed above each line.The</text></predicate><text>listed above each line.The</text></EVENT>

<EVENT end="205" id="V1842205" lisp="(ONT::EVENT ONT::V1842205 ONT::INCREASE :AFFECTED ONT::V1842199 :FORCE ONT::TRUE)" paragraph="paragraph206" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="178" uttnum="233"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="205" id="V1842205" start="178"><type>ONT::INCREASE</type><text>VMM18 melanoma cells grown</text></predicate><arg2 end="205" id="V1842199" role=":AFFECTED" start="178"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells grown</text></arg2><text>VMM18 melanoma cells grown</text></EVENT>
Argument:V1842199

<EVENT end="320" id="V1842429" lisp="(ONT::EVENT ONT::V1842429 ONT::INCREASE :AFFECTED ONT::V1842423 :FORCE ONT::TRUE)" paragraph="paragraph206" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="284" uttnum="233"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="320" id="V1842429" start="284"><type>ONT::INCREASE</type><text>VMM18 melanoma cells grown in media</text></predicate><arg2 end="320" id="V1842423" role=":AFFECTED" start="284"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells grown in media</text></arg2><text>VMM18 melanoma cells grown in media</text></EVENT>
Argument:V1842423

<EVENT end="410" id="V1853438" lisp="(ONT::EVENT ONT::V1853438 ONT::INCREASE :FORCE ONT::TRUE)" paragraph="paragraph206" rule="-RULE20_1_AGENT_AFFECTED-NONE" start="401" uttnum="233"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="410" id="V1853438" start="401"><type>ONT::INCREASE</type><text>grown in</text></predicate><text>grown in</text></EVENT>

<EVENT end="457" id="V1853556" lisp="(ONT::EVENT ONT::V1853556 ONT::PHOSPHORYLATION :AFFECTED ONT::V1853593)" paragraph="paragraph206" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="432" uttnum="233"><type>ONT::PHOSPHORYLATION</type><predicate end="457" id="V1853556" start="432"><type>ONT::PHOSPHORYLATION</type><text>Phosphorylation of 4EBP1</text></predicate><arg2 end="457" id="V1853593" role=":AFFECTED" start="448"><type>ONT::GENE-PROTEIN</type><text normalization="">of 4EBP1</text></arg2><text>Phosphorylation of 4EBP1</text></EVENT>
Argument:V1853593

SENTENCES EXTRACTED:
The R2 values for the linear regression lines determined using Microsoft Excel are listed above each line.The solid dark line with the squares represents the data collected from VMM18 melanoma cells grown in media with 5% serum.The thin line with the circles represents the data from VMM18 melanoma cells grown in media containing 0.5% serum.B, Western blot analysis of 4EBP1 from melanoma cell lines grown in 5.0% FBS and 0.5% FBS.Phosphorylation of 4EBP1 was assayed by its reduced migration in SDS-PAGE and the proteins were detected by immunoblotting.
1289294P21-1.txt

EVENTS EXTRACTED:
<EVENT end="391" id="V2667277" lisp="(ONT::EVENT ONT::V2667277 ONT::TRANSLOCATE :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph230" rule="-RULE10_4_AGENT_AFFECTED-NONE" start="284" uttnum="257"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="391" id="V2667277" start="284"><type>ONT::TRANSLOCATE</type><text>falls below the line, for each of these melanoma cell lines, indicating that the combination is synergistic</text></predicate><text>falls below the line, for each of these melanoma cell lines, indicating that the combination is synergistic</text></EVENT>

<EVENT end="461" id="V2678459" lisp="(ONT::EVENT ONT::V2678459 ONT::TRANSFORM)" paragraph="paragraph230" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="438" uttnum="257"><type>ONT::TRANSFORM</type><predicate end="461" id="V2678459" start="438"><type>ONT::TRANSFORM</type><text>the V599E substitution,</text></predicate><text>the V599E substitution,</text></EVENT>

<EVENT end="510" id="V2679823" lisp="(ONT::EVENT ONT::V2679823 ONT::MODULATE :AFFECTED ONT::V2679818)" paragraph="paragraph230" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="481" uttnum="257"><type>ONT::MODULATE</type><predicate end="510" id="V2679823" start="481"><type>ONT::MODULATE</type><text>to the combination treatment</text></predicate><arg2 end="500" id="V2679818" role=":AFFECTED" start="488"><type>ONT::COMBINE-OBJECTS</type><text normalization="COMBINATION">combination</text></arg2><text>to the combination treatment</text></EVENT>
Argument:V2679818

SENTENCES EXTRACTED:
These were plotted on the ordinate.The IC70 concentration for BAY43-9006 alone was in the range of approximately 5 to 10 nM, in different cell lines, and these were plotted on the abscissa.Compared to the single agents, the IC70 for the dose pairs (rapamycin and BAY43-9006 together) falls below the line, for each of these melanoma cell lines, indicating that the combination is synergistic  (Figure 3).Furthermore, VMM18, which contains the V599E substitution, was more sensitive to the combination treatment than melanoma cell lines with wild-type B-Raf, consistent with the enhanced sensitivity at the 10 nM dose of each agent (Figure 2 above).
1289294P30-1.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
This suggests that administration of a combination of an mTOR inhibitor (rapamycin or CCI-779) and BAY43-9006 could be an especially effective approach to therapy of melanoma..
1289294P3.txt

EVENTS EXTRACTED:
<EVENT end="43" id="V1422441" lisp="(ONT::EVENT ONT::V1422441 ONT::TRANSFORM :AFFECTED ONT::V1422433 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph194" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="0" uttnum="221"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="43" id="V1422441" start="0"><type>ONT::TRANSFORM</type><text>Another molecular pathway commonly mutated</text></predicate><arg2 end="26" id="V1422433" role=":AFFECTED" start="0"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">Another molecular pathway</text></arg2><text>Another molecular pathway commonly mutated</text></EVENT>
Argument:V1422433

<EVENT end="200" id="V1435835" lisp="(ONT::EVENT ONT::V1435835 ONT::ACTIVATE :AFFECTED ONT::V1435905)" paragraph="paragraph194" rule="-RULE40_2_AGENT_AFFECTED-AFFECTED" start="129" uttnum="221"><type>ONT::ACTIVATE</type><predicate end="200" id="V1435835" start="129"><type>ONT::ACTIVATE</type><text>to constitutive activation of the mTOR kinase signaling pathway [11-13]</text></predicate><arg2 end="200" id="V1435905" role=":AFFECTED" start="156"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">of the mTOR kinase signaling pathway [11-13]</text></arg2><text>to constitutive activation of the mTOR kinase signaling pathway [11-13]</text></EVENT>
Argument:V1435905

<EVENT end="227" id="V1448386" lisp="(ONT::EVENT ONT::V1448386 ONT::INHIBIT :AFFECTED ONT::V1448432)" paragraph="paragraph194" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="201" uttnum="221"><type>ONT::INHIBIT</type><predicate end="227" id="V1448386" start="201"><type>ONT::INHIBIT</type><text>Inhibition of mTOR kinase</text></predicate><arg2 end="227" id="V1448432" role=":AFFECTED" start="212"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR kinase</text></arg2><text>Inhibition of mTOR kinase</text></EVENT>
Argument:V1448432

<EVENT end="610" id="V1475916" lisp="(ONT::EVENT ONT::V1475916 ONT::INHIBIT :AFFECTED ONT::V1475969 :FORCE ONT::TRUE)" paragraph="paragraph194" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="516" uttnum="221"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="610" id="V1475916" start="516"><type>ONT::INHIBIT</type><text>to suppress the neo-intima formation during restenosis in response to balloon angioplasty [16]</text></predicate><arg2 end="553" id="V1475969" role=":AFFECTED" start="528"><type>ONT::PRODUCE</type><text normalization="">the neo-intima formation</text></arg2><text>to suppress the neo-intima formation during restenosis in response to balloon angioplasty [16]</text></EVENT>
Argument:V1475969
NESTED EVENT!!!

<EVENT end="553" id="V1475969" lisp="(ONT::EVENT ONT::V1475969 ONT::PRODUCE)" paragraph="paragraph194" rule="-RULE40_2_AGENT_AFFECTED-RESULT-NONE" start="528" uttnum="221"><type>ONT::PRODUCE</type><predicate end="553" id="V1475969" start="528"><type>ONT::PRODUCE</type><text>the neo-intima formation</text></predicate><text>the neo-intima formation</text></EVENT>

SENTENCES EXTRACTED:
Another molecular pathway commonly mutated (30â€“60%) in melanomas involves loss of the PTEN tumor suppressor gene, which can lead to constitutive activation of the mTOR kinase signaling pathway [11-13] .Inhibition of mTOR kinase is feasible with the macrolide natural product rapamycin (aka: sirolimus, RAPA, Rapamune, AY-22989, and NSC-226080) .Rapamycin is an FDA-approved agent used as immunosuppressive therapy post organ transplant [14,15] .More recent clinical application of rapamycin has been with coated stents to suppress the neo-intima formation during restenosis in response to balloon angioplasty [16].
1289294P29.txt

EVENTS EXTRACTED:
<EVENT end="91" id="V3234044" lisp="(ONT::EVENT ONT::V3234044 ONT::BIND :FORCE ONT::TRUE :AGENT ONT::V3234563 :TENSE W::PRES)" paragraph="paragraph247" rule="-RULE40_4_AFFECTED_AFFECTED1-NONE" start="67" uttnum="274"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="91" id="V3234044" start="67"><type>ONT::BIND</type><text>Y43-9006 interacts with</text></predicate><arg1 end="76" id="V3234563" role=":AGENT" start="67"><type>ONT::SEQUENCE</type><text normalization="">Y43-9006</text></arg1><text>Y43-9006 interacts with</text></EVENT>
Argument:V3234563

<EVENT end="188" id="V3249550" lisp="(ONT::EVENT ONT::V3249550 ONT::ACTIVITY :AGENT ONT::V3249637 :AFFECTED ONT::V3249547)" paragraph="paragraph247" rule="-ACTIVITY1" start="153" uttnum="274"><type>ONT::ACTIVITY</type><predicate end="188" id="V3249550" start="153"><type>ONT::ACTIVITY</type><text>the kinase activity of V599E B-Raf</text></predicate><arg1 end="188" id="V3249637" role=":AGENT" start="173"><type>ONT::GENE-PROTEIN</type><text normalization="">of V599E B-Raf</text></arg1><arg2 end="164" id="V3249547" role=":AFFECTED" start="153"><type>ONT::GENE-PROTEIN</type><text normalization="">the kinase</text></arg2><text>the kinase activity of V599E B-Raf</text></EVENT>
Argument:V3249637
Argument:V3249547

<EVENT end="312" id="V3250044" lisp="(ONT::EVENT ONT::V3250044 ONT::TRANSFORM :AFFECTED ONT::V3250041)" paragraph="paragraph247" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="297" uttnum="274"><type>ONT::TRANSFORM</type><predicate end="312" id="V3250044" start="297"><type>ONT::TRANSFORM</type><text>V599E mutation</text></predicate><arg2 end="303" id="V3250041" role=":AFFECTED" start="297"><type>ONT::MUTATION</type><text normalization="">V599E</text></arg2><text>V599E mutation</text></EVENT>
Argument:V3250041

<EVENT end="363" id="V3250107" lisp="(ONT::EVENT ONT::V3250107 ONT::MODULATE :AGENT ONT::V3250126)" paragraph="paragraph247" rule="-RULE10_1_AGENT_AFFECTED-AGENT" start="334" uttnum="274"><type>ONT::MODULATE</type><predicate end="363" id="V3250107" start="334"><type>ONT::MODULATE</type><text>the effects of this drug [33]</text></predicate><arg1 end="363" id="V3250126" role=":AGENT" start="346"><type>ONT::MEDICATION</type><text normalization="">of this drug [33]</text></arg1><text>the effects of this drug [33]</text></EVENT>
Argument:V3250126

<EVENT end="464" id="V3262626" lisp="(ONT::EVENT ONT::V3262626 ONT::INHIBIT :AFFECTED ONT::V3262542 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph247" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="373" uttnum="274"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="464" id="V3262626" start="373"><type>ONT::INHIBIT</type><text>in the present study, proliferation of the human melanoma cells was inhibited by BAY43-9006</text></predicate><arg2 end="437" id="V3262542" role=":AFFECTED" start="395"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">proliferation of the human melanoma cells</text></arg2><text>in the present study, proliferation of the human melanoma cells was inhibited by BAY43-9006</text></EVENT>
Argument:V3262542

<EVENT end="535" id="V3271206" lisp="(ONT::EVENT ONT::V3271206 ONT::TRANSFORM :AFFECTED ONT::V3271247 :FORCE ONT::TRUE)" paragraph="paragraph247" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="515" uttnum="274"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="535" id="V3271206" start="515"><type>ONT::TRANSFORM</type><text>mutated B-Raf V599E</text></predicate><arg2 end="535" id="V3271247" role=":AFFECTED" start="515"><type>ONT::GENE-PROTEIN</type><text normalization="">mutated B-Raf V599E</text></arg2><text>mutated B-Raf V599E</text></EVENT>
Argument:V3271247

SENTENCES EXTRACTED:
With regards to B-Raf, recent structural studies have shown that BAY43-9006 interacts with an inactive conformation of B-Raf [33] .In biochemical assays, the kinase activity of V599E B-Raf is less sensitive to inhibition by BAY43-9006 than wild-type B-Raf, suggesting that melanomas with the B-Raf V599E mutation might be resistant to the effects of this drug [33].However, in the present study, proliferation of the human melanoma cells was inhibited by BAY43-9006, and at a dose of 10 nM, the cells that contained mutated B-Raf V599E were more sensitive than cells with wild-type B-Raf.
1289294P7.txt

EVENTS EXTRACTED:
<EVENT end="46" id="V1716620" lisp="(ONT::EVENT ONT::V1716620 ONT::INHIBIT :AFFECTED ONT::V1716617 :FORCE ONT::TRUE)" paragraph="paragraph202" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="229"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="46" id="V1716620" start="0"><type>ONT::INHIBIT</type><text>The MEK1/2 inhibitor U0126 (Catalog # 662005)</text></predicate><arg2 end="11" id="V1716617" role=":AFFECTED" start="4"><type>ONT::PROTEIN-FAMILY</type><text normalization="">MEK1/2</text></arg2><text>The MEK1/2 inhibitor U0126 (Catalog # 662005)</text></EVENT>
Argument:V1716617

SENTENCES EXTRACTED:
The MEK1/2 inhibitor U0126 (Catalog # 662005) and BAY43-9006 (Catalog # 553011) were purchased from Calbiochem, and stock solutions were made in DMSO.Rapamycin (R-5000) was purchased from LC Laboratories and a stock solution was made in DMSO..
1289294P23-1.txt

EVENTS EXTRACTED:
<EVENT end="69" id="V2809726" lisp="(ONT::EVENT ONT::V2809726 ONT::TRANSFORM :AGENT ONT::V2809621 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph234" rule="-RULE5_1_AGENT_AFFECTED-AGENT" start="0" uttnum="261"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="69" id="V2809726" start="0"><type>ONT::TRANSFORM</type><text>The phosphorylation of p70S6K and 4EBP1 retards migration in SDS-PAGE</text></predicate><arg1 end="40" id="V2809621" role=":AGENT" start="0"><type>ONT::PHOSPHORYLATION</type><text normalization="">The phosphorylation of p70S6K and 4EBP1</text></arg1><text>The phosphorylation of p70S6K and 4EBP1 retards migration in SDS-PAGE</text></EVENT>
Argument:V2809621

<EVENT end="40" id="V2809621" lisp="(ONT::EVENT ONT::V2809621 ONT::PHOSPHORYLATION :AFFECTED ONT::V2809693 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph234" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="0" uttnum="261"><type>ONT::PHOSPHORYLATION</type><predicate end="40" id="V2809621" start="0"><type>ONT::PHOSPHORYLATION</type><text>The phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="40" id="V2809693" role=":AFFECTED" start="20"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2809693

<EVENT end="257" id="V2810087" lisp="(ONT::EVENT ONT::V2810087 ONT::MODULATE :AFFECTED ONT::V2810152)" paragraph="paragraph234" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="223" uttnum="261"><type>ONT::MODULATE</type><predicate end="257" id="V2810087" start="223"><type>ONT::MODULATE</type><text>Treatment of VMM18 melanoma cells</text></predicate><arg2 end="257" id="V2810152" role=":AFFECTED" start="233"><type>ONT::CELL</type><text normalization="">of VMM18 melanoma cells</text></arg2><text>Treatment of VMM18 melanoma cells</text></EVENT>
Argument:V2810152

<EVENT end="298" id="V2810326" lisp="(ONT::EVENT ONT::V2810326 ONT::INHIBIT :AFFECTED ONT::V2810319 :FORCE ONT::TRUE)" paragraph="paragraph234" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="278" uttnum="261"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="298" id="V2810326" start="278"><type>ONT::INHIBIT</type><text>rapamycin inhibited</text></predicate><arg2 end="298" id="V2810319" role=":AFFECTED" start="278"><type>ONT::MOLECULE</type><text normalization="">rapamycin inhibited</text></arg2><text>rapamycin inhibited</text></EVENT>
Argument:V2810319

<EVENT end="355" id="V2810360" lisp="(ONT::EVENT ONT::V2810360 ONT::PHOSPHORYLATION :INEVENT ONT::V2810348 :AFFECTED ONT::V2810432 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph234" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="298" uttnum="261"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V2810348" /></features><predicate end="355" id="V2810360" start="298"><type>ONT::PHOSPHORYLATION</type><text>the serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="355" id="V2810432" role=":AFFECTED" start="335"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2810432

<EVENT end="355" id="V2810348" lisp="(ONT::EVENT ONT::V2810348 ONT::STIMULATE :AFFECTED ONT::V2810360 :FORCE ONT::TRUE)" paragraph="paragraph234" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="298" uttnum="261"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="355" id="V2810348" start="298"><type>ONT::STIMULATE</type><text>the serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="355" id="V2810360" role=":AFFECTED" start="298"><type>ONT::PHOSPHORYLATION</type><text normalization="">the serum-stimulated phosphorylation of p70S6K and 4EBP1</text></arg2><text>the serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2810360
NESTED EVENT!!!

<EVENT end="417" id="V2822551" lisp="(ONT::EVENT ONT::V2822551 ONT::MODULATE :AFFECTED ONT::V2822604)" paragraph="paragraph234" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="373" uttnum="261"><type>ONT::MODULATE</type><predicate end="417" id="V2822551" start="373"><type>ONT::MODULATE</type><text>.Parallel treatment of VMM18 melanoma cells</text></predicate><arg2 end="417" id="V2822604" role=":AFFECTED" start="393"><type>ONT::CELL</type><text normalization="">of VMM18 melanoma cells</text></arg2><text>.Parallel treatment of VMM18 melanoma cells</text></EVENT>
Argument:V2822604

<EVENT end="525" id="V2822848" lisp="(ONT::EVENT ONT::V2822848 ONT::INHIBIT :AFFECTED ONT::V2822875 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph234" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="440" uttnum="261"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="525" id="V2822848" start="440"><type>ONT::INHIBIT</type><text>Y43-9006 unexpectedly inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="525" id="V2822875" role=":AFFECTED" start="472"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of p70S6K and 4EBP1</text></arg2><text>Y43-9006 unexpectedly inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2822875
NESTED EVENT!!!

<EVENT end="525" id="V2822875" lisp="(ONT::EVENT ONT::V2822875 ONT::PHOSPHORYLATION :INEVENT ONT::V2822863 :AFFECTED ONT::V2822947 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph234" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="472" uttnum="261"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V2822863" /></features><predicate end="525" id="V2822875" start="472"><type>ONT::PHOSPHORYLATION</type><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="525" id="V2822947" role=":AFFECTED" start="505"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2822947

<EVENT end="525" id="V2822863" lisp="(ONT::EVENT ONT::V2822863 ONT::STIMULATE :AFFECTED ONT::V2822875 :FORCE ONT::TRUE)" paragraph="paragraph234" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="472" uttnum="261"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="525" id="V2822863" start="472"><type>ONT::STIMULATE</type><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="525" id="V2822875" role=":AFFECTED" start="472"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of p70S6K and 4EBP1</text></arg2><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2822875
NESTED EVENT!!!

SENTENCES EXTRACTED:
The phosphorylation of p70S6K and 4EBP1 retards migration in SDS-PAGE.Antibodies to these proteins were used to show all the protein and therefore enable evaluation of the fraction phosphorylated under different conditions.Treatment of VMM18 melanoma cells with a 10 nM dose of rapamycin inhibited the serum-stimulated phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 3) .Parallel treatment of VMM18 melanoma cells with a 10 nM dose of BAY43-9006 unexpectedly inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 4).
1289294P29-1.txt

EVENTS EXTRACTED:
<EVENT end="306" id="V3308268" lisp="(ONT::EVENT ONT::V3308268 ONT::MODULATE :EPI ONT::V3308279)" paragraph="paragraph248" rule="-NEUTRALTOAGENT,-RULE50_0_AGENT_NEUTRAL-EVENT,-RULE10_1_AGENT_AFFECTED-NONE" start="280" uttnum="275"><type>ONT::MODULATE</type><epistemic-modality id="V3308279" /><predicate end="306" id="V3308268" start="280"><type>ONT::MODULATE</type><text>clinical effects observed</text></predicate><text>clinical effects observed</text></EVENT>

<EVENT end="333" id="V3308355" lisp="(ONT::EVENT ONT::V3308355 ONT::MODULATE)" paragraph="paragraph248" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="320" uttnum="275"><type>ONT::MODULATE</type><predicate end="333" id="V3308355" start="320"><type>ONT::MODULATE</type><text>some effects</text></predicate><text>some effects</text></EVENT>

<EVENT end="378" id="V3308462" lisp="(ONT::EVENT ONT::V3308462 ONT::ACTIVITY :AGENT ONT::V3308454)" paragraph="paragraph248" rule="-ACTIVITY1" start="354" uttnum="275"><type>ONT::ACTIVITY</type><predicate end="378" id="V3308462" start="354"><type>ONT::ACTIVITY</type><text>of B-raf kinase activity</text></predicate><arg1 end="370" id="V3308454" role=":AGENT" start="363"><type>ONT::GENE-PROTEIN</type><text normalization="">kinase</text></arg1><text>of B-raf kinase activity</text></EVENT>
Argument:V3308454

SENTENCES EXTRACTED:
In clinical studies with BAY43-9006 plus chemotherapy, objective tumor regressions were more common in patients who had wild-type B-raf [34] .The findings of the current report support continued investigation of BAY43-9006 for treatment of patients with melanoma, and suggest that clinical effects observed may be due to some effects that are independent of B-raf kinase activity..
1289294P23-2.txt

EVENTS EXTRACTED:
<EVENT end="67" id="V2834689" lisp="(ONT::EVENT ONT::V2834689 ONT::ACTIVITY :AGENT ONT::V2835520)" paragraph="paragraph235" rule="-ACTIVITY1" start="46" uttnum="262"><type>ONT::ACTIVITY</type><predicate end="67" id="V2834689" start="46"><type>ONT::ACTIVITY</type><text>Raf-MEK-ERK activity</text></predicate><arg1 end="58" id="V2835520" role=":AGENT" start="46"><type>ONT::GENE-PROTEIN</type><text normalization="">Raf-MEK-ERK</text></arg1><text>Raf-MEK-ERK activity</text></EVENT>
Argument:V2835520

<EVENT end="126" id="V2834728" lisp="(ONT::EVENT ONT::V2834728 ONT::PHOSPHORYLATION :AFFECTED ONT::V2834836 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph235" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="71" uttnum="262"><type>ONT::PHOSPHORYLATION</type><predicate end="126" id="V2834728" start="71"><type>ONT::PHOSPHORYLATION</type><text>the phosphorylation of mTOR substrates p70S6K and 4EBP1</text></predicate><arg2 end="126" id="V2834836" role=":AFFECTED" start="91"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR substrates p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the phosphorylation of mTOR substrates p70S6K and 4EBP1</text></EVENT>
Argument:V2834836

<EVENT end="162" id="V2834879" lisp="(ONT::EVENT ONT::V2834879 ONT::MODULATE :AFFECTED ONT::V2834869)" paragraph="paragraph235" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="127" uttnum="262"><type>ONT::MODULATE</type><predicate end="162" id="V2834879" start="127"><type>ONT::MODULATE</type><text>Combination treatment with a 10 nM</text></predicate><arg2 end="139" id="V2834869" role=":AFFECTED" start="127"><type>ONT::COMBINE-OBJECTS</type><text normalization="COMBINATION">Combination</text></arg2><text>Combination treatment with a 10 nM</text></EVENT>
Argument:V2834869

<EVENT end="292" id="V2835281" lisp="(ONT::EVENT ONT::V2835281 ONT::INHIBIT :AFFECTED ONT::V2835286 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph235" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="212" uttnum="262"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="292" id="V2835281" start="212"><type>ONT::INHIBIT</type><text>blocked phosphorylation of p70S6K and 4EBP1 as effectively as either drug alone</text></predicate><arg2 end="256" id="V2835286" role=":AFFECTED" start="220"><type>ONT::PHOSPHORYLATION</type><text normalization="">phosphorylation of p70S6K and 4EBP1</text></arg2><text>blocked phosphorylation of p70S6K and 4EBP1 as effectively as either drug alone</text></EVENT>
Argument:V2835286
NESTED EVENT!!!

<EVENT end="256" id="V2835286" lisp="(ONT::EVENT ONT::V2835286 ONT::PHOSPHORYLATION :AFFECTED ONT::V2835358 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph235" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="220" uttnum="262"><type>ONT::PHOSPHORYLATION</type><predicate end="256" id="V2835286" start="220"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="256" id="V2835358" role=":AFFECTED" start="236"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2835358

<EVENT end="408" id="V2846437" lisp="(ONT::EVENT ONT::V2846437 ONT::INHIBIT :AFFECTED ONT::V2846416 :FORCE ONT::TRUE :DEGREE (ONT::DEGREE-MODIFIER W::MORE) :TENSE W::PAST :PASSIVE +)" paragraph="paragraph235" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="329" uttnum="262"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><mods><degree><type>ONT::DEGREE-MODIFIER</type><value>MORE</value></degree></mods><predicate end="408" id="V2846437" start="329"><type>ONT::INHIBIT</type><text>cell proliferation was suppressed more effectively by this combination of drugs</text></predicate><arg2 end="348" id="V2846416" role=":AFFECTED" start="329"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">cell proliferation</text></arg2><text>cell proliferation was suppressed more effectively by this combination of drugs</text></EVENT>
Argument:V2846416

<EVENT end="529" id="V2854447" lisp="(ONT::EVENT ONT::V2854447 ONT::DECREASE :AFFECTED ONT::V2854511)" paragraph="paragraph235" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="436" uttnum="262"><type>ONT::DECREASE</type><predicate end="529" id="V2854447" start="436"><type>ONT::DECREASE</type><text>a detectable further decrease in phosphorylation of the mTOR target proteins p70S6K and 4EBP1</text></predicate><arg2 end="529" id="V2854511" role=":AFFECTED" start="466"><type>ONT::PHOSPHORYLATION</type><text normalization="">in phosphorylation of the mTOR target proteins p70S6K and 4EBP1</text></arg2><text>a detectable further decrease in phosphorylation of the mTOR target proteins p70S6K and 4EBP1</text></EVENT>
Argument:V2854511
NESTED EVENT!!!

<EVENT end="529" id="V2854511" lisp="(ONT::EVENT ONT::V2854511 ONT::PHOSPHORYLATION :AFFECTED ONT::V2854570 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph235" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="466" uttnum="262"><type>ONT::PHOSPHORYLATION</type><predicate end="529" id="V2854511" start="466"><type>ONT::PHOSPHORYLATION</type><text>in phosphorylation of the mTOR target proteins p70S6K and 4EBP1</text></predicate><arg2 end="529" id="V2854570" role=":AFFECTED" start="485"><type>ONT::PROTEIN</type><text normalization="">of the mTOR target proteins p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>in phosphorylation of the mTOR target proteins p70S6K and 4EBP1</text></EVENT>
Argument:V2854570

SENTENCES EXTRACTED:
There is not a well-documented requirement of Raf-MEK-ERK activity for the phosphorylation of mTOR substrates p70S6K and 4EBP1.Combination treatment with a 10 nM dose of rapamycin plus a 10 nM dose of BAY43-9006 blocked phosphorylation of p70S6K and 4EBP1 as effectively as either drug alone (Figure 4, lane 5).Thus, even though cell proliferation was suppressed more effectively by this combination of drugs, this was not reflected in a detectable further decrease in phosphorylation of the mTOR target proteins p70S6K and 4EBP1.
1289294P8-1.txt

EVENTS EXTRACTED:
<EVENT end="65" id="V1804960" lisp="(ONT::EVENT ONT::V1804960 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph204" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="30" uttnum="231"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="65" id="V1804960" start="30"><type>ONT::MODULATE</type><text>washed and treated with inhibitors</text></predicate><text>washed and treated with inhibitors</text></EVENT>

<EVENT end="65" id="V1804945" lisp="(ONT::EVENT ONT::V1804945 ONT::TRANSFORM :FORCE ONT::TRUE)" paragraph="paragraph204" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="30" uttnum="231"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="65" id="V1804945" start="30"><type>ONT::TRANSFORM</type><text>washed and treated with inhibitors</text></predicate><text>washed and treated with inhibitors</text></EVENT>

<EVENT end="65" id="V1804976" lisp="(ONT::EVENT ONT::V1804976 ONT::INHIBIT)" paragraph="paragraph204" rule="-RULE30_1_AGENT_FORMAL-NONE" start="54" uttnum="231"><type>ONT::INHIBIT</type><predicate end="65" id="V1804976" start="54"><type>ONT::INHIBIT</type><text>inhibitors</text></predicate><text>inhibitors</text></EVENT>

SENTENCES EXTRACTED:
After 12â€“16 h, the cells were washed and treated with inhibitors as indicated for one hour.Cells were then washed and grown in RPMI medium with 5% FBS for 48 hours.Cell numbers were assayed with Cell Titer-Glo (Promega Catalog # G7571) according to the instructions provided by the manufacturer.The triplicate values were all within 5% and the mean values were calculated and plotted with error bars representing the standard deviation of triplicate samples from 3 independent experiments..
1289294P8.txt

EVENTS EXTRACTED:
<EVENT end="572" id="V1782567" lisp="(ONT::EVENT ONT::V1782567 ONT::MODULATE :EPI ONT::V1782555 :AGENT ONT::V1782632 :AFFECTED ONT::V1782744)" paragraph="paragraph203" rule="-RULE50_0_AGENT_NEUTRAL-EVENT,-RULE10_1_AGENT_AFFECTED" start="443" uttnum="230"><type>ONT::MODULATE</type><epistemic-modality id="V1782555" /><predicate end="572" id="V1782567" start="443"><type>ONT::MODULATE</type><text>VMM18.For experiments to examine the effects of the signal transduction inhibitors on serum-dependent melanoma cell proliferation</text></predicate><arg1 end="526" id="V1782632" role=":AGENT" start="488"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">of the signal transduction inhibitors</text></arg1><arg2 end="572" id="V1782744" role=":AFFECTED" start="526"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">on serum-dependent melanoma cell proliferation</text></arg2><text>VMM18.For experiments to examine the effects of the signal transduction inhibitors on serum-dependent melanoma cell proliferation</text></EVENT>
Argument:V1782632
Argument:V1782744

SENTENCES EXTRACTED:
Melanoma cells (25,000 cells per well) were plated in 96-well plates in RPMI plus either 5% FBS or 0.5% FBS, and cell numbers were assayed at time 0 and after 4, 8, 16, 24, 48, and 72 hours using Cell Titer 96 Aqueous (Promega Catalog# G3580; Madison, WI), according to the instructions provided by the manufacturer.Serum-dependent rates of growth were calculated using the slope of the lines from the growth curves, as shown in Figure 1A for VMM18.For experiments to examine the effects of the signal transduction inhibitors on serum-dependent melanoma cell proliferation, melanoma cells (1,000 cells per well) were plated in triplicate in a 96-well plates with 5% fetal bovine serum and allowed to adhere overnight.
1289294P19-1.txt

EVENTS EXTRACTED:
<EVENT end="108" id="V2468815" lisp="(ONT::EVENT ONT::V2468815 ONT::MODULATE)" paragraph="paragraph226" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="96" uttnum="253"><type>ONT::MODULATE</type><predicate end="108" id="V2468815" start="96"><type>ONT::MODULATE</type><text>the control</text></predicate><text>the control</text></EVENT>

<EVENT end="136" id="V2468829" lisp="(ONT::EVENT ONT::V2468829 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph226" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="109" uttnum="253"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="136" id="V2468829" start="109"><type>ONT::MODULATE</type><text>treated with vehicle, DMSO)</text></predicate><text>treated with vehicle, DMSO)</text></EVENT>

<EVENT end="490" id="V2506456" lisp="(ONT::EVENT ONT::V2506456 ONT::STIMULATE :AFFECTED ONT::V2506470 :FORCE ONT::TRUE)" paragraph="paragraph226" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="413" uttnum="253"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="490" id="V2506456" start="413"><type>ONT::STIMULATE</type><text>The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></predicate><arg2 end="490" id="V2506470" role=":AFFECTED" start="413"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></arg2><text>The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></EVENT>
Argument:V2506470

<EVENT end="572" id="V2506768" lisp="(ONT::EVENT ONT::V2506768 ONT::MODULATE :AFFECTED ONT::V2506746 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph226" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="529" uttnum="253"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="572" id="V2506768" start="529"><type>ONT::MODULATE</type><text>melanoma cells were treated with rapamycin</text></predicate><arg2 end="544" id="V2506746" role=":AFFECTED" start="529"><type>ONT::CELL</type><text normalization="">melanoma cells</text></arg2><text>melanoma cells were treated with rapamycin</text></EVENT>
Argument:V2506746

<EVENT end="623" id="V2506917" lisp="(ONT::EVENT ONT::V2506917 ONT::TRANSLOCATE :FORCE ONT::TRUE)" paragraph="paragraph226" rule="-RULE10_4_AGENT_AFFECTED-NONE" start="605" uttnum="253"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="623" id="V2506917" start="605"><type>ONT::TRANSLOCATE</type><text>ranging from 0.01</text></predicate><text>ranging from 0.01</text></EVENT>

SENTENCES EXTRACTED:
The mean value for triplicate samples from three independent experiments is plotted relative to the control (treated with vehicle, DMSO) .Error bars are present at each point on the graph.The Student T test was performed and the bracket and asterisk represents a statistically significant difference between VMM39 (wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002.B, The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells were assayed as described above except melanoma cells were treated with rapamycin instead of BAY43-9006 with doses ranging from 0.01 nM to 100 nM.
1289294P2-1.txt

EVENTS EXTRACTED:
<EVENT end="242" id="V1371161" lisp="(ONT::EVENT ONT::V1371161 ONT::PHOSPHORYLATION :AGENT ONT::V1371157 :AFFECTED ONT::V1371183 :SITEMOD (ONT::ON W::ON) :SITE ONT::V1371248 :FORCE ONT::TRUE :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))) :TENSE W::PRES)" paragraph="paragraph192" rule="-RULE60_4_AGENT_AFFECTED-LOC4-GD" start="187" uttnum="219"><type>ONT::PHOSPHORYLATION</type><force>ONT::TRUE</force><predicate end="242" id="V1371161" start="187"><type>ONT::PHOSPHORYLATION</type><text>B-Raf phosphorylates MEK1 and MEK2 on Ser217 and Ser221</text></predicate><arg1 end="193" id="V1371157" role=":AGENT" start="187"><type>ONT::GENE-PROTEIN</type><text normalization="">B-Raf</text></arg1><arg2 end="222" id="V1371183" role=":AFFECTED" start="208"><type>ONT::GENE-PROTEIN</type><text normalization="">MEK1 and MEK2</text></arg2><site end="242" id="V1371248" start="225"><type>ONT::MOLECULAR-SITE</type><text normalization="">Ser217 and Ser221</text></site><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>B-Raf phosphorylates MEK1 and MEK2 on Ser217 and Ser221</text></EVENT>
Argument:V1371157
Argument:V1371183

<EVENT end="263" id="V1386055" lisp="(ONT::EVENT ONT::V1386055 ONT::ACTIVATE :AFFECTED ONT::V1386060 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph192" rule="-RULE40_2_AGENT_AFFECTED-ROBUSTPRO-AFFECTED-ONLY" start="244" uttnum="219"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="263" id="V1386055" start="244"><type>ONT::ACTIVATE</type><text>which activates it</text></predicate><arg2 end="263" id="V1386060" role=":AFFECTED" start="260"><type>ONT::REFERENTIAL-SEM</type><text normalization="IT">it</text></arg2><text>which activates it</text></EVENT>
Argument:V1386060

<EVENT end="361" id="V1386094" lisp="(ONT::EVENT ONT::V1386094 ONT::PHOSPHORYLATION :AFFECTED ONT::V1386111 :SITEMOD (ONT::AT-LOC W::AT) :SITE ONT::V1386265 :FORCE ONT::TRUE :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))) :TENSE W::PRES)" paragraph="paragraph192" rule="-RULE60_4_AGENT_AFFECTED-LOC4-GD-AFFECTED" start="271" uttnum="219"><type>ONT::PHOSPHORYLATION</type><force>ONT::TRUE</force><predicate end="361" id="V1386094" start="271"><type>ONT::PHOSPHORYLATION</type><text>phosphorylate ERKs, at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2 [8,9]</text></predicate><arg2 end="291" id="V1386111" role=":AFFECTED" start="285"><type>ONT::GENE-PROTEIN</type><text normalization="">ERKs,</text></arg2><site end="341" id="V1386265" start="294"><type>ONT::MOLECULAR-SITE</type><text normalization="">Thr202/Tyr204 for human ERK1 and Thr185/Tyr187</text></site><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylate ERKs, at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2 [8,9]</text></EVENT>
Argument:V1386111

<EVENT end="379" id="V1398582" lisp="(ONT::EVENT ONT::V1398582 ONT::TRANSFORM)" paragraph="paragraph192" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="362" uttnum="219"><type>ONT::TRANSFORM</type><predicate end="379" id="V1398582" start="362"><type>ONT::TRANSFORM</type><text>Mutations in RAF</text></predicate><text>Mutations in RAF</text></EVENT>

<EVENT end="429" id="V1398665" lisp="(ONT::EVENT ONT::V1398665 ONT::ACTIVATE :AFFECTED ONT::V1398684)" paragraph="paragraph192" rule="-RULE40_2_AGENT_AFFECTED-AFFECTED" start="391" uttnum="219"><type>ONT::ACTIVATE</type><predicate end="429" id="V1398665" start="391"><type>ONT::ACTIVATE</type><text>constitutive activation of Raf kinase</text></predicate><arg2 end="429" id="V1398684" role=":AFFECTED" start="415"><type>ONT::GENE-PROTEIN</type><text normalization="">of Raf kinase</text></arg2><text>constitutive activation of Raf kinase</text></EVENT>
Argument:V1398684

<EVENT end="737" id="V1399354" lisp="(ONT::EVENT ONT::V1399354 ONT::ACTIVATE :AGENT ONT::V1399335 :AFFECTED ONT::V1399366 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph192" rule="-RULE40_2_AGENT_AFFECTED" start="675" uttnum="219"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="737" id="V1399354" start="675"><type>ONT::ACTIVATE</type><text>growth factor receptors that activate the Ras/ERK pathway [10]</text></predicate><arg1 end="737" id="V1399335" role=":AGENT" start="675"><type>ONT::PROTEIN</type><text normalization="">growth factor receptors that activate the Ras/ERK pathway [10]</text></arg1><arg2 end="737" id="V1399366" role=":AFFECTED" start="713"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">the Ras/ERK pathway [10]</text></arg2><text>growth factor receptors that activate the Ras/ERK pathway [10]</text></EVENT>
Argument:V1399335
Argument:V1399366

SENTENCES EXTRACTED:
B-Raf is a component of a cell signaling pathway which includes the upstream activator of Raf, called Ras, and the direct substrate of Raf, called MEK1/2 and the MEK substrate ERK1/2 [7] .B-Raf phosphorylates MEK1 and MEK2 on Ser217 and Ser221, which activates it to dual phosphorylate ERKs, at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2 [8,9] .Mutations in RAF which cause constitutive activation of Raf kinase are thought to promote events leading to carcinogenesis.Pre-clinical and early phase I studies have suggested that BAY 43-9006 may be of therapeutic value not only in human tumors containing ras gene mutations, but also in tumors over-expressing growth factor receptors that activate the Ras/ERK pathway [10].
1289294P3-2.txt

EVENTS EXTRACTED:
<EVENT end="111" id="V1528818" lisp="(ONT::EVENT ONT::V1528818 ONT::TRANSFORM :RES ONT::V1528831 :AGENT ONT::V1528748 :AFFECTED ONT::V1528853 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph196" rule="-RESULT1,-RULE5_1_AGENT_AFFECTED" start="0" uttnum="223"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="111" id="V1528818" start="0"><type>ONT::TRANSFORM</type><text>Pharmacokinetic analysis revealed that CCI-779 was progressively converted into rapamycin, its main metabolite,</text></predicate><arg1 end="51" id="V1528748" role=":AGENT" start="0"><type>ONT::TEST</type><text normalization="">Pharmacokinetic analysis revealed that CCI-779 was</text></arg1><arg2 end="111" id="V1528853" role=":AFFECTED" start="91"><type>ONT::CHEMICAL</type><text normalization="">its main metabolite,</text></arg2><arg3 end="91" id="V1528831" role=":RES" start="80"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">rapamycin,</text></arg3><text>Pharmacokinetic analysis revealed that CCI-779 was progressively converted into rapamycin, its main metabolite,</text></EVENT>
Argument:V1528748
Argument:V1528853
Argument:V1528831

<EVENT end="188" id="V1534259" lisp="(ONT::EVENT ONT::V1534259 ONT::ACTIVATE)" paragraph="paragraph196" rule="-RULE40_2_AGENT_AFFECTED-NONE" start="112" uttnum="223"><type>ONT::ACTIVATE</type><predicate end="188" id="V1534259" start="112"><type>ONT::ACTIVATE</type><text>beginning as early as 15 minutes after infusion of the drug [20], therefore,</text></predicate><text>beginning as early as 15 minutes after infusion of the drug [20], therefore,</text></EVENT>

SENTENCES EXTRACTED:
Pharmacokinetic analysis revealed that CCI-779 was progressively converted into rapamycin, its main metabolite, beginning as early as 15 minutes after infusion of the drug [20], therefore, we used rapamycin in our studies..
1289294P10-2.txt

EVENTS EXTRACTED:
<EVENT end="203" id="V2017196" lisp="(ONT::EVENT ONT::V2017196 ONT::INHIBIT :AFFECTED ONT::V2017174 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph210" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="170" uttnum="237"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="203" id="V2017196" start="170"><type>ONT::INHIBIT</type><text>Membranes were blocked in 1% BSA</text></predicate><arg2 end="180" id="V2017174" role=":AFFECTED" start="170"><type>ONT::CELL-PART</type><text normalization="">Membranes</text></arg2><text>Membranes were blocked in 1% BSA</text></EVENT>
Argument:V2017174

<EVENT end="323" id="V2017762" lisp="(ONT::EVENT ONT::V2017762 ONT::MODULATE :AGENT ONT::V2017743 :FORCE ONT::TRUE :FORMAL ONT::V2017792)" paragraph="paragraph210" rule="-RULE10_1_AGENT_AFFECTED-AGENT" start="305" uttnum="237"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="323" id="V2017762" start="305"><type>ONT::MODULATE</type><text>antibodies listed</text></predicate><arg1 end="323" id="V2017743" role=":AGENT" start="305"><type>ONT::PROTEIN</type><text normalization="">antibodies listed</text></arg1><arg2 end="338" id="V2017792" role=":FORMAL" start="305"><type>ONT::REFERENTIAL-SEM</type><text normalization="BELOW.PROTEINS">antibodies listed below.Proteins</text></arg2><text>antibodies listed</text></EVENT>
Argument:V2017743
Argument:V2017792

<EVENT end="503" id="V2031336" lisp="(ONT::EVENT ONT::V2031336 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph210" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="466" uttnum="237"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="503" id="V2031336" start="466"><type>ONT::MODULATE</type><text>to expose to Kodak BioMax film.Films</text></predicate><text>to expose to Kodak BioMax film.Films</text></EVENT>

<EVENT end="544" id="V2031421" lisp="(ONT::EVENT ONT::V2031421 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph210" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="503" uttnum="237"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="544" id="V2031421" start="503"><type>ONT::MODULATE</type><text>exposed within the linear response range</text></predicate><text>exposed within the linear response range</text></EVENT>

SENTENCES EXTRACTED:
Proteins were resuspended in SDS-containing sample buffer, heated for 10 min at 100Â°C, and 10 ng/lane was resolved by SDS-PAGE and transferred to Immobilon-P (Millipore) .Membranes were blocked in 1% BSA in 50 mM Tris-Cl (pH 7.5), 0.9% NaCl, 0.05% Tween 20, and 0.01% antifoam A.Membranes were probed with antibodies listed below.Proteins were detected with Pierce SuperSignal West Pico Chemiluminescent substrate (#34080) as recommended by the manufacturer and used to expose to Kodak BioMax film.Films exposed within the linear response range were scanned and used for densitometry analysis by Image Quant 5.2..
1289294P9.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
A, Growth curves of VMM18 melanoma cells in 5% and 0.5% serum-containing media.VMM18 melanoma cells were cultured in media containing either 5% or 0.5% serum and were assayed in triplicate at times 0, 4, 8, 16, 24, 48, and 72 hours using Cell Titer 96 Aqueous (Promega; Madison, WI) according to the directions supplied by the manufacturer.The absorbance at 490 nm (OD 490) measures the quantity of formazan product from the MTS-based assay and is directly proportional to the number of live cells present.
1289294P31-1.txt

EVENTS EXTRACTED:
<EVENT end="185" id="V3427200" lisp="(ONT::EVENT ONT::V3427200 ONT::DECREASE :AGENT ONT::V3427107 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph252" rule="-RULE20_1_AGENT_AFFECTED-AGENT" start="92" uttnum="279"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="185" id="V3427200" start="92"><type>ONT::DECREASE</type><text>inhibition of PI3K with LY294002 or inhibition of mTOR by rapamycin reduced the level of ERK</text></predicate><arg1 end="160" id="V3427107" role=":AGENT" start="92"><type>ONT::INHIBIT-EFFECT</type><text normalization="INHIBITION">inhibition of PI3K with LY294002 or inhibition of mTOR by rapamycin</text></arg1><text>inhibition of PI3K with LY294002 or inhibition of mTOR by rapamycin reduced the level of ERK</text></EVENT>
Argument:V3427107

<EVENT end="125" id="V3427030" lisp="(ONT::EVENT ONT::V3427030 ONT::INHIBIT :AFFECTED ONT::V3427073)" paragraph="paragraph252" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="92" uttnum="279"><type>ONT::INHIBIT</type><predicate end="125" id="V3427030" start="92"><type>ONT::INHIBIT</type><text>inhibition of PI3K with LY294002</text></predicate><arg2 end="111" id="V3427073" role=":AFFECTED" start="103"><type>ONT::GENE-PROTEIN</type><text normalization="">of PI3K</text></arg2><text>inhibition of PI3K with LY294002</text></EVENT>
Argument:V3427073

<EVENT end="160" id="V3427114" lisp="(ONT::EVENT ONT::V3427114 ONT::INHIBIT :AGENT ONT::V3427186 :AFFECTED ONT::V3427156)" paragraph="paragraph252" rule="-RULE30_1_AGENT_AFFECTED" start="128" uttnum="279"><type>ONT::INHIBIT</type><predicate end="160" id="V3427114" start="128"><type>ONT::INHIBIT</type><text>inhibition of mTOR by rapamycin</text></predicate><arg1 end="160" id="V3427186" role=":AGENT" start="147"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">by rapamycin</text></arg1><arg2 end="147" id="V3427156" role=":AFFECTED" start="139"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR</text></arg2><text>inhibition of mTOR by rapamycin</text></EVENT>
Argument:V3427186
Argument:V3427156

<EVENT end="209" id="V3427238" lisp="(ONT::EVENT ONT::V3427238 ONT::PHOSPHORYLATION :SITE ONT::V3427232)" paragraph="paragraph252" rule="-RULE60_4_AGENT_AFFECTED-LOC11-NONE" start="185" uttnum="279"><type>ONT::PHOSPHORYLATION</type><predicate end="209" id="V3427238" start="185"><type>ONT::PHOSPHORYLATION</type><text>Tyr-phosphorylation [35]</text></predicate><site end="209" id="V3427232" start="185"><type>ONT::AMINO-ACID</type><text normalization="">Tyr-phosphorylation [35]</text></site><text>Tyr-phosphorylation [35]</text></EVENT>

<EVENT end="295" id="V3439477" lisp="(ONT::EVENT ONT::V3439477 ONT::INHIBIT :AGENT ONT::V3439527 :AFFECTED ONT::V3439343 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph252" rule="-RULE30_1_AGENT_AFFECTED" start="229" uttnum="279"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="295" id="V3439477" start="229"><type>ONT::INHIBIT</type><text>PKC-dependent activation of mTOR and p70S6K was inhibited by U0126</text></predicate><arg1 end="295" id="V3439527" role=":AGENT" start="287"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">by U0126</text></arg1><arg2 end="273" id="V3439343" role=":AFFECTED" start="229"><type>ONT::ACTIVATE</type><text normalization="">PKC-dependent activation of mTOR and p70S6K</text></arg2><text>PKC-dependent activation of mTOR and p70S6K was inhibited by U0126</text></EVENT>
Argument:V3439527
Argument:V3439343
NESTED EVENT!!!

<EVENT end="273" id="V3439343" lisp="(ONT::EVENT ONT::V3439343 ONT::ACTIVATE :INEVENT ONT::V3439332 :AFFECTED ONT::V3439389)" paragraph="paragraph252" rule="-INEVENT2B,-RULE40_2_AGENT_AFFECTED-AFFECTED" start="229" uttnum="279"><type>ONT::ACTIVATE</type><features><inevent id="V3439332" /></features><predicate end="273" id="V3439343" start="229"><type>ONT::ACTIVATE</type><text>PKC-dependent activation of mTOR and p70S6K</text></predicate><arg2 end="273" id="V3439389" role=":AFFECTED" start="254"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR and p70S6K</text></arg2><text>PKC-dependent activation of mTOR and p70S6K</text></EVENT>
Argument:V3439389

<EVENT end="366" id="V3442080" lisp="(ONT::EVENT ONT::V3442080 ONT::INHIBIT :AFFECTED ONT::V3442106 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph252" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="335" uttnum="279"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="366" id="V3442080" start="335"><type>ONT::INHIBIT</type><text>.Rapamycin inhibited the FGF-2</text></predicate><arg2 end="366" id="V3442106" role=":AFFECTED" start="356"><type>ONT::GENE-PROTEIN</type><text normalization="">the FGF-2</text></arg2><text>.Rapamycin inhibited the FGF-2</text></EVENT>
Argument:V3442106

<EVENT end="495" id="V3454157" lisp="(ONT::EVENT ONT::V3454157 ONT::INHIBIT :AGENT ONT::V3454152 :FORCE ONT::TRUE :AFFECTED ONT::V3454178 :TENSE W::PAST)" paragraph="paragraph252" rule="-RULE30_1_AGENT_FORMAL-AGENT" start="450" uttnum="279"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="495" id="V3454157" start="450"><type>ONT::INHIBIT</type><text>PD098059 inhibited one and not the other [37]</text></predicate><arg1 end="459" id="V3454152" role=":AGENT" start="450"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">PD098059</text></arg1><arg2 end="495" id="V3454178" role=":AFFECTED" start="469"><type>ONT::NUMBER</type><text normalization="">one and not the other [37]</text></arg2><text>PD098059 inhibited one and not the other [37]</text></EVENT>
Argument:V3454152
Argument:V3454178

SENTENCES EXTRACTED:
In vascular smooth muscle cells under hyperglycemic conditions (25 mM versus 5 mM glucose), inhibition of PI3K with LY294002 or inhibition of mTOR by rapamycin reduced the level of ERK Tyr-phosphorylation [35].In cardiomyocytes, PKC-dependent activation of mTOR and p70S6K was inhibited by U0126, implicating a requirement for MEK [36] .Rapamycin inhibited the FGF-2 induced proliferation of two different small cell lung cancer lines (SCLC), whereas PD098059 inhibited one and not the other [37] .Combination of rapamycin and PD098059 was not tested.
1289294P2-2.txt

EVENTS EXTRACTED:
<EVENT end="118" id="V1410580" lisp="(ONT::EVENT ONT::V1410580 ONT::MODULATE :AGENT ONT::V1410636 :FORCE ONT::TRUE)" paragraph="paragraph193" rule="-RULE10_1_AGENT_AFFECTED-AGENT" start="42" uttnum="220"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="118" id="V1410580" start="42"><type>ONT::MODULATE</type><text>the effects of BAY 43-9006 in combination with any other kinase inhibitors..</text></predicate><arg1 end="69" id="V1410636" role=":AGENT" start="54"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">of BAY 43-9006</text></arg1><text>the effects of BAY 43-9006 in combination with any other kinase inhibitors..</text></EVENT>
Argument:V1410636

SENTENCES EXTRACTED:
However, these studies have not addressed the effects of BAY 43-9006 in combination with any other kinase inhibitors..
1289294P13.txt

EVENTS EXTRACTED:
<EVENT end="147" id="V2112300" lisp="(ONT::EVENT ONT::V2112300 ONT::BIND :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph214" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="74" uttnum="241"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="147" id="V2112300" start="74"><type>ONT::BIND</type><text>was purchased from Upstate.4E-BP1 Antibody (Catalog #9452, used at 1:500)</text></predicate><text>was purchased from Upstate.4E-BP1 Antibody (Catalog #9452, used at 1:500)</text></EVENT>

<EVENT end="420" id="V2137866" lisp="(ONT::EVENT ONT::V2137866 ONT::BIND :FORCE ONT::TRUE)" paragraph="paragraph214" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="365" uttnum="241"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="420" id="V2137866" start="365"><type>ONT::BIND</type><text>purchased from Upstate.Anti-MAP Kinase 2/ERK2 antibody</text></predicate><text>purchased from Upstate.Anti-MAP Kinase 2/ERK2 antibody</text></EVENT>

<EVENT end="497" id="V2152268" lisp="(ONT::EVENT ONT::V2152268 ONT::BIND :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph214" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="453" uttnum="241"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="497" id="V2152268" start="453"><type>ONT::BIND</type><text>was also purchased from Upstate.Phospho-MEK1</text></predicate><text>was also purchased from Upstate.Phospho-MEK1</text></EVENT>

<EVENT end="587" id="V2152403" lisp="(ONT::EVENT ONT::V2152403 ONT::BIND :AFFECTED ONT::V2152311 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph214" rule="-RULE40_4_AGENT_AFFECTED-AFFECTED" start="498" uttnum="241"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="587" id="V2152403" start="498"><type>ONT::BIND</type><text>2 (Ser217/221) Antibody (Catalog#2354S, used at 1:1000) was purchased from Cell Signaling</text></predicate><arg2 end="554" id="V2152311" role=":AFFECTED" start="498"><type>ONT::PROTEIN</type><text normalization="">2 (Ser217/221) Antibody (Catalog#2354S, used at 1:1000)</text></arg2><text>2 (Ser217/221) Antibody (Catalog#2354S, used at 1:1000) was purchased from Cell Signaling</text></EVENT>
Argument:V2152311

SENTENCES EXTRACTED:
Anti-p70S6 Kinase, clone SB20 Antibody (Catalog # 05-781, used at 1:8000) was purchased from Upstate.4E-BP1 Antibody (Catalog #9452, used at 1:500) was purchased from Cell Signaling.GAPDH Antibody (Catalog # MAB374, used at 1:500) was purchased from Chemicon International.Anti-phospho MAP Kinase (ERK1/2), clone 12D4 antibody (Catalog # 05-481, used at 1:500) was purchased from Upstate.Anti-MAP Kinase 2/ERK2 antibody (Catalog #06-333, used at 1:500) was also purchased from Upstate.Phospho-MEK1/2 (Ser217/221) Antibody (Catalog#2354S, used at 1:1000) was purchased from Cell Signaling.
1289294P11-1.txt

EVENTS EXTRACTED:
<EVENT end="59" id="V2072262" lisp="(ONT::EVENT ONT::V2072262 ONT::MODULATE :AFFECTED ONT::V2072251)" paragraph="paragraph212" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="27" uttnum="239"><type>ONT::MODULATE</type><predicate end="59" id="V2072262" start="27"><type>ONT::MODULATE</type><text>a loading control (bottom panel)</text></predicate><arg2 end="37" id="V2072251" role=":AFFECTED" start="29"><type>ONT::BIND</type><text normalization="">loading</text></arg2><text>a loading control (bottom panel)</text></EVENT>
Argument:V2072251
NESTED EVENT!!!

<EVENT end="37" id="V2072251" lisp="(ONT::EVENT ONT::V2072251 ONT::BIND)" paragraph="paragraph212" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="29" uttnum="239"><type>ONT::BIND</type><predicate end="37" id="V2072251" start="29"><type>ONT::BIND</type><text>loading</text></predicate><text>loading</text></EVENT>

SENTENCES EXTRACTED:
GAPDH was immunoblotted as a loading control (bottom panel)..
1289294P25-2.txt

EVENTS EXTRACTED:
<EVENT end="67" id="V3036047" lisp="(ONT::EVENT ONT::V3036047 ONT::INHIBIT :AFFECTED ONT::V3036065)" paragraph="paragraph240" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="267"><type>ONT::INHIBIT</type><predicate end="67" id="V3036047" start="0"><type>ONT::INHIBIT</type><text>This inhibition of ERK phosphorylation by combination of rapamycin</text></predicate><arg2 end="39" id="V3036065" role=":AFFECTED" start="16"><type>ONT::PHOSPHORYLATION</type><text normalization="">of ERK phosphorylation</text></arg2><text>This inhibition of ERK phosphorylation by combination of rapamycin</text></EVENT>
Argument:V3036065
NESTED EVENT!!!

<EVENT end="39" id="V3036065" lisp="(ONT::EVENT ONT::V3036065 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph240" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="16" uttnum="267"><type>ONT::PHOSPHORYLATION</type><predicate end="39" id="V3036065" start="16"><type>ONT::PHOSPHORYLATION</type><text>of ERK phosphorylation</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>of ERK phosphorylation</text></EVENT>

<EVENT end="142" id="V3036296" lisp="(ONT::EVENT ONT::V3036296 ONT::INHIBIT :AFFECTED ONT::V3036311)" paragraph="paragraph240" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="102" uttnum="267"><type>ONT::INHIBIT</type><predicate end="142" id="V3036296" start="102"><type>ONT::INHIBIT</type><text>inhibition of MEK by the U0126 compound</text></predicate><arg2 end="120" id="V3036311" role=":AFFECTED" start="113"><type>ONT::PROTEIN-FAMILY</type><text normalization="">of MEK</text></arg2><text>inhibition of MEK by the U0126 compound</text></EVENT>
Argument:V3036311

SENTENCES EXTRACTED:
This inhibition of ERK phosphorylation by combination of rapamycin and BAY43-9006 was as effective as inhibition of MEK by the U0126 compound (Figure 5, compare lanes 5 and 6)..
1289294P10-1.txt

EVENTS EXTRACTED:
<EVENT end="318" id="V1978866" lisp="(ONT::EVENT ONT::V1978866 ONT::TRANSFORM :AFFECTED ONT::V1978844 :FORCE ONT::TRUE :FREQUENCY (ONT::REPETITION W::TWICE) :TENSE W::PAST :PASSIVE +)" paragraph="paragraph209" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="272" uttnum="236"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><mods><frequency><type>ONT::REPETITION</type><value>TWICE</value></frequency></mods><predicate end="318" id="V1978866" start="272"><type>ONT::TRANSFORM</type><text>the pellet was washed twice with cold acetone</text></predicate><arg2 end="283" id="V1978844" role=":AFFECTED" start="272"><type>ONT::EVENT-OF-CHANGE</type><text normalization="PELLET">the pellet</text></arg2><text>the pellet was washed twice with cold acetone</text></EVENT>
Argument:V1978844

SENTENCES EXTRACTED:
Cells were lysed in one ml of ice-cold 5% trichloroacetic acid for 10 minutes, scraped from the dish using a Costar cell lifter and the slurry was transferred to a 1.5-ml microcentrifuge tube and centrifuged for 10 minutes at 10,000 Ã— g.The supernatant was discarded, and the pellet was washed twice with cold acetone to extract away the trichloroacetic acid and the proteins resuspended in resolubilization buffer (20 mM Tris, 23 mM glycine, 1 mM EDTA, and 10 mM Î²-glycerophosphate) .Protein yields were determined by BCA analysis.
1289294P18-1.txt

EVENTS EXTRACTED:
<EVENT end="102" id="V2399009" lisp="(ONT::EVENT ONT::V2399009 ONT::TRANSFORM :FORCE ONT::TRUE :AGENT ONT::V2398989 :TENSE W::PAST)" paragraph="paragraph224" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="64" uttnum="251"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="102" id="V2399009" start="64"><type>ONT::TRANSFORM</type><text>cell numbers decreased after two days,</text></predicate><arg1 end="77" id="V2398989" role=":AGENT" start="64"><type>ONT::QUANTITY-ABSTR</type><text normalization="NUMBER">cell numbers</text></arg1><text>cell numbers decreased after two days,</text></EVENT>
Argument:V2398989

<EVENT end="218" id="V2412539" lisp="(ONT::EVENT ONT::V2412539 ONT::INHIBIT :INEVENT ONT::V2412527 :EPI ONT::V2412493)" paragraph="paragraph224" rule="-INEVENT2B,-RULE50_0_AGENT_FORMAL-EVENT,-RULE30_1_AGENT_FORMAL-NONE" start="168" uttnum="251"><type>ONT::INHIBIT</type><epistemic-modality id="V2412493" /><features><inevent id="V2412527" /></features><predicate end="218" id="V2412539" start="168"><type>ONT::INHIBIT</type><text>cells showed dose-dependent inhibition with 0.01 n</text></predicate><text>cells showed dose-dependent inhibition with 0.01 n</text></EVENT>

SENTENCES EXTRACTED:
We found that micromolar concentrations were cytotoxic, because cell numbers decreased after two days, whereas nanomolar concentrations were growth inhibitory.Melanoma cells showed dose-dependent inhibition with 0.01 nM to 100 nM of BAY43-9006 (Figure 2A), or rapamycin (Figure 2B) .Proliferation of the cells was inhibited in either 5% or 0.5% serum..
1289294P22.txt

EVENTS EXTRACTED:
<EVENT end="243" id="V2715825" lisp="(ONT::EVENT ONT::V2715825 ONT::BIND :AFFECTED ONT::V2715835 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph232" rule="-RULE40_4_AFFECTED_AFFECTED1-ROBUSTPRO-AFFECTED-ONLY" start="232" uttnum="259"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="243" id="V2715825" start="232"><type>ONT::BIND</type><text>pairs that</text></predicate><arg2 end="243" id="V2715835" role=":AFFECTED" start="238"><type>ONT::REFERENTIAL-SEM</type><text normalization="THAT">that</text></arg2><text>pairs that</text></EVENT>
Argument:V2715835

SENTENCES EXTRACTED:
Isobologram analyses of inhibition of melanoma cell proliferation.A, VMM39 melanoma cells, B, VMM5A melanoma cells, and C, VMM18 melanoma cells.The straight line connecting the IC70 points (additivity line) is the locus of all dose pairs that should give the same effect.A dose pair (data point) below the line is synergistic, a dose pair on the line is additive, and a dose pair above the line is antagonistic.Note: all graphs are on a log-scale..
1289294P23.txt

EVENTS EXTRACTED:
<EVENT end="105" id="V2744109" lisp="(ONT::EVENT ONT::V2744109 ONT::MODULATE :AFFECTED ONT::V2744087 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph233" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="260"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="105" id="V2744109" start="0"><type>ONT::MODULATE</type><text>Melanoma cells were treated with rapamycin and BAY 43-9006, either singly or in combination, for one hour</text></predicate><arg2 end="15" id="V2744087" role=":AFFECTED" start="0"><type>ONT::CELL</type><text normalization="">Melanoma cells</text></arg2><text>Melanoma cells were treated with rapamycin and BAY 43-9006, either singly or in combination, for one hour</text></EVENT>
Argument:V2744087

<EVENT end="173" id="V2755778" lisp="(ONT::EVENT ONT::V2755778 ONT::PTM :EPI ONT::V2755852 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph233" rule="-RULE50_0_AGENT_NEUTRAL-EVENT,-RULE50_4_AGENT_AFFECTED-NONE" start="111" uttnum="260"><type>ONT::PTM</type><name>protein phosphorylation</name><epistemic-modality id="V2755852" /><predicate end="173" id="V2755778" start="111"><type>ONT::PTM</type><text>protein phosphorylation was examined by Western blot analysis</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>protein phosphorylation was examined by Western blot analysis</text></EVENT>

<EVENT end="257" id="V2756039" lisp="(ONT::EVENT ONT::V2756039 ONT::DECREASE :AFFECTED ONT::V2756044 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph233" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="233" uttnum="260"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="257" id="V2756039" start="233"><type>ONT::DECREASE</type><text>reduces phosphorylation</text></predicate><arg2 end="257" id="V2756044" role=":AFFECTED" start="241"><type>ONT::PHOSPHORYLATION</type><text normalization="">phosphorylation</text></arg2><text>reduces phosphorylation</text></EVENT>
Argument:V2756044
NESTED EVENT!!!

<EVENT end="229" id="V2755979" lisp="(ONT::EVENT ONT::V2755979 ONT::INHIBIT :AFFECTED ONT::V2756025 :FORCE ONT::TRUE)" paragraph="paragraph233" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="201" uttnum="260"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="229" id="V2755979" start="201"><type>ONT::INHIBIT</type><text>an inhibitor of mTOR kinase</text></predicate><arg2 end="229" id="V2756025" role=":AFFECTED" start="214"><type>ONT::GENE-PROTEIN</type><text normalization="">of mTOR kinase</text></arg2><text>an inhibitor of mTOR kinase</text></EVENT>
Argument:V2756025

<EVENT end="257" id="V2756044" lisp="(ONT::EVENT ONT::V2756044 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph233" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="241" uttnum="260"><type>ONT::PHOSPHORYLATION</type><predicate end="257" id="V2756044" start="241"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation</text></EVENT>

<EVENT end="362" id="V2769951" lisp="(ONT::EVENT ONT::V2769951 ONT::DECREASE :AFFECTED ONT::V2769801 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph233" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="298" uttnum="260"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="362" id="V2769951" start="298"><type>ONT::DECREASE</type><text>BAY 43-9006 is a chemical inhibitor of B-Raf kinase and reduces</text></predicate><arg2 end="310" id="V2769801" role=":AFFECTED" start="298"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">BAY 43-9006</text></arg2><text>BAY 43-9006 is a chemical inhibitor of B-Raf kinase and reduces</text></EVENT>
Argument:V2769801

<EVENT end="350" id="V2769870" lisp="(ONT::EVENT ONT::V2769870 ONT::INHIBIT :AFFECTED ONT::V2769931)" paragraph="paragraph233" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="313" uttnum="260"><type>ONT::INHIBIT</type><predicate end="350" id="V2769870" start="313"><type>ONT::INHIBIT</type><text>a chemical inhibitor of B-Raf kinase</text></predicate><arg2 end="350" id="V2769931" role=":AFFECTED" start="334"><type>ONT::GENE-PROTEIN</type><text normalization="">of B-Raf kinase</text></arg2><text>a chemical inhibitor of B-Raf kinase</text></EVENT>
Argument:V2769931

<EVENT end="400" id="V2769955" lisp="(ONT::EVENT ONT::V2769955 ONT::PHOSPHORYLATION :AFFECTED ONT::V2769980 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph233" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="362" uttnum="260"><type>ONT::PHOSPHORYLATION</type><predicate end="400" id="V2769955" start="362"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation of MEK and ERK [26,27]</text></predicate><arg2 end="393" id="V2769980" role=":AFFECTED" start="378"><type>ONT::GENE-PROTEIN</type><text normalization="">of MEK and ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation of MEK and ERK [26,27]</text></EVENT>
Argument:V2769980

<EVENT end="505" id="V2785578" lisp="(ONT::EVENT ONT::V2785578 ONT::STIMULATE :AGENT ONT::V2785459 :AFFECTED ONT::V2785581 :FORCE ONT::TRUE :TENSE W::PAST :PERF +)" paragraph="paragraph233" rule="-RULE30_1_AGENT_AFFECTED" start="401" uttnum="260"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="505" id="V2785578" start="401"><type>ONT::STIMULATE</type><text>VMM18 melanoma cells grown in the presence of 5% serum had enhanced phosphorylation of p70S6K and 4EBP1</text></predicate><arg1 end="456" id="V2785459" role=":AGENT" start="401"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells grown in the presence of 5% serum</text></arg1><arg2 end="505" id="V2785581" role=":AFFECTED" start="469"><type>ONT::PHOSPHORYLATION</type><text normalization="">phosphorylation of p70S6K and 4EBP1</text></arg2><text>VMM18 melanoma cells grown in the presence of 5% serum had enhanced phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2785459
Argument:V2785581
NESTED EVENT!!!

<EVENT end="505" id="V2785581" lisp="(ONT::EVENT ONT::V2785581 ONT::PHOSPHORYLATION :AFFECTED ONT::V2785653 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph233" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="469" uttnum="260"><type>ONT::PHOSPHORYLATION</type><predicate end="505" id="V2785581" start="469"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="505" id="V2785653" role=":AFFECTED" start="485"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2785653

<EVENT end="456" id="V2785465" lisp="(ONT::EVENT ONT::V2785465 ONT::INCREASE :AFFECTED ONT::V2785459 :FORCE ONT::TRUE)" paragraph="paragraph233" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="401" uttnum="260"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="456" id="V2785465" start="401"><type>ONT::INCREASE</type><text>VMM18 melanoma cells grown in the presence of 5% serum</text></predicate><arg2 end="456" id="V2785459" role=":AFFECTED" start="401"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells grown in the presence of 5% serum</text></arg2><text>VMM18 melanoma cells grown in the presence of 5% serum</text></EVENT>
Argument:V2785459

SENTENCES EXTRACTED:
Melanoma cells were treated with rapamycin and BAY 43-9006, either singly or in combination, for one hour, and protein phosphorylation was examined by Western blot analysis 24 hours later.Rapamycin is an inhibitor of mTOR kinase and reduces phosphorylation of its substrates, p70S6K and 4EBP1 [17] .BAY 43-9006 is a chemical inhibitor of B-Raf kinase and reduces phosphorylation of MEK and ERK [26,27] .VMM18 melanoma cells grown in the presence of 5% serum had enhanced phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 2) relative to cells grown in the absence of serum (Figure 4, PBS, lane 1).
1289294P1.txt

EVENTS EXTRACTED:
<EVENT end="193" id="V1270686" lisp="(ONT::EVENT ONT::V1270686 ONT::DECREASE :AGENT ONT::V1270660 :MODALITY (ONT::ABILITY W::CAN) :FORCE ONT::POSSIBLE :TENSE W::PRES)" paragraph="paragraph189" rule="-RULE20_1_AGENT_AFFECTED-ROBUSTPRO-AGENT-ONLY" start="112" uttnum="216"><type>ONT::DECREASE</type><force>ONT::POSSIBLE</force><modality>W::CAN</modality><predicate end="193" id="V1270686" start="112"><type>ONT::DECREASE</type><text>for development of effective therapies that can slow progression of solid tumors</text></predicate><arg1 end="156" id="V1270660" role=":AGENT" start="151"><type>ONT::REFERENTIAL-SEM</type><text normalization="THAT">that</text></arg1><text>for development of effective therapies that can slow progression of solid tumors</text></EVENT>
Argument:V1270660

<EVENT end="193" id="V1270692" lisp="(ONT::EVENT ONT::V1270692 ONT::INCREASE :AFFECTED ONT::V1270723)" paragraph="paragraph189" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="165" uttnum="216"><type>ONT::INCREASE</type><predicate end="193" id="V1270692" start="165"><type>ONT::INCREASE</type><text>progression of solid tumors</text></predicate><arg2 end="193" id="V1270723" role=":AFFECTED" start="177"><type>ONT::CANCER</type><text normalization="">of solid tumors</text></arg2><text>progression of solid tumors</text></EVENT>
Argument:V1270723

<EVENT end="225" id="V1270753" lisp="(ONT::EVENT ONT::V1270753 ONT::INHIBIT :AFFECTED ONT::V1270765 :FORCE ONT::TRUE)" paragraph="paragraph189" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="193" uttnum="216"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="225" id="V1270753" start="193"><type>ONT::INHIBIT</type><text>by blocking the action of those</text></predicate><arg2 end="225" id="V1270765" role=":AFFECTED" start="205"><type>ONT::ACTIVITY-EVENT</type><text normalization="ACTION">the action of those</text></arg2><text>by blocking the action of those</text></EVENT>
Argument:V1270765

<EVENT end="350" id="V1270891" lisp="(ONT::EVENT ONT::V1270891 ONT::PRODUCE :FORCE ONT::TRUE)" paragraph="paragraph189" rule="-RULE40_2_AGENT_AFFECTED-RESULT-NONE" start="281" uttnum="216"><type>ONT::PRODUCE</type><force>ONT::TRUE</force><predicate end="350" id="V1270891" start="281"><type>ONT::PRODUCE</type><text>based on the therapeutic effectiveness of imatinib mesylate (Gleevec)</text></predicate><text>based on the therapeutic effectiveness of imatinib mesylate (Gleevec)</text></EVENT>

<EVENT end="445" id="V1281795" lisp="(ONT::EVENT ONT::V1281795 ONT::INHIBIT :AFFECTED ONT::V1281884 :FORCE ONT::TRUE)" paragraph="paragraph189" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="377" uttnum="216"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="445" id="V1281795" start="377"><type>ONT::INHIBIT</type><text>a specific inhibitor of the BCR-ABL oncogene protein tyrosine kinase</text></predicate><arg2 end="445" id="V1281884" role=":AFFECTED" start="398"><type>ONT::PROTEIN</type><text normalization="">of the BCR-ABL oncogene protein tyrosine kinase</text></arg2><text>a specific inhibitor of the BCR-ABL oncogene protein tyrosine kinase</text></EVENT>
Argument:V1281884

SENTENCES EXTRACTED:
In human cancers, mutant oncogenes are frequently associated with disease progression [1].Thus, there is a need for development of effective therapies that can slow progression of solid tumors by blocking the action of those oncogenes.Cancer therapy has undergone a paradigm shift based on the therapeutic effectiveness of imatinib mesylate (Gleevec) .This drug was designed as a specific inhibitor of the BCR-ABL oncogene protein tyrosine kinase, known to be responsible for chronic myeloid leukemia (CML) cells [2].
1289294P31.txt

EVENTS EXTRACTED:
<EVENT end="388" id="V3392283" lisp="(ONT::EVENT ONT::V3392283 ONT::INHIBIT :EPI ONT::V3392171 :AFFECTED ONT::V3392310 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph251" rule="-RULE50_0_AGENT_FORMAL-EVENT,-RULE30_1_AGENT_AFFECTED-AFFECTED" start="301" uttnum="278"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><epistemic-modality id="V3392171" /><predicate end="388" id="V3392283" start="301"><type>ONT::INHIBIT</type><text>we found that BAY43-9006 inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="388" id="V3392310" role=":AFFECTED" start="336"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of p70S6K and 4EBP1</text></arg2><text>we found that BAY43-9006 inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V3392310
NESTED EVENT!!!

<EVENT end="388" id="V3392310" lisp="(ONT::EVENT ONT::V3392310 ONT::PHOSPHORYLATION :INEVENT ONT::V3392298 :AFFECTED ONT::V3392382 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph251" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="336" uttnum="278"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V3392298" /></features><predicate end="388" id="V3392310" start="336"><type>ONT::PHOSPHORYLATION</type><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="388" id="V3392382" role=":AFFECTED" start="369"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V3392382

<EVENT end="388" id="V3392298" lisp="(ONT::EVENT ONT::V3392298 ONT::STIMULATE :AFFECTED ONT::V3392310 :FORCE ONT::TRUE)" paragraph="paragraph251" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="336" uttnum="278"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="388" id="V3392298" start="336"><type>ONT::STIMULATE</type><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="388" id="V3392310" role=":AFFECTED" start="336"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of p70S6K and 4EBP1</text></arg2><text>serum-stimulated phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V3392310
NESTED EVENT!!!

<EVENT end="463" id="V3405387" lisp="(ONT::EVENT ONT::V3405387 ONT::INHIBIT :AGENT ONT::V3405373 :AFFECTED ONT::V3405414 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph251" rule="-RULE30_1_AGENT_AFFECTED" start="394" uttnum="278"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="463" id="V3405387" start="394"><type>ONT::INHIBIT</type><text>rapamycin blocked serum-stimulated phosphorylation of ERK.Previously</text></predicate><arg1 end="404" id="V3405373" role=":AGENT" start="394"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">rapamycin</text></arg1><arg2 end="463" id="V3405414" role=":AFFECTED" start="412"><type>ONT::PHOSPHORYLATION</type><text normalization="PHOSPHORYLATION">serum-stimulated phosphorylation of ERK.Previously</text></arg2><text>rapamycin blocked serum-stimulated phosphorylation of ERK.Previously</text></EVENT>
Argument:V3405373
Argument:V3405414

<EVENT end="463" id="V3405401" lisp="(ONT::EVENT ONT::V3405401 ONT::STIMULATE :AFFECTED ONT::V3405414 :FORCE ONT::TRUE)" paragraph="paragraph251" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="412" uttnum="278"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="463" id="V3405401" start="412"><type>ONT::STIMULATE</type><text>serum-stimulated phosphorylation of ERK.Previously</text></predicate><arg2 end="463" id="V3405414" role=":AFFECTED" start="412"><type>ONT::PHOSPHORYLATION</type><text normalization="PHOSPHORYLATION">serum-stimulated phosphorylation of ERK.Previously</text></arg2><text>serum-stimulated phosphorylation of ERK.Previously</text></EVENT>
Argument:V3405414

<EVENT end="558" id="V3405553" lisp="(ONT::EVENT ONT::V3405553 ONT::SIGNALING)" paragraph="paragraph251" rule="-RULE5_1_AGENT_AFFECTED-NONE" start="541" uttnum="278"><type>ONT::SIGNALING</type><predicate end="558" id="V3405553" start="541"><type>ONT::SIGNALING</type><text>signaling [35-40]</text></predicate><text>signaling [35-40]</text></EVENT>

SENTENCES EXTRACTED:
Our results indicate that rapamycin and BAY43-9006 inhibit their cognate targets in melanoma cells (mTOR and B-Raf respectively), as well as downstream effectors thought to be in other pathways, providing evidence for cellular cross-talk between the different signaling pathways studied.Specifically, we found that BAY43-9006 inhibited serum-stimulated phosphorylation of p70S6K and 4EBP1, and rapamycin blocked serum-stimulated phosphorylation of ERK.Previously published results have suggested interdependence between mTOR and Raf-MEK-ERK signaling [35-40].
1289294P17-1.txt

EVENTS EXTRACTED:
<EVENT end="78" id="V2366503" lisp="(ONT::EVENT ONT::V2366503 ONT::PHOSPHORYLATION :AFFECTED ONT::V2366561 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph222" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="20" uttnum="249"><type>ONT::PHOSPHORYLATION</type><predicate end="78" id="V2366503" start="20"><type>ONT::PHOSPHORYLATION</type><text>the relative phosphorylation of ERK relative to total ERK</text></predicate><arg2 end="78" id="V2366561" role=":AFFECTED" start="49"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK relative to total ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the relative phosphorylation of ERK relative to total ERK</text></EVENT>
Argument:V2366561

SENTENCES EXTRACTED:
The quantitation of the relative phosphorylation of ERK relative to total ERK is shown between the blots, demonstrating about a two-fold increase in phosphorylation.The phosphorylation of ERK paralleled the relative increase in proliferation for each of these cell lines..
1289294P5.txt

EVENTS EXTRACTED:
<EVENT end="464" id="V1633470" lisp="(ONT::EVENT ONT::V1633470 ONT::TRANSFORM :AFFECTED ONT::V1633446 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph199" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="398" uttnum="226"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="464" id="V1633470" start="398"><type>ONT::TRANSFORM</type><text>cells were incubated in Dulbecco's Phosphate buffered saline (PBS)</text></predicate><arg2 end="404" id="V1633446" role=":AFFECTED" start="398"><type>ONT::CELL</type><text normalization="">cells</text></arg2><text>cells were incubated in Dulbecco's Phosphate buffered saline (PBS)</text></EVENT>
Argument:V1633446

<EVENT end="635" id="V1644819" lisp="(ONT::EVENT ONT::V1644819 ONT::TRANSFORM)" paragraph="paragraph199" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="622" uttnum="226"><type>ONT::TRANSFORM</type><predicate end="635" id="V1644819" start="622"><type>ONT::TRANSFORM</type><text>mutation [23]</text></predicate><text>mutation [23]</text></EVENT>

SENTENCES EXTRACTED:
Melanoma cell lines used in this study were derived from tumors from patients at the University of Virginia (VMM5A, VMM18, and VMM39), as described previously [21,22] .All of the cell lines were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum, 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100 Î¼g/ml) at 37Â°C in 5% CO2, unless otherwise indicated.As a control, cells were incubated in Dulbecco's Phosphate buffered saline (PBS) .VMM39 is a representative cell line from human melanomas known to contain a wild-type B-Raf gene and VMM18 and VMM5A both contain the V599E B-Raf activating mutation [23].
1289294P25-1.txt

EVENTS EXTRACTED:
<EVENT end="72" id="V2982378" lisp="(ONT::EVENT ONT::V2982378 ONT::INHIBIT :AFFECTED ONT::V2982429)" paragraph="paragraph239" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="30" uttnum="266"><type>ONT::INHIBIT</type><predicate end="72" id="V2982378" start="30"><type>ONT::INHIBIT</type><text>with the inhibition of B-Raf by BAY43-9006</text></predicate><arg2 end="59" id="V2982429" role=":AFFECTED" start="50"><type>ONT::GENE-PROTEIN</type><text normalization="">of B-Raf</text></arg2><text>with the inhibition of B-Raf by BAY43-9006</text></EVENT>
Argument:V2982429

<EVENT end="161" id="V2994223" lisp="(ONT::EVENT ONT::V2994223 ONT::MODULATE :AFFECTED ONT::V2994201 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph239" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="92" uttnum="266"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="161" id="V2994223" start="92"><type>ONT::MODULATE</type><text>when VMM18 melanoma cells were treated with a 10 nM dose of rapamycin</text></predicate><arg2 end="118" id="V2994201" role=":AFFECTED" start="97"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells</text></arg2><text>when VMM18 melanoma cells were treated with a 10 nM dose of rapamycin</text></EVENT>
Argument:V2994201

<EVENT end="239" id="V3007093" lisp="(ONT::EVENT ONT::V3007093 ONT::DECREASE :AFFECTED ONT::V3007058 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph239" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="163" uttnum="266"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="239" id="V3007093" start="163"><type>ONT::DECREASE</type><text>the dual phosphorylation of ERK was reduced by about half (Figure 5, lane 3)</text></predicate><arg2 end="195" id="V3007058" role=":AFFECTED" start="163"><type>ONT::PHOSPHORYLATION</type><text normalization="">the dual phosphorylation of ERK</text></arg2><text>the dual phosphorylation of ERK was reduced by about half (Figure 5, lane 3)</text></EVENT>
Argument:V3007058
NESTED EVENT!!!

<EVENT end="195" id="V3007058" lisp="(ONT::EVENT ONT::V3007058 ONT::PHOSPHORYLATION :AFFECTED ONT::V3007071 :MODA (ONT::N-TUPLE-VAL W::DUAL) :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph239" rule="-RULE60_4_AGENT_AFFECTED-MODA1_1-AFFECTED" start="163" uttnum="266"><type>ONT::PHOSPHORYLATION</type><mods><mod><type>ONT::N-TUPLE-VAL</type><value>DUAL</value></mod></mods><predicate end="195" id="V3007058" start="163"><type>ONT::PHOSPHORYLATION</type><text>the dual phosphorylation of ERK</text></predicate><arg2 end="195" id="V3007071" role=":AFFECTED" start="188"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the dual phosphorylation of ERK</text></EVENT>
Argument:V3007071

<EVENT end="296" id="V3023721" lisp="(ONT::EVENT ONT::V3023721 ONT::ACTIVITY :AGENT ONT::V3023718)" paragraph="paragraph239" rule="-ACTIVITY1" start="282" uttnum="266"><type>ONT::ACTIVITY</type><predicate end="296" id="V3023721" start="282"><type>ONT::ACTIVITY</type><text>mTOR activity</text></predicate><arg1 end="287" id="V3023718" role=":AGENT" start="282"><type>ONT::GENE-PROTEIN</type><text normalization="">mTOR</text></arg1><text>mTOR activity</text></EVENT>
Argument:V3023718

<EVENT end="364" id="V3023776" lisp="(ONT::EVENT ONT::V3023776 ONT::NO-CHANGE :AFFECTED ONT::V3023786 :FORCE ONT::TRUE)" paragraph="paragraph239" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="308" uttnum="266"><type>ONT::NO-CHANGE</type><force>ONT::TRUE</force><predicate end="364" id="V3023776" start="308"><type>ONT::NO-CHANGE</type><text>to maintain the phosphorylation of ERK in melanoma cells</text></predicate><arg2 end="364" id="V3023786" role=":AFFECTED" start="320"><type>ONT::PHOSPHORYLATION</type><text normalization="">the phosphorylation of ERK in melanoma cells</text></arg2><text>to maintain the phosphorylation of ERK in melanoma cells</text></EVENT>
Argument:V3023786
NESTED EVENT!!!

<EVENT end="364" id="V3023786" lisp="(ONT::EVENT ONT::V3023786 ONT::PHOSPHORYLATION :AFFECTED ONT::V3023799 :LOC ONT::V3023887 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph239" rule="-RULE60_4_AGENT_AFFECTED-CELL_LOC2-GD-OTHERS-AFFECTED" start="320" uttnum="266"><type>ONT::PHOSPHORYLATION</type><predicate end="364" id="V3023786" start="320"><type>ONT::PHOSPHORYLATION</type><text>the phosphorylation of ERK in melanoma cells</text></predicate><arg2 end="347" id="V3023799" role=":AFFECTED" start="340"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><location end="364" id="V3023887" start="350"><type>ONT::CELL</type><text normalization="">melanoma cells</text></location><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the phosphorylation of ERK in melanoma cells</text></EVENT>
Argument:V3023799

<EVENT end="416" id="V3023907" lisp="(ONT::EVENT ONT::V3023907 ONT::MODULATE :AFFECTED ONT::V3030940)" paragraph="paragraph239" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="365" uttnum="266"><type>ONT::MODULATE</type><predicate end="416" id="V3023907" start="365"><type>ONT::MODULATE</type><text>Combination treatment of a 10 nM dose of rapamycin</text></predicate><arg2 end="416" id="V3030940" role=":AFFECTED" start="387"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">of a 10 nM dose of rapamycin</text></arg2><text>Combination treatment of a 10 nM dose of rapamycin</text></EVENT>
Argument:V3030940

<EVENT end="500" id="V3024269" lisp="(ONT::EVENT ONT::V3024269 ONT::DECREASE :AGENT ONT::V3024264 :AFFECTED ONT::V3024281 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph239" rule="-RULE20_1_AGENT_AFFECTED" start="437" uttnum="266"><type>ONT::DECREASE</type><force>ONT::TRUE</force><predicate end="500" id="V3024269" start="437"><type>ONT::DECREASE</type><text>BAY 43-9006 reduced the phosphorylation of ERK to a level even</text></predicate><arg1 end="449" id="V3024264" role=":AGENT" start="437"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">BAY 43-9006</text></arg1><arg2 end="484" id="V3024281" role=":AFFECTED" start="457"><type>ONT::PHOSPHORYLATION</type><text normalization="">the phosphorylation of ERK</text></arg2><text>BAY 43-9006 reduced the phosphorylation of ERK to a level even</text></EVENT>
Argument:V3024264
Argument:V3024281
NESTED EVENT!!!

<EVENT end="484" id="V3024281" lisp="(ONT::EVENT ONT::V3024281 ONT::PHOSPHORYLATION :AFFECTED ONT::V3024294 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph239" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="457" uttnum="266"><type>ONT::PHOSPHORYLATION</type><predicate end="484" id="V3024281" start="457"><type>ONT::PHOSPHORYLATION</type><text>the phosphorylation of ERK</text></predicate><arg2 end="484" id="V3024294" role=":AFFECTED" start="477"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the phosphorylation of ERK</text></EVENT>
Argument:V3024294

SENTENCES EXTRACTED:
These results were consistent with the inhibition of B-Raf by BAY43-9006.On the other hand, when VMM18 melanoma cells were treated with a 10 nM dose of rapamycin, the dual phosphorylation of ERK was reduced by about half (Figure 5, lane 3) .Our interpretation of this result is that mTOR activity is required to maintain the phosphorylation of ERK in melanoma cells.Combination treatment of a 10 nM dose of rapamycin plus a 10 nM dose of BAY 43-9006 reduced the phosphorylation of ERK to a level even below that seen in cells grown in the absence of serum (Figure 5, lane 5).
1289294P3-1.txt

EVENTS EXTRACTED:
<EVENT end="24" id="V1489928" lisp="(ONT::EVENT ONT::V1489928 ONT::ACTIVITY :AGENT ONT::V1489940)" paragraph="paragraph195" rule="-ACTIVITY1" start="0" uttnum="222"><type>ONT::ACTIVITY</type><predicate end="24" id="V1489928" start="0"><type>ONT::ACTIVITY</type><text>The action of rapamycin</text></predicate><arg1 end="24" id="V1489940" role=":AGENT" start="11"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">of rapamycin</text></arg1><text>The action of rapamycin</text></EVENT>
Argument:V1489940

<EVENT end="87" id="V1490013" lisp="(ONT::EVENT ONT::V1490013 ONT::BIND :AFFECTED ONT::V1490080)" paragraph="paragraph195" rule="-RULE40_4_AFFECTED_AFFECTED1-AFFECTED" start="49" uttnum="222"><type>ONT::BIND</type><predicate end="87" id="V1490013" start="49"><type>ONT::BIND</type><text>binding to the receptor protein FKBP12</text></predicate><arg2 end="87" id="V1490080" role=":AFFECTED" start="57"><type>ONT::PROTEIN</type><text normalization="">to the receptor protein FKBP12</text></arg2><text>binding to the receptor protein FKBP12</text></EVENT>
Argument:V1490080

<EVENT end="148" id="V1505041" lisp="(ONT::EVENT ONT::V1505041 ONT::BIND :AGENT ONT::V1505036 :AFFECTED ONT::V1505123 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph195" rule="-RULE40_4_AGENT_AFFECTED" start="89" uttnum="222"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="148" id="V1505041" start="89"><type>ONT::BIND</type><text>this drug-protein complex binds to the mTOR protein kinase</text></predicate><arg1 end="115" id="V1505036" role=":AGENT" start="89"><type>ONT::MEDICATION</type><text normalization="">this drug-protein complex</text></arg1><arg2 end="148" id="V1505123" role=":AFFECTED" start="121"><type>ONT::GENE-PROTEIN</type><text normalization="">to the mTOR protein kinase</text></arg2><text>this drug-protein complex binds to the mTOR protein kinase</text></EVENT>
Argument:V1505036
Argument:V1505123

<EVENT end="184" id="V1505137" lisp="(ONT::EVENT ONT::V1505137 ONT::INHIBIT :AGENT ONT::V1505036 :AFFECTED ONT::V1505153 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph195" rule="-RULE30_1_AGENT_AFFECTED" start="89" uttnum="222"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="184" id="V1505137" start="89"><type>ONT::INHIBIT</type><text>this drug-protein complex binds to the mTOR protein kinase and interferes with phosphorylation</text></predicate><arg1 end="115" id="V1505036" role=":AGENT" start="89"><type>ONT::MEDICATION</type><text normalization="">this drug-protein complex</text></arg1><arg2 end="184" id="V1505153" role=":AFFECTED" start="163"><type>ONT::PHOSPHORYLATION</type><text normalization="">with phosphorylation</text></arg2><text>this drug-protein complex binds to the mTOR protein kinase and interferes with phosphorylation</text></EVENT>
Argument:V1505036
Argument:V1505153
NESTED EVENT!!!

<EVENT end="184" id="V1505153" lisp="(ONT::EVENT ONT::V1505153 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph195" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="163" uttnum="222"><type>ONT::PHOSPHORYLATION</type><predicate end="184" id="V1505153" start="163"><type>ONT::PHOSPHORYLATION</type><text>with phosphorylation</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>with phosphorylation</text></EVENT>

<EVENT end="453" id="V1518037" lisp="(ONT::EVENT ONT::V1518037 ONT::INHIBIT :AFFECTED ONT::V1518091)" paragraph="paragraph195" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="406" uttnum="222"><type>ONT::INHIBIT</type><predicate end="453" id="V1518037" start="406"><type>ONT::INHIBIT</type><text>inhibition of cell growth and protein synthesis</text></predicate><arg2 end="453" id="V1518091" role=":AFFECTED" start="417"><type>ONT::EVENT-OF-CHANGE</type><text normalization="">of cell growth and protein synthesis</text></arg2><text>inhibition of cell growth and protein synthesis</text></EVENT>
Argument:V1518091

<EVENT end="453" id="V1518118" lisp="(ONT::EVENT ONT::V1518118 ONT::TRANSLATE :DRUM ((:DRUM (TERM :ID GO::|0006412| :NAME &quot;translation&quot; :SCORE 0.70732 :MATCHES ((MATCH :SCORE 0.70732 :MATCHED &quot;protein synthesis&quot; :STATUS &quot;EXACT synonym&quot; :EXACT 2)) :ONT-TYPES (ONT::GENE-TRANSLATION)) (SPECIALIST :EUI E0578981 :CITATION-FORM &quot;protein synthesis&quot; :MATCHES ((MATCH :SCORE 1.0 :MATCHED &quot;protein synthesis&quot; :EXACT 2))))))" paragraph="paragraph195" rule="-RULE50_4_AGENT_AFFECTED-NONE" start="436" uttnum="222"><type>ONT::TRANSLATE</type><predicate end="453" id="V1518118" start="436"><type>ONT::TRANSLATE</type><text>protein synthesis</text></predicate><drum-terms><drum-term dbid="GO:0006412" match-score="0.70732" matched-name="protein synthesis" name="translation"><types><type>ONT::GENE-TRANSLATION</type></types></drum-term></drum-terms><text>protein synthesis</text></EVENT>

<EVENT end="506" id="V1518289" lisp="(ONT::EVENT ONT::V1518289 ONT::PRODUCE :AGENT ONT::V1518341 :FORCE ONT::TRUE)" paragraph="paragraph195" rule="-RULE40_2_AGENT_AFFECTED-RESULT-AGENT" start="455" uttnum="222"><type>ONT::PRODUCE</type><force>ONT::TRUE</force><predicate end="506" id="V1518289" start="455"><type>ONT::PRODUCE</type><text>as well as cell cycle arrest, imposed by rapamycin</text></predicate><arg1 end="506" id="V1518341" role=":AGENT" start="493"><type>ONT::MOLECULE</type><text normalization="">by rapamycin</text></arg1><text>as well as cell cycle arrest, imposed by rapamycin</text></EVENT>
Argument:V1518341

SENTENCES EXTRACTED:
The action of rapamycin is understood to involve binding to the receptor protein FKBP12; this drug-protein complex binds to the mTOR protein kinase and interferes with phosphorylation of two well-recognized downstream targets, p70S6K (p70 ribosomal S6 kinase) and 4EBP1 (aka: 4E binding protein 1, eukaryotic translation initiation factor 4E binding protein, and PHAS-1) [17] .An appreciation of the potent inhibition of cell growth and protein synthesis, as well as cell cycle arrest, imposed by rapamycin led to testing of its derivatives, in particular CCI-779, as cytostatic agents, especially for various cancers refractory to other forms of cancer chemotherapy [18-20].
1289294P19.txt

EVENTS EXTRACTED:
<EVENT end="150" id="V2442616" lisp="(ONT::EVENT ONT::V2442616 ONT::STIMULATE :AFFECTED ONT::V2442630 :FORCE ONT::TRUE)" paragraph="paragraph225" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="73" uttnum="252"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="150" id="V2442616" start="73"><type>ONT::STIMULATE</type><text>The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></predicate><arg2 end="150" id="V2442630" role=":AFFECTED" start="73"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></arg2><text>The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells</text></EVENT>
Argument:V2442630

<EVENT end="304" id="V2456387" lisp="(ONT::EVENT ONT::V2456387 ONT::MODULATE)" paragraph="paragraph225" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="292" uttnum="252"><type>ONT::MODULATE</type><predicate end="304" id="V2456387" start="292"><type>ONT::MODULATE</type><text>the control</text></predicate><text>the control</text></EVENT>

<EVENT end="327" id="V2456408" lisp="(ONT::EVENT ONT::V2456408 ONT::INCREASE :AFFECTED ONT::V2456413 :FORCE ONT::TRUE)" paragraph="paragraph225" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="312" uttnum="252"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="327" id="V2456408" start="312"><type>ONT::INCREASE</type><text>any added drug</text></predicate><arg2 end="327" id="V2456413" role=":AFFECTED" start="312"><type>ONT::MEDICATION</type><text normalization="">any added drug</text></arg2><text>any added drug</text></EVENT>
Argument:V2456413

<EVENT end="396" id="V2456494" lisp="(ONT::EVENT ONT::V2456494 ONT::MODULATE :INEVENT ONT::V2456487)" paragraph="paragraph225" rule="-NEUTRALTOAGENT,-INEVENT2B,-RULE10_1_AGENT_AFFECTED-NONE" start="359" uttnum="252"><type>ONT::MODULATE</type><features><inevent id="V2456487" /></features><predicate end="396" id="V2456494" start="359"><type>ONT::MODULATE</type><text>following treatment with an inhibitor</text></predicate><text>following treatment with an inhibitor</text></EVENT>

<EVENT end="396" id="V2456487" lisp="(ONT::EVENT ONT::V2456487 ONT::TRANSLOCATE :AGENT ONT::V2456494 :FORCE ONT::TRUE)" paragraph="paragraph225" rule="-RULE10_4_AGENT_AFFECTED-AGENT" start="359" uttnum="252"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="396" id="V2456487" start="359"><type>ONT::TRANSLOCATE</type><text>following treatment with an inhibitor</text></predicate><arg1 end="396" id="V2456494" role=":AGENT" start="359"><type>ONT::MODULATE</type><text normalization="">following treatment with an inhibitor</text></arg1><text>following treatment with an inhibitor</text></EVENT>
Argument:V2456494

<EVENT end="429" id="V2456559" lisp="(ONT::EVENT ONT::V2456559 ONT::MODULATE :AFFECTED ONT::V2456527 :FORCE ONT::TRUE :FORMAL ONT::V2456624 :TENSE W::PAST :PASSIVE +)" paragraph="paragraph225" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="397" uttnum="252"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="429" id="V2456559" start="397"><type>ONT::MODULATE</type><text>Cells were treated for one hour</text></predicate><arg1 end="403" id="V2456527" role=":AFFECTED" start="397"><type>ONT::CELL</type><text normalization="">Cells</text></arg1><arg2 end="429" id="V2456624" role=":FORMAL" start="416"><type>ONT::QUANTITY</type><text normalization="">for one hour</text></arg2><text>Cells were treated for one hour</text></EVENT>
Argument:V2456527
Argument:V2456624

<EVENT end="537" id="V2456989" lisp="(ONT::EVENT ONT::V2456989 ONT::STIMULATE :AFFECTED ONT::V2457002 :FORCE ONT::TRUE)" paragraph="paragraph225" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="506" uttnum="252"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="537" id="V2456989" start="506"><type>ONT::STIMULATE</type><text>serum-stimulated proliferation</text></predicate><arg2 end="537" id="V2457002" role=":AFFECTED" start="506"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">serum-stimulated proliferation</text></arg2><text>serum-stimulated proliferation</text></EVENT>
Argument:V2457002

SENTENCES EXTRACTED:
Inhibition of various melanoma cell lines by BAY43-9006 and rapamycin.A, The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells was assayed in triplicate by Cell Titer Glo (Promega; Madison, WI) .Inhibition was determined as the difference between the number of cells in the control without any added drug compared to the number of cells following treatment with an inhibitor.Cells were treated for one hour with doses of BAY43-9006 ranging from 0.01 nM to 100 nM and were assayed for serum-stimulated proliferation after 48 hours.
1289294P5-1.txt

EVENTS EXTRACTED:
<EVENT end="227" id="V1664751" lisp="(ONT::EVENT ONT::V1664751 ONT::TRANSFORM)" paragraph="paragraph200" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="214" uttnum="227"><type>ONT::TRANSFORM</type><predicate end="227" id="V1664751" start="214"><type>ONT::TRANSFORM</type><text>mutation [23]</text></predicate><text>mutation [23]</text></EVENT>

SENTENCES EXTRACTED:
Other human melanoma cell lines listed in Table 1 include VMM12, a malignant melanoma cell line derived from tumors from a patient at the University of Virginia which is known to contain the V599E B-Raf activating mutation [23] .DM122 is a melanoma cell line derived from tumors from a patient at Duke University, and is known to contain a wild-type B-Raf gene (data not shown) .DM6 and DM331 are melanoma cell lines derived from tumors obtained from patients at Duke University, however, their B-Raf status remains to be determined..
1289294P2.txt

EVENTS EXTRACTED:
<EVENT end="86" id="V1317593" lisp="(ONT::EVENT ONT::V1317593 ONT::TRANSFORM :INEVENT ONT::V1317588)" paragraph="paragraph191" rule="-INEVENT2B,-RULE5_1_AFFECTED_AFFECTED1-NONE" start="57" uttnum="218"><type>ONT::TRANSFORM</type><features><inevent id="V1317588" /></features><predicate end="86" id="V1317593" start="57"><type>ONT::TRANSFORM</type><text>activating mutations in B-Raf</text></predicate><text>activating mutations in B-Raf</text></EVENT>

<EVENT end="86" id="V1317588" lisp="(ONT::EVENT ONT::V1317588 ONT::ACTIVATE :AGENT ONT::V1317593 :FORCE ONT::TRUE)" paragraph="paragraph191" rule="-RULE40_2_AGENT_AFFECTED-AGENT" start="57" uttnum="218"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="86" id="V1317588" start="57"><type>ONT::ACTIVATE</type><text>activating mutations in B-Raf</text></predicate><arg1 end="86" id="V1317593" role=":AGENT" start="57"><type>ONT::TRANSFORM</type><text normalization="">activating mutations in B-Raf</text></arg1><text>activating mutations in B-Raf</text></EVENT>
Argument:V1317593

<EVENT end="153" id="V1333101" lisp="(ONT::EVENT ONT::V1333101 ONT::TRANSFORM)" paragraph="paragraph191" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="93" uttnum="218"><type>ONT::TRANSFORM</type><predicate end="153" id="V1333101" start="93"><type>ONT::TRANSFORM</type><text>80% of these mutations caused by a single substitution V599E</text></predicate><text>80% of these mutations caused by a single substitution V599E</text></EVENT>

<EVENT end="153" id="V1332548" lisp="(ONT::EVENT ONT::V1332548 ONT::TRANSFORM :INEVENT ONT::V1332553)" paragraph="paragraph191" rule="-INEVENT2B,-RULE5_1_AFFECTED_AFFECTED1-NONE" start="97" uttnum="218"><type>ONT::TRANSFORM</type><features><inevent id="V1332553" /></features><predicate end="153" id="V1332548" start="97"><type>ONT::TRANSFORM</type><text>of these mutations caused by a single substitution V599E</text></predicate><text>of these mutations caused by a single substitution V599E</text></EVENT>

<EVENT end="153" id="V1332628" lisp="(ONT::EVENT ONT::V1332628 ONT::TRANSFORM)" paragraph="paragraph191" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="123" uttnum="218"><type>ONT::TRANSFORM</type><predicate end="153" id="V1332628" start="123"><type>ONT::TRANSFORM</type><text>by a single substitution V599E</text></predicate><text>by a single substitution V599E</text></EVENT>

<EVENT end="226" id="V1332675" lisp="(ONT::EVENT ONT::V1332675 ONT::TRANSFORM :AFFECTED ONT::V1332703 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph191" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="155" uttnum="218"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="226" id="V1332675" start="155"><type>ONT::TRANSFORM</type><text>make this protein kinase an especially promising target for inhibition</text></predicate><arg2 end="180" id="V1332703" role=":AFFECTED" start="160"><type>ONT::GENE-PROTEIN</type><text normalization="">this protein kinase</text></arg2><text>make this protein kinase an especially promising target for inhibition</text></EVENT>
Argument:V1332703

<EVENT end="226" id="V1332761" lisp="(ONT::EVENT ONT::V1332761 ONT::INHIBIT)" paragraph="paragraph191" rule="-RULE30_1_AGENT_FORMAL-NONE" start="215" uttnum="218"><type>ONT::INHIBIT</type><predicate end="226" id="V1332761" start="215"><type>ONT::INHIBIT</type><text>inhibition</text></predicate><text>inhibition</text></EVENT>

<EVENT end="284" id="V1344715" lisp="(ONT::EVENT ONT::V1344715 ONT::PRODUCE :AFFECTED-RESULT ONT::V1344671 :FORCE ONT::TRUE)" paragraph="paragraph191" rule="-RULE40_2_AGENT_AFFECTED-RESULT-AFFECTED-RESULT" start="240" uttnum="218"><type>ONT::PRODUCE</type><force>ONT::TRUE</force><predicate end="284" id="V1344715" start="240"><type>ONT::PRODUCE</type><text>lead compounds have been produced and tested</text></predicate><arg2 end="284" id="V1344671" role=":AFFECTED-RESULT" start="240"><type>ONT::CHEMICAL</type><text normalization="">lead compounds have been produced and tested</text></arg2><text>lead compounds have been produced and tested</text></EVENT>
Argument:V1344671

<EVENT end="606" id="V1347574" lisp="(ONT::EVENT ONT::V1347574 ONT::INHIBIT :AFFECTED ONT::V1347702 :FORCE ONT::TRUE)" paragraph="paragraph191" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="566" uttnum="218"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="606" id="V1347574" start="566"><type>ONT::INHIBIT</type><text>to inhibit both B-Raf and C-Raf kinases</text></predicate><arg2 end="606" id="V1347702" role=":AFFECTED" start="577"><type>ONT::GENE-PROTEIN</type><text normalization="">both B-Raf and C-Raf kinases</text></arg2><text>to inhibit both B-Raf and C-Raf kinases</text></EVENT>
Argument:V1347702

SENTENCES EXTRACTED:
The recent discovery that 60â€“70% of human melanomas have activating mutations in B-Raf  (with 80% of these mutations caused by a single substitution V599E) make this protein kinase an especially promising target for inhibition [3,4].Indeed, lead compounds have been produced and tested, and currently are working their way through clinical trials.One example is BAY43-9006 (aka: sorafenib, N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea), an investigational compound, currently in phase II and III clinical trials, designed to inhibit both B-Raf and C-Raf kinases [5,6].
1289294P4-1.txt

EVENTS EXTRACTED:
<EVENT end="80" id="V1567800" lisp="(ONT::EVENT ONT::V1567800 ONT::INHIBIT :AGENT ONT::V1568367 :AFFECTED ONT::V1567834 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph198" rule="-RULE30_1_AGENT_AFFECTED" start="0" uttnum="225"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="80" id="V1567800" start="0"><type>ONT::INHIBIT</type><text>Each of these drugs inhibited the serum-stimulated phosphorylation of known Raf</text></predicate><arg1 end="20" id="V1568367" role=":AGENT" start="0"><type>ONT::MEDICATION</type><text normalization="">Each of these drugs</text></arg1><arg2 end="80" id="V1567834" role=":AFFECTED" start="30"><type>ONT::PHOSPHORYLATION</type><text normalization="">the serum-stimulated phosphorylation of known Raf</text></arg2><text>Each of these drugs inhibited the serum-stimulated phosphorylation of known Raf</text></EVENT>
Argument:V1568367
Argument:V1567834
NESTED EVENT!!!

<EVENT end="80" id="V1567834" lisp="(ONT::EVENT ONT::V1567834 ONT::PHOSPHORYLATION :INEVENT ONT::V1567822 :AFFECTED ONT::V1567869 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph198" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="30" uttnum="225"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V1567822" /></features><predicate end="80" id="V1567834" start="30"><type>ONT::PHOSPHORYLATION</type><text>the serum-stimulated phosphorylation of known Raf</text></predicate><arg2 end="80" id="V1567869" role=":AFFECTED" start="67"><type>ONT::GENE-PROTEIN</type><text normalization="">of known Raf</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the serum-stimulated phosphorylation of known Raf</text></EVENT>
Argument:V1567869

<EVENT end="80" id="V1567822" lisp="(ONT::EVENT ONT::V1567822 ONT::STIMULATE :AFFECTED ONT::V1567834 :FORCE ONT::TRUE)" paragraph="paragraph198" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="30" uttnum="225"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="80" id="V1567822" start="30"><type>ONT::STIMULATE</type><text>the serum-stimulated phosphorylation of known Raf</text></predicate><arg2 end="80" id="V1567834" role=":AFFECTED" start="30"><type>ONT::PHOSPHORYLATION</type><text normalization="">the serum-stimulated phosphorylation of known Raf</text></arg2><text>the serum-stimulated phosphorylation of known Raf</text></EVENT>
Argument:V1567834
NESTED EVENT!!!

<EVENT end="206" id="V1568008" lisp="(ONT::EVENT ONT::V1568008 ONT::INHIBIT :AGENT ONT::V1568400 :AFFECTED ONT::V1568013 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph198" rule="-RULE30_1_AGENT_AFFECTED" start="129" uttnum="225"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="206" id="V1568008" start="129"><type>ONT::INHIBIT</type><text>each of the drugs inhibited phosphorylation in both the Raf and mTOR pathways</text></predicate><arg1 end="147" id="V1568400" role=":AGENT" start="129"><type>ONT::MEDICATION</type><text normalization="">each of the drugs</text></arg1><arg2 end="206" id="V1568013" role=":AFFECTED" start="157"><type>ONT::PHOSPHORYLATION</type><text normalization="">phosphorylation in both the Raf and mTOR pathways</text></arg2><text>each of the drugs inhibited phosphorylation in both the Raf and mTOR pathways</text></EVENT>
Argument:V1568400
Argument:V1568013
NESTED EVENT!!!

<EVENT end="206" id="V1568013" lisp="(ONT::EVENT ONT::V1568013 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph198" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="157" uttnum="225"><type>ONT::PHOSPHORYLATION</type><predicate end="206" id="V1568013" start="157"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation in both the Raf and mTOR pathways</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation in both the Raf and mTOR pathways</text></EVENT>

<EVENT end="474" id="V1594684" lisp="(ONT::EVENT ONT::V1594684 ONT::INHIBIT :AFFECTED ONT::V1594690 :FORCE ONT::TRUE)" paragraph="paragraph198" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="404" uttnum="225"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="474" id="V1594684" start="404"><type>ONT::INHIBIT</type><text>at inhibiting proliferation of wild-type B-Raf and V599E mutant B-Raf</text></predicate><arg2 end="474" id="V1594690" role=":AFFECTED" start="418"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">proliferation of wild-type B-Raf and V599E mutant B-Raf</text></arg2><text>at inhibiting proliferation of wild-type B-Raf and V599E mutant B-Raf</text></EVENT>
Argument:V1594690

SENTENCES EXTRACTED:
Each of these drugs inhibited the serum-stimulated phosphorylation of known Raf and mTOR substrates.What was unexpected was that each of the drugs inhibited phosphorylation in both the Raf and mTOR pathways, suggesting there was interdependence or cross-talk between these pathways in melanoma cells.Furthermore, the combination of rapamycin with BAY43-9006 was synergistic compared to either drug alone at inhibiting proliferation of wild-type B-Raf and V599E mutant B-Raf melanoma cell lines..
1289294P18.txt

EVENTS EXTRACTED:
<EVENT end="123" id="V2381500" lisp="(ONT::EVENT ONT::V2381500 ONT::MODULATE :AGENT ONT::V2381514)" paragraph="paragraph223" rule="-RULE10_1_AGENT_AFFECTED-AGENT" start="88" uttnum="250"><type>ONT::MODULATE</type><predicate end="123" id="V2381500" start="88"><type>ONT::MODULATE</type><text>the effects of inhibition of B-Raf</text></predicate><arg1 end="123" id="V2381514" role=":AGENT" start="100"><type>ONT::INHIBIT</type><text normalization="">of inhibition of B-Raf</text></arg1><text>the effects of inhibition of B-Raf</text></EVENT>
Argument:V2381514

<EVENT end="123" id="V2381514" lisp="(ONT::EVENT ONT::V2381514 ONT::INHIBIT :AFFECTED ONT::V2381565)" paragraph="paragraph223" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="100" uttnum="250"><type>ONT::INHIBIT</type><predicate end="123" id="V2381514" start="100"><type>ONT::INHIBIT</type><text>of inhibition of B-Raf</text></predicate><arg2 end="123" id="V2381565" role=":AFFECTED" start="114"><type>ONT::GENE-PROTEIN</type><text normalization="">of B-Raf</text></arg2><text>of inhibition of B-Raf</text></EVENT>
Argument:V2381565

<EVENT end="247" id="V2381890" lisp="(ONT::EVENT ONT::V2381890 ONT::MODULATE)" paragraph="paragraph223" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="218" uttnum="250"><type>ONT::MODULATE</type><predicate end="247" id="V2381890" start="218"><type>ONT::MODULATE</type><text>treatment with a single dose</text></predicate><text>treatment with a single dose</text></EVENT>

<EVENT end="536" id="V2393516" lisp="(ONT::EVENT ONT::V2393516 ONT::TRANSFORM :AFFECTED ONT::V2393491 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph223" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="475" uttnum="250"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="536" id="V2393516" start="475"><type>ONT::TRANSFORM</type><text>the cells were cultured for two days in the presence of serum</text></predicate><arg2 end="485" id="V2393491" role=":AFFECTED" start="475"><type>ONT::CELL</type><text normalization="">the cells</text></arg2><text>the cells were cultured for two days in the presence of serum</text></EVENT>
Argument:V2393491

SENTENCES EXTRACTED:
We examined the serum-dependent proliferation of multiple human melanoma cell lines and the effects of inhibition of B-Raf by BAY43-9006 and of mTOR by rapamycin.Melanoma cell lines were tested for proliferation after treatment with a single dose of BAY43-9006 or rapamycin using Cell Titer-Glo (Promega Corporation, Madison, WI), a luminescence-based ATP cell viability assay.Cells were exposed to different doses of either drug for one hour.Then, the media was changed and the cells were cultured for two days in the presence of serum.
1289294P12.txt

EVENTS EXTRACTED:
<EVENT end="55" id="V2085823" lisp="(ONT::EVENT ONT::V2085823 ONT::PHOSPHORYLATION :INEVENT ONT::V2085943 :AFFECTED ONT::V2085840 :LOC ONT::V2085938 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85217 :MATCHES ((MATCH :SCORE 0.85217 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 1 :INITIAL-CAP-NO-CAPS 1)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph213" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-CELL_LOC2-GD-OTHERS-AFFECTED" start="0" uttnum="240"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V2085943" /></features><predicate end="55" id="V2085823" start="0"><type>ONT::PHOSPHORYLATION</type><text>Phosphorylation of ERK in VMM18 melanoma cells treated</text></predicate><arg2 end="23" id="V2085840" role=":AFFECTED" start="16"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><location end="47" id="V2085938" start="26"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells</text></location><drum-terms><drum-term dbid="GO:0006468" match-score="0.85217" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>Phosphorylation of ERK in VMM18 melanoma cells treated</text></EVENT>
Argument:V2085840

<EVENT end="55" id="V2085943" lisp="(ONT::EVENT ONT::V2085943 ONT::MODULATE :AFFECTED ONT::V2085823 :FORCE ONT::TRUE)" paragraph="paragraph213" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="240"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="55" id="V2085943" start="0"><type>ONT::MODULATE</type><text>Phosphorylation of ERK in VMM18 melanoma cells treated</text></predicate><arg2 end="55" id="V2085823" role=":AFFECTED" start="0"><type>ONT::PHOSPHORYLATION</type><text normalization="">Phosphorylation of ERK in VMM18 melanoma cells treated</text></arg2><text>Phosphorylation of ERK in VMM18 melanoma cells treated</text></EVENT>
Argument:V2085823
NESTED EVENT!!!

<EVENT end="132" id="V2086117" lisp="(ONT::EVENT ONT::V2086117 ONT::PHOSPHORYLATION :EPI ONT::V2086152 :AFFECTED ONT::V2086130 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph213" rule="-RULE50_0_AGENT_NEUTRAL-EVENT,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="92" uttnum="240"><type>ONT::PHOSPHORYLATION</type><epistemic-modality id="V2086152" /><predicate end="132" id="V2086117" start="92"><type>ONT::PHOSPHORYLATION</type><text>The phosphorylation of ERK was analyzed</text></predicate><arg2 end="119" id="V2086130" role=":AFFECTED" start="112"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The phosphorylation of ERK was analyzed</text></EVENT>
Argument:V2086130

<EVENT end="196" id="V2086209" lisp="(ONT::EVENT ONT::V2086209 ONT::CONSUME :LOC ONT::V2086317)" paragraph="paragraph213" rule="-RULE40_4_AGENT_AFFECTED-CELL_LOC2-GD-OTHERS-NONE" start="135" uttnum="240"><type>ONT::CONSUME</type><predicate end="196" id="V2086209" start="135"><type>ONT::CONSUME</type><text>phosophosite-specific immunoblotting in VMM18 melanoma cells</text></predicate><location end="196" id="V2086317" start="175"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells</text></location><text>phosophosite-specific immunoblotting in VMM18 melanoma cells</text></EVENT>

<EVENT end="220" id="V2086351" lisp="(ONT::EVENT ONT::V2086351 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph213" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="196" uttnum="240"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="220" id="V2086351" start="196"><type>ONT::MODULATE</type><text>cultured and treated as</text></predicate><text>cultured and treated as</text></EVENT>

<EVENT end="220" id="V2086321" lisp="(ONT::EVENT ONT::V2086321 ONT::TRANSFORM :FORCE ONT::TRUE)" paragraph="paragraph213" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="196" uttnum="240"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="220" id="V2086321" start="196"><type>ONT::TRANSFORM</type><text>cultured and treated as</text></predicate><text>cultured and treated as</text></EVENT>

<EVENT end="368" id="V2086680" lisp="(ONT::EVENT ONT::V2086680 ONT::PHOSPHORYLATION :AFFECTED ONT::V2086693 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph213" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="332" uttnum="240"><type>ONT::PHOSPHORYLATION</type><predicate end="368" id="V2086680" start="332"><type>ONT::PHOSPHORYLATION</type><text>The relative phosphorylation of ERK</text></predicate><arg2 end="368" id="V2086693" role=":AFFECTED" start="361"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The relative phosphorylation of ERK</text></EVENT>
Argument:V2086693

SENTENCES EXTRACTED:
Phosphorylation of ERK in VMM18 melanoma cells treated with rapamycin, BAY43-9006, or U0126.The phosphorylation of ERK was analyzed by phosophosite-specific immunoblotting in VMM18 melanoma cells cultured and treated as described in Figure 4.The total amount of ERK protein was determined by immunoblotting with a separate antibody.The relative phosphorylation of ERK was quantitated by densitometry analysis using Image Quant 5.2 software and the values are given below the top panel..
1289294P15.txt

EVENTS EXTRACTED:
SENTENCES EXTRACTED:
All of the research involving human subjects was approved by the University of Virginia's IRB (Human Investigation Committee) in accordance with assurances filed with and approved by the Department of Health and Human Services.Informed consent was obtained from all of the study participants..
1289294P11.txt

EVENTS EXTRACTED:
<EVENT end="32" id="V2043479" lisp="(ONT::EVENT ONT::V2043479 ONT::PHOSPHORYLATION :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85217 :MATCHES ((MATCH :SCORE 0.85217 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 1 :INITIAL-CAP-NO-CAPS 1)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph211" rule="-RULE60_4_AGENT_AFFECTED-NONE" start="0" uttnum="238"><type>ONT::PHOSPHORYLATION</type><predicate end="32" id="V2043479" start="0"><type>ONT::PHOSPHORYLATION</type><text>Phosphorylation of mTOR targets</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85217" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>Phosphorylation of mTOR targets</text></EVENT>

<EVENT end="64" id="V2043634" lisp="(ONT::EVENT ONT::V2043634 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph211" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="32" uttnum="238"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="64" id="V2043634" start="32"><type>ONT::MODULATE</type><text>in VMM18 melanoma cells treated</text></predicate><text>in VMM18 melanoma cells treated</text></EVENT>

<EVENT end="141" id="V2043808" lisp="(ONT::EVENT ONT::V2043808 ONT::PHOSPHORYLATION :AFFECTED ONT::V2043880 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph211" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="101" uttnum="238"><type>ONT::PHOSPHORYLATION</type><predicate end="141" id="V2043808" start="101"><type>ONT::PHOSPHORYLATION</type><text>The phosphorylation of p70S6K and 4EBP1</text></predicate><arg2 end="141" id="V2043880" role=":AFFECTED" start="121"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>The phosphorylation of p70S6K and 4EBP1</text></EVENT>
Argument:V2043880

<EVENT end="412" id="V2044619" lisp="(ONT::EVENT ONT::V2044619 ONT::MODULATE :AFFECTED ONT::V2044589 :FORCE ONT::FALSE :NEGATION +)" paragraph="paragraph211" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="384" uttnum="238"><type>ONT::MODULATE</type><negation>+</negation><force>ONT::FALSE</force><predicate end="412" id="V2044619" start="384"><type>ONT::MODULATE</type><text>Cells not treated with drugs</text></predicate><arg2 end="412" id="V2044589" role=":AFFECTED" start="384"><type>ONT::CELL</type><text normalization="">Cells not treated with drugs</text></arg2><text>Cells not treated with drugs</text></EVENT>
Argument:V2044589

SENTENCES EXTRACTED:
Phosphorylation of mTOR targets in VMM18 melanoma cells treated with rapamycin, BAY43-9006, or U0126.The phosphorylation of p70S6K and 4EBP1 was assayed by migration in SDS-PAGE and the proteins detected by immunoblotting.Control VMM18 cells grown in PBS without serum were analyzed in lane 1 and VMM18 melanoma cells in lanes 2â€“6 were grown 24 hours in media that contained 5% serum.Cells not treated with drugs  (lanes 1 and 2) were compared to cells pre-treated for one hour with rapamycin (lane 3), BAY43-9006 (lane 4), a combination of rapamycin and BAY43-9006 (lane 5), or U0126 (lane 6).
1289294P20.txt

EVENTS EXTRACTED:
<EVENT end="101" id="V2543014" lisp="(ONT::EVENT ONT::V2543014 ONT::INHIBIT)" paragraph="paragraph228" rule="-RULE30_1_AGENT_FORMAL-NONE" start="80" uttnum="255"><type>ONT::INHIBIT</type><predicate end="101" id="V2543014" start="80"><type>ONT::INHIBIT</type><text>of inhibition at 10 n</text></predicate><text>of inhibition at 10 n</text></EVENT>

<EVENT end="222" id="V2543363" lisp="(ONT::EVENT ONT::V2543363 ONT::TRANSFORM :AFFECTED ONT::V2543360)" paragraph="paragraph228" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="177" uttnum="255"><type>ONT::TRANSFORM</type><predicate end="222" id="V2543363" start="177"><type>ONT::TRANSFORM</type><text>the V599E mutation in B-Raf (VMM5A and VMM18)</text></predicate><arg2 end="187" id="V2543360" role=":AFFECTED" start="181"><type>ONT::MUTATION</type><text normalization="">V599E</text></arg2><text>the V599E mutation in B-Raf (VMM5A and VMM18)</text></EVENT>
Argument:V2543360

<EVENT end="564" id="V2586026" lisp="(ONT::EVENT ONT::V2586026 ONT::INHIBIT :AFFECTED ONT::V2586039 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph228" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="451" uttnum="255"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="564" id="V2586026" start="451"><type>ONT::INHIBIT</type><text>Therefore, nanomolar concentrations of either BAY43-9006 or rapamycin inhibit the proliferation of melanoma cells</text></predicate><arg2 end="564" id="V2586039" role=":AFFECTED" start="529"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">the proliferation of melanoma cells</text></arg2><text>Therefore, nanomolar concentrations of either BAY43-9006 or rapamycin inhibit the proliferation of melanoma cells</text></EVENT>
Argument:V2586039

<EVENT end="604" id="V2599103" lisp="(ONT::EVENT ONT::V2599103 ONT::TRANSFORM :AFFECTED ONT::V2599144 :FORCE ONT::TRUE)" paragraph="paragraph228" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="591" uttnum="255"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="604" id="V2599103" start="591"><type>ONT::TRANSFORM</type><text>mutated B-Raf</text></predicate><arg2 end="604" id="V2599144" role=":AFFECTED" start="591"><type>ONT::GENE-PROTEIN</type><text normalization="">mutated B-Raf</text></arg2><text>mutated B-Raf</text></EVENT>
Argument:V2599144

SENTENCES EXTRACTED:
Among the melanoma cell lines, there was a significant difference in the amount of inhibition at 10 nM BAY43-9006 or rapamycin.We observed that melanoma cell lines that contain the V599E mutation in B-Raf (VMM5A and VMM18) were more sensitive to BAY43-9006 and to rapamycin, compared to cell lines with wild-type B-Raf (VMM39) .This difference in growth inhibition was observed in two additional cell lines, one wild-type (DM122) and one V599E (VMM12) .Therefore, nanomolar concentrations of either BAY43-9006 or rapamycin inhibit the proliferation of melanoma cells, whether or not they have mutated B-Raf..
1289294P23-3.txt

EVENTS EXTRACTED:
<EVENT end="86" id="V2863618" lisp="(ONT::EVENT ONT::V2863618 ONT::MODULATE :AFFECTED ONT::V2863663 :AGENT ONT::V2863613 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph236" rule="-RULE10_1_AGENT_AFFECTED-ROBUSTPRO-AGENT" start="0" uttnum="263"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="86" id="V2863618" start="0"><type>ONT::MODULATE</type><text>As an additional control, we treated VMM18 melanoma cells with U0126, a MEK inhibitor,</text></predicate><arg1 end="29" id="V2863613" role=":AGENT" start="26"><type>ONT::PERSON</type><text normalization="WE">we</text></arg1><arg2 end="58" id="V2863663" role=":AFFECTED" start="37"><type>ONT::CELL</type><text normalization="">VMM18 melanoma cells</text></arg2><text>As an additional control, we treated VMM18 melanoma cells with U0126, a MEK inhibitor,</text></EVENT>
Argument:V2863613
Argument:V2863663

<EVENT end="24" id="V2863601" lisp="(ONT::EVENT ONT::V2863601 ONT::MODULATE)" paragraph="paragraph236" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="3" uttnum="263"><type>ONT::MODULATE</type><predicate end="24" id="V2863601" start="3"><type>ONT::MODULATE</type><text>an additional control</text></predicate><text>an additional control</text></EVENT>

<EVENT end="159" id="V2872737" lisp="(ONT::EVENT ONT::V2872737 ONT::INHIBIT :AFFECTED ONT::V2872764 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph236" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="87" uttnum="263"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="159" id="V2872737" start="87"><type>ONT::INHIBIT</type><text>which blocked serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></predicate><arg2 end="159" id="V2872764" role=":AFFECTED" start="101"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></arg2><text>which blocked serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></EVENT>
Argument:V2872764
NESTED EVENT!!!

<EVENT end="159" id="V2872764" lisp="(ONT::EVENT ONT::V2872764 ONT::PHOSPHORYLATION :INEVENT ONT::V2872751 :AFFECTED ONT::V2872776 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph236" rule="-INEVENT2B,-RULE60_4_AGENT_AFFECTED-AFFECTED" start="101" uttnum="263"><type>ONT::PHOSPHORYLATION</type><features><inevent id="V2872751" /></features><predicate end="159" id="V2872764" start="101"><type>ONT::PHOSPHORYLATION</type><text>serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></predicate><arg2 end="159" id="V2872776" role=":AFFECTED" start="134"><type>ONT::GENE-PROTEIN</type><text normalization="">of both p70S6K and 4EBP1</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></EVENT>
Argument:V2872776

<EVENT end="159" id="V2872751" lisp="(ONT::EVENT ONT::V2872751 ONT::STIMULATE :AFFECTED ONT::V2872764 :FORCE ONT::TRUE)" paragraph="paragraph236" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="101" uttnum="263"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="159" id="V2872751" start="101"><type>ONT::STIMULATE</type><text>serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></predicate><arg2 end="159" id="V2872764" role=":AFFECTED" start="101"><type>ONT::PHOSPHORYLATION</type><text normalization="">serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></arg2><text>serum-stimulated phosphorylation of both p70S6K and 4EBP1</text></EVENT>
Argument:V2872764
NESTED EVENT!!!

<EVENT end="257" id="V2883070" lisp="(ONT::EVENT ONT::V2883070 ONT::PHOSPHORYLATION :AFFECTED ONT::V2883094 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph236" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="235" uttnum="263"><type>ONT::PHOSPHORYLATION</type><predicate end="257" id="V2883070" start="235"><type>ONT::PHOSPHORYLATION</type><text>phosphorylation of p70</text></predicate><arg2 end="257" id="V2883094" role=":AFFECTED" start="251"><type>ONT::GENE-PROTEIN</type><text normalization="">of p70</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>phosphorylation of p70</text></EVENT>
Argument:V2883094

SENTENCES EXTRACTED:
As an additional control, we treated VMM18 melanoma cells with U0126, a MEK inhibitor, which blocked serum-stimulated phosphorylation of both p70S6K and 4EBP1 (Figure 4, lane 6) .This result showed that MEK/ERK activities contribute to phosphorylation of p70S6K and 4EBP1..
1289294P25.txt

EVENTS EXTRACTED:
<EVENT end="60" id="V2945636" lisp="(ONT::EVENT ONT::V2945636 ONT::PHOSPHORYLATION :MODA (ONT::N-TUPLE-VAL W::DUAL) :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph238" rule="-RULE60_4_AGENT_AFFECTED-MODA1_1-NONE" start="25" uttnum="265"><type>ONT::PHOSPHORYLATION</type><mods><mod><type>ONT::N-TUPLE-VAL</type><value>DUAL</value></mod></mods><predicate end="60" id="V2945636" start="25"><type>ONT::PHOSPHORYLATION</type><text>the dual phosphorylation (Tyr/Thr)</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the dual phosphorylation (Tyr/Thr)</text></EVENT>

<EVENT end="264" id="V2958393" lisp="(ONT::EVENT ONT::V2958393 ONT::PHOSPHORYLATION :MODA (ONT::N-TUPLE-VAL W::DUAL) :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph238" rule="-RULE60_4_AGENT_AFFECTED-MODA1_1-NONE" start="226" uttnum="265"><type>ONT::PHOSPHORYLATION</type><mods><mod><type>ONT::N-TUPLE-VAL</type><value>DUAL</value></mod></mods><predicate end="264" id="V2958393" start="226"><type>ONT::PHOSPHORYLATION</type><text>the dual phosphorylation (Ser217/221)</text></predicate><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the dual phosphorylation (Ser217/221)</text></EVENT>

<EVENT end="317" id="V2971166" lisp="(ONT::EVENT ONT::V2971166 ONT::MODULATE :AFFECTED ONT::V2971223)" paragraph="paragraph238" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="283" uttnum="265"><type>ONT::MODULATE</type><predicate end="317" id="V2971166" start="283"><type>ONT::MODULATE</type><text>Treatment of VMM18 melanoma cells</text></predicate><arg2 end="317" id="V2971223" role=":AFFECTED" start="293"><type>ONT::CELL</type><text normalization="">of VMM18 melanoma cells</text></arg2><text>Treatment of VMM18 melanoma cells</text></EVENT>
Argument:V2971223

<EVENT end="409" id="V2971479" lisp="(ONT::EVENT ONT::V2971479 ONT::DECREASE :AFFECTED ONT::V2971553)" paragraph="paragraph238" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="359" uttnum="265"><type>ONT::DECREASE</type><predicate end="409" id="V2971479" start="359"><type>ONT::DECREASE</type><text>a 75% decrease in the dual phosphorylation of ERK</text></predicate><arg2 end="409" id="V2971553" role=":AFFECTED" start="374"><type>ONT::PHOSPHORYLATION</type><text normalization="">in the dual phosphorylation of ERK</text></arg2><text>a 75% decrease in the dual phosphorylation of ERK</text></EVENT>
Argument:V2971553
NESTED EVENT!!!

<EVENT end="409" id="V2971553" lisp="(ONT::EVENT ONT::V2971553 ONT::PHOSPHORYLATION :AFFECTED ONT::V2971566 :MODA (ONT::N-TUPLE-VAL W::DUAL) :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph238" rule="-RULE60_4_AGENT_AFFECTED-MODA1_1-AFFECTED" start="374" uttnum="265"><type>ONT::PHOSPHORYLATION</type><mods><mod><type>ONT::N-TUPLE-VAL</type><value>DUAL</value></mod></mods><predicate end="409" id="V2971553" start="374"><type>ONT::PHOSPHORYLATION</type><text>in the dual phosphorylation of ERK</text></predicate><arg2 end="409" id="V2971566" role=":AFFECTED" start="402"><type>ONT::GENE-PROTEIN</type><text normalization="">of ERK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>in the dual phosphorylation of ERK</text></EVENT>
Argument:V2971566

<EVENT end="501" id="V2971620" lisp="(ONT::EVENT ONT::V2971620 ONT::PHOSPHORYLATION :AFFECTED ONT::V2971633 :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph238" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="440" uttnum="265"><type>ONT::PHOSPHORYLATION</type><predicate end="501" id="V2971620" start="440"><type>ONT::PHOSPHORYLATION</type><text>the phosphorylation of MEK below detection levels (not shown)</text></predicate><arg2 end="467" id="V2971633" role=":AFFECTED" start="460"><type>ONT::PROTEIN-FAMILY</type><text normalization="">of MEK</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>the phosphorylation of MEK below detection levels (not shown)</text></EVENT>
Argument:V2971633

SENTENCES EXTRACTED:
In VMM18 melanoma cells, the dual phosphorylation (Tyr/Thr) of ERK was 9-fold higher in cells grown in 5% serum relative to cells grown in the absence of serum (Figure 5, lanes 2 versus 1) .There also was an increased level in the dual phosphorylation (Ser217/221) of MEK (not shown) .Treatment of VMM18 melanoma cells with a 10 nM dose of BAY 43-9006 produced a 75% decrease in the dual phosphorylation of ERK (Figure 5, lane 4) and reduced the phosphorylation of MEK below detection levels (not shown).
1289294P33-1.txt

EVENTS EXTRACTED:
<EVENT end="177" id="V3568434" lisp="(ONT::EVENT ONT::V3568434 ONT::MODULATE :AFFECTED ONT::V3568439 :AGENT ONT::V3568429 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph256" rule="-RULE10_1_AGENT_AFFECTED-ROBUSTPRO-AGENT" start="109" uttnum="283"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="177" id="V3568434" start="109"><type>ONT::MODULATE</type><text>we exposed effects on pathways not thought to be targeted by agents</text></predicate><arg1 end="112" id="V3568429" role=":AGENT" start="109"><type>ONT::PERSON</type><text normalization="WE">we</text></arg1><arg2 end="177" id="V3568439" role=":AFFECTED" start="120"><type>ONT::MODULATE</type><text normalization="">effects on pathways not thought to be targeted by agents</text></arg2><text>we exposed effects on pathways not thought to be targeted by agents</text></EVENT>
Argument:V3568429
Argument:V3568439
NESTED EVENT!!!

<EVENT end="177" id="V3568439" lisp="(ONT::EVENT ONT::V3568439 ONT::MODULATE :AFFECTED ONT::V3568472)" paragraph="paragraph256" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="120" uttnum="283"><type>ONT::MODULATE</type><predicate end="177" id="V3568439" start="120"><type>ONT::MODULATE</type><text>effects on pathways not thought to be targeted by agents</text></predicate><arg2 end="140" id="V3568472" role=":AFFECTED" start="128"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">on pathways</text></arg2><text>effects on pathways not thought to be targeted by agents</text></EVENT>
Argument:V3568472

<EVENT end="177" id="V3568553" lisp="(ONT::EVENT ONT::V3568553 ONT::MODULATE :AFFECTED ONT::V3568439 :EPI ONT::V3568501 :FORCE ONT::TRUE :PASSIVE +)" paragraph="paragraph256" rule="-NEUTRALTOAGENT,-RULE50_0_EXPERIENCER_FORMAL-EVENT,-RULE10_1_NEUTRAL_NEUTRAL1-NEUTRAL1" start="120" uttnum="283"><type>ONT::MODULATE</type><force>ONT::TRUE</force><epistemic-modality id="V3568501" /><predicate end="177" id="V3568553" start="120"><type>ONT::MODULATE</type><text>effects on pathways not thought to be targeted by agents</text></predicate><arg2 end="177" id="V3568439" role=":AFFECTED" start="120"><type>ONT::MODULATE</type><text normalization="">effects on pathways not thought to be targeted by agents</text></arg2><text>effects on pathways not thought to be targeted by agents</text></EVENT>
Argument:V3568439
NESTED EVENT!!!

<EVENT end="316" id="V3568892" lisp="(ONT::EVENT ONT::V3568892 ONT::INHIBIT :AFFECTED ONT::V3568952 :FORCE ONT::TRUE)" paragraph="paragraph256" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="274" uttnum="283"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="316" id="V3568892" start="274"><type>ONT::INHIBIT</type><text>at inhibiting melanoma cell proliferation</text></predicate><arg2 end="316" id="V3568952" role=":AFFECTED" start="288"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">melanoma cell proliferation</text></arg2><text>at inhibiting melanoma cell proliferation</text></EVENT>
Argument:V3568952

SENTENCES EXTRACTED:
Our results show synergistic inhibition of cell proliferation with drugs against different pathways.Further, we exposed effects on pathways not thought to be targeted by agents currently used in the clinic.Because a combination of rapamycin and BAY43-9006 is more effective at inhibiting melanoma cell proliferation than either drug alone, further studies of this combination in animal models and clinical trials deserve to be examined..
1289294P21.txt

EVENTS EXTRACTED:
<EVENT end="345" id="V2620790" lisp="(ONT::EVENT ONT::V2620790 ONT::INHIBIT :FORCE ONT::TRUE)" paragraph="paragraph229" rule="-RULE30_1_AGENT_FORMAL-NONE" start="325" uttnum="256"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="345" id="V2620790" start="325"><type>ONT::INHIBIT</type><text>inhibiting melanoma</text></predicate><text>inhibiting melanoma</text></EVENT>

<EVENT end="622" id="V2635762" lisp="(ONT::EVENT ONT::V2635762 ONT::INHIBIT :AFFECTED ONT::V2635759)" paragraph="paragraph229" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="591" uttnum="256"><type>ONT::INHIBIT</type><predicate end="622" id="V2635762" start="591"><type>ONT::INHIBIT</type><text>a 70% growth inhibition (IC70)</text></predicate><arg2 end="604" id="V2635759" role=":AFFECTED" start="593"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">70% growth</text></arg2><text>a 70% growth inhibition (IC70)</text></EVENT>
Argument:V2635759

SENTENCES EXTRACTED:
Melanoma cell proliferation was inhibited by either BAY43-9006 or rapamycin over the 0.01 â€“ 100 nM concentration range.A combination of the two drugs was markedly more effective than either drug alone at inhibiting serum-stimulated melanoma cell proliferation.For example, 0.01 nM of each drug together was more effective at inhibiting melanoma cell proliferation than 1 nM of either drug alone.To assess synergism versus additivity quantitatively, we used a focused isobologram method (Figure 3) .Treatment of three melanoma cell lines (VMM39, VMM5A, and VMM18) with rapamycin alone induced a 70% growth inhibition (IC70) from approximately 10 nM (VMM39) to 2 nM (VMM5A and VMM18).
1289294P13-1.txt

EVENTS EXTRACTED:
<EVENT end="76" id="V2166713" lisp="(ONT::EVENT ONT::V2166713 ONT::BIND :AGENT ONT::V2166697 :AFFECTED ONT::V2166768 :FORCE ONT::TRUE)" paragraph="paragraph215" rule="-RULE40_4_AGENT_AFFECTED" start="16" uttnum="242"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="76" id="V2166713" start="16"><type>ONT::BIND</type><text>peroxidase-linked species-specific whole antibody from sheep</text></predicate><arg1 end="34" id="V2166697" role=":AGENT" start="16"><type>ONT::GENE-PROTEIN</type><text normalization="">peroxidase-linked</text></arg1><arg2 end="76" id="V2166768" role=":AFFECTED" start="16"><type>ONT::MACROMOLECULAR-COMPLEX</type><text normalization="">peroxidase-linked species-specific whole antibody from sheep</text></arg2><text>peroxidase-linked species-specific whole antibody from sheep</text></EVENT>
Argument:V2166697
Argument:V2166768

<EVENT end="185" id="V2179035" lisp="(ONT::EVENT ONT::V2179035 ONT::BIND :AFFECTED ONT::V2178933 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph215" rule="-RULE40_4_AGENT_AFFECTED-AFFECTED" start="78" uttnum="242"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="185" id="V2179035" start="78"><type>ONT::BIND</type><text>secondary antibody (Catalog #NA931, used at 1:5000) was purchased from Amersham Biosciences.Anti-rabbit IgG</text></predicate><arg2 end="130" id="V2178933" role=":AFFECTED" start="78"><type>ONT::MACROMOLECULAR-COMPLEX</type><text normalization="">secondary antibody (Catalog #NA931, used at 1:5000)</text></arg2><text>secondary antibody (Catalog #NA931, used at 1:5000) was purchased from Amersham Biosciences.Anti-rabbit IgG</text></EVENT>
Argument:V2178933

<EVENT end="247" id="V2190636" lisp="(ONT::EVENT ONT::V2190636 ONT::BIND :AGENT ONT::V2190620 :AFFECTED ONT::V2190699 :FORCE ONT::TRUE)" paragraph="paragraph215" rule="-RULE40_4_AGENT_AFFECTED" start="187" uttnum="242"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="247" id="V2190636" start="187"><type>ONT::BIND</type><text>peroxidase-linked species-specific whole secondary antibody</text></predicate><arg1 end="205" id="V2190620" role=":AGENT" start="187"><type>ONT::GENE-PROTEIN</type><text normalization="">peroxidase-linked</text></arg1><arg2 end="247" id="V2190699" role=":AFFECTED" start="187"><type>ONT::PROTEIN</type><text normalization="">peroxidase-linked species-specific whole secondary antibody</text></arg2><text>peroxidase-linked species-specific whole secondary antibody</text></EVENT>
Argument:V2190620
Argument:V2190699

<EVENT end="326" id="V2190816" lisp="(ONT::EVENT ONT::V2190816 ONT::BIND :FORCE ONT::TRUE)" paragraph="paragraph215" rule="-RULE40_4_AGENT_AFFECTED-NONE" start="297" uttnum="242"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="326" id="V2190816" start="297"><type>ONT::BIND</type><text>also purchased from Amersham</text></predicate><text>also purchased from Amersham</text></EVENT>

SENTENCES EXTRACTED:
Anti-Mouse IgG, peroxidase-linked species-specific whole antibody from sheep, secondary antibody (Catalog #NA931, used at 1:5000) was purchased from Amersham Biosciences.Anti-rabbit IgG, peroxidase-linked species-specific whole secondary antibody from donkey (Catalog # NA934, used at 1:5000) was also purchased from Amersham Biosciences..
1289294P4.txt

EVENTS EXTRACTED:
<EVENT end="38" id="V1542483" lisp="(ONT::EVENT ONT::V1542483 ONT::MODULATE :AFFECTED ONT::V1542395 :FORCE ONT::TRUE :TENSE W::PRES :PASSIVE +)" paragraph="paragraph197" rule="-NEUTRALTOAGENT,-RULE10_1_NEUTRAL_NEUTRAL1-NEUTRAL1" start="0" uttnum="224"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="38" id="V1542483" start="0"><type>ONT::MODULATE</type><text>Our interest is in combining targeted</text></predicate><arg2 end="13" id="V1542395" role=":AFFECTED" start="0"><type>ONT::EVOKE-ATTENTION</type><text normalization="INTEREST">Our interest</text></arg2><text>Our interest is in combining targeted</text></EVENT>
Argument:V1542395

<EVENT end="109" id="V1542636" lisp="(ONT::EVENT ONT::V1542636 ONT::MODULATE)" paragraph="paragraph197" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="93" uttnum="224"><type>ONT::MODULATE</type><predicate end="109" id="V1542636" start="93"><type>ONT::MODULATE</type><text>such treatments</text></predicate><text>such treatments</text></EVENT>

<EVENT end="300" id="V1542913" lisp="(ONT::EVENT ONT::V1542913 ONT::INHIBIT :INEVENT ONT::V1542910 :AFFECTED ONT::V1542981)" paragraph="paragraph197" rule="-INEVENT2B,-RULE30_1_AGENT_AFFECTED-AFFECTED" start="246" uttnum="224"><type>ONT::INHIBIT</type><features><inevent id="V1542910" /></features><predicate end="300" id="V1542913" start="246"><type>ONT::INHIBIT</type><text>in enhanced inhibition of melanoma cell proliferation</text></predicate><arg2 end="300" id="V1542981" role=":AFFECTED" start="269"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">of melanoma cell proliferation</text></arg2><text>in enhanced inhibition of melanoma cell proliferation</text></EVENT>
Argument:V1542981

<EVENT end="300" id="V1542910" lisp="(ONT::EVENT ONT::V1542910 ONT::STIMULATE :AFFECTED ONT::V1542913 :FORCE ONT::TRUE)" paragraph="paragraph197" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="246" uttnum="224"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="300" id="V1542910" start="246"><type>ONT::STIMULATE</type><text>in enhanced inhibition of melanoma cell proliferation</text></predicate><arg2 end="300" id="V1542913" role=":AFFECTED" start="246"><type>ONT::INHIBIT</type><text normalization="">in enhanced inhibition of melanoma cell proliferation</text></arg2><text>in enhanced inhibition of melanoma cell proliferation</text></EVENT>
Argument:V1542913
NESTED EVENT!!!

<EVENT end="381" id="V1555875" lisp="(ONT::EVENT ONT::V1555875 ONT::MODULATE :AFFECTED ONT::V1555911)" paragraph="paragraph197" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="358" uttnum="224"><type>ONT::MODULATE</type><predicate end="381" id="V1555875" start="358"><type>ONT::MODULATE</type><text>effects on two pathways</text></predicate><arg2 end="381" id="V1555911" role=":AFFECTED" start="366"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">on two pathways</text></arg2><text>effects on two pathways</text></EVENT>
Argument:V1555911

<EVENT end="426" id="V1555983" lisp="(ONT::EVENT ONT::V1555983 ONT::STIMULATE :AFFECTED ONT::V1555998 :FORCE ONT::TRUE)" paragraph="paragraph197" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="395" uttnum="224"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="426" id="V1555983" start="395"><type>ONT::STIMULATE</type><text>that serum-stimulated melanoma</text></predicate><arg2 end="426" id="V1555998" role=":AFFECTED" start="395"><type>ONT::CANCER</type><text normalization="">that serum-stimulated melanoma</text></arg2><text>that serum-stimulated melanoma</text></EVENT>
Argument:V1555998

<EVENT end="478" id="V1556074" lisp="(ONT::EVENT ONT::V1556074 ONT::INHIBIT :AGENT ONT::V1556111 :AFFECTED ONT::V1556050 :FORCE ONT::TRUE :TENSE W::PRES :PASSIVE +)" paragraph="paragraph197" rule="-RULE30_1_AGENT_AFFECTED" start="426" uttnum="224"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><predicate end="478" id="V1556074" start="426"><type>ONT::INHIBIT</type><text>cell proliferation is inhibited by either rapamycin</text></predicate><arg1 end="478" id="V1556111" role=":AGENT" start="458"><type>ONT::PHARMACOLOGIC-SUBSTANCE</type><text normalization="">by either rapamycin</text></arg1><arg2 end="445" id="V1556050" role=":AFFECTED" start="426"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">cell proliferation</text></arg2><text>cell proliferation is inhibited by either rapamycin</text></EVENT>
Argument:V1556111
Argument:V1556050

SENTENCES EXTRACTED:
Our interest is in combining targeted agents for these pathways in an effort to determine if such treatments will be effective in the treatment of melanoma.We hypothesized that the combination of multiple targeted therapeutic agents would result in enhanced inhibition of melanoma cell proliferation compared to either drug alone, because of synergy between effects on two pathways.Here we show that serum-stimulated melanoma cell proliferation is inhibited by either rapamycin or BAY43-9006, with B-Raf V599E mutants showing an increased sensitivity to each drug at 10 nM compared to melanoma cells with wild-type B-Raf.
1289294P28.txt

EVENTS EXTRACTED:
<EVENT end="49" id="V3179209" lisp="(ONT::EVENT ONT::V3179209 ONT::ACTIVATE :AGENT ONT::V3179112 :AFFECTED ONT::V3179216 :FORCE ONT::TRUE :TENSE W::PRES :PERF +)" paragraph="paragraph245" rule="-RULE40_2_AGENT_AFFECTED" start="0" uttnum="272"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="49" id="V3179209" start="0"><type>ONT::ACTIVATE</type><text>Human tumors deficient in PTEN have activated Akt</text></predicate><arg1 end="31" id="V3179112" role=":AGENT" start="0"><type>ONT::CANCER</type><text normalization="">Human tumors deficient in PTEN</text></arg1><arg2 end="49" id="V3179216" role=":AFFECTED" start="46"><type>ONT::GENE-PROTEIN</type><text normalization="">Akt</text></arg2><text>Human tumors deficient in PTEN have activated Akt</text></EVENT>
Argument:V3179112
Argument:V3179216

<EVENT end="103" id="V3179311" lisp="(ONT::EVENT ONT::V3179311 ONT::INHIBIT :AFFECTED ONT::V3179308)" paragraph="paragraph245" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="80" uttnum="272"><type>ONT::INHIBIT</type><predicate end="103" id="V3179311" start="80"><type>ONT::INHIBIT</type><text>to mTOR inhibitors [13]</text></predicate><arg2 end="88" id="V3179308" role=":AFFECTED" start="83"><type>ONT::GENE-PROTEIN</type><text normalization="">mTOR</text></arg2><text>to mTOR inhibitors [13]</text></EVENT>
Argument:V3179308

<EVENT end="566" id="V3213521" lisp="(ONT::EVENT ONT::V3213521 ONT::INHIBIT :EPI ONT::V3213410 :AFFECTED ONT::V3213491 :FORCE ONT::TRUE :TENSE W::PRES :PASSIVE +)" paragraph="paragraph245" rule="-RULE50_0_NEUTRAL_FORMAL-EVENT,-RULE30_1_AGENT_AFFECTED-AFFECTED" start="460" uttnum="272"><type>ONT::INHIBIT</type><force>ONT::TRUE</force><epistemic-modality id="V3213410" /><predicate end="566" id="V3213521" start="460"><type>ONT::INHIBIT</type><text>our data show that melanoma cell proliferation is effectively inhibited in vitro by low doses of rapamycin</text></predicate><arg2 end="507" id="V3213491" role=":AFFECTED" start="479"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">melanoma cell proliferation</text></arg2><text>our data show that melanoma cell proliferation is effectively inhibited in vitro by low doses of rapamycin</text></EVENT>
Argument:V3213491

SENTENCES EXTRACTED:
Human tumors deficient in PTEN have activated Akt, and are especially sensitive to mTOR inhibitors [13].However, pharmacogenomic profiling indicates that melanomas are not, in general, PTEN deficient and therefore would be unresponsive to mTOR inhibitors.Results from a phase II trial using CCI-779 alone showed only one response among 33 observed patients [32] .These data suggest that CCI-779 is not sufficiently active in melanoma as a single agent.However, our data show that melanoma cell proliferation is effectively inhibited in vitro by low doses of rapamycin.
1289294P14.txt

EVENTS EXTRACTED:
<EVENT end="505" id="V2244834" lisp="(ONT::EVENT ONT::V2244834 ONT::TRANSLOCATE :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph216" rule="-RULE10_4_AGENT_AFFECTED-NONE" start="482" uttnum="243"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><predicate end="505" id="V2244834" start="482"><type>ONT::TRANSLOCATE</type><text>which fall on the line</text></predicate><text>which fall on the line</text></EVENT>

SENTENCES EXTRACTED:
To assess whether a combination dose of rapamycin and BAY43-9006 is synergistic or simply additive, a focused isobologram method was used as described previously [24] .An IC70 was selected, and these doses of each drug alone were plotted as the ordinate and abscissa in a Cartesian log-log plot.The straight line connecting these IC70 values is the locus of points (dose pairs) that produce a simply additive combination.In an isobologram, the IC70 dose pairs for two drugs together which fall on the line indicate an additive effect.
1289294P27.txt

EVENTS EXTRACTED:
<EVENT end="196" id="V3115258" lisp="(ONT::EVENT ONT::V3115258 ONT::PHOSPHORYLATION :AGENT ONT::V3115079 :AFFECTED ONT::V3115263 :FORCE ONT::TRUE :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph243" rule="-RULE60_4_AGENT_AFFECTED" start="112" uttnum="270"><type>ONT::PHOSPHORYLATION</type><force>ONT::TRUE</force><predicate end="196" id="V3115258" start="112"><type>ONT::PHOSPHORYLATION</type><text>kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK,</text></predicate><arg1 end="119" id="V3115079" role=":AGENT" start="112"><type>ONT::GENE-PROTEIN</type><text normalization="">kinase</text></arg1><arg2 end="196" id="V3115263" role=":AFFECTED" start="192"><type>ONT::PROTEIN-FAMILY</type><text normalization="">MEK,</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK,</text></EVENT>
Argument:V3115079
Argument:V3115263

<EVENT end="196" id="V3115108" lisp="(ONT::EVENT ONT::V3115108 ONT::ACTIVATE :AGENT ONT::V3115279 :AFFECTED ONT::V3115079 :FORCE ONT::TRUE)" paragraph="paragraph243" rule="-RULE40_2_AGENT_AFFECTED" start="112" uttnum="270"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="196" id="V3115108" start="112"><type>ONT::ACTIVATE</type><text>kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK,</text></predicate><arg1 end="143" id="V3115279" role=":AGENT" start="132"><type>ONT::MOLECULAR-PART</type><text normalization="">by GTP-Ras</text></arg1><arg2 end="119" id="V3115079" role=":AFFECTED" start="112"><type>ONT::GENE-PROTEIN</type><text normalization="">kinase</text></arg2><text>kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK,</text></EVENT>
Argument:V3115279
Argument:V3115079

<EVENT end="242" id="V3128286" lisp="(ONT::EVENT ONT::V3128286 ONT::ACTIVATE :AFFECTED ONT::V3128293 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph243" rule="-RULE40_2_AGENT_AFFECTED-AFFECTED" start="197" uttnum="270"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="242" id="V3128286" start="197"><type>ONT::ACTIVATE</type><text>which in turn activates ERK to phosphorylate</text></predicate><arg2 end="242" id="V3128293" role=":AFFECTED" start="221"><type>ONT::GENE-PROTEIN</type><text normalization="">ERK to phosphorylate</text></arg2><text>which in turn activates ERK to phosphorylate</text></EVENT>
Argument:V3128293

<EVENT end="242" id="V3128322" lisp="(ONT::EVENT ONT::V3128322 ONT::PHOSPHORYLATION :AFFECTED ONT::V3128293 :FORCE ONT::TRUE :DRUM ((:DRUM (TERM :ID GO::|0006468| :NAME &quot;protein phosphorylation&quot; :SCORE 0.85366 :MATCHES ((MATCH :SCORE 0.85366 :MATCHED &quot;protein phosphorylation&quot; :STATUS &quot;name&quot; :EXACT 2)) :ONT-TYPES (ONT::POST-TRANSLATIONAL-MODIFICATION)))))" paragraph="paragraph243" rule="-RULE60_4_AGENT_AFFECTED-AFFECTED" start="221" uttnum="270"><type>ONT::PHOSPHORYLATION</type><force>ONT::TRUE</force><predicate end="242" id="V3128322" start="221"><type>ONT::PHOSPHORYLATION</type><text>ERK to phosphorylate</text></predicate><arg2 end="242" id="V3128293" role=":AFFECTED" start="221"><type>ONT::GENE-PROTEIN</type><text normalization="">ERK to phosphorylate</text></arg2><drum-terms><drum-term dbid="GO:0006468" match-score="0.85366" matched-name="protein phosphorylation" name="protein phosphorylation"><types><type>ONT::POST-TRANSLATIONAL-MODIFICATION</type></types></drum-term></drum-terms><text>ERK to phosphorylate</text></EVENT>
Argument:V3128293

<EVENT end="334" id="V3128454" lisp="(ONT::EVENT ONT::V3128454 ONT::STIMULATE :AFFECTED ONT::V3128488 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph243" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="303" uttnum="270"><type>ONT::STIMULATE</type><force>ONT::TRUE</force><predicate end="334" id="V3128454" start="303"><type>ONT::STIMULATE</type><text>that promote cell division [30]</text></predicate><arg2 end="334" id="V3128488" role=":AFFECTED" start="316"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">cell division [30]</text></arg2><text>that promote cell division [30]</text></EVENT>
Argument:V3128488

<EVENT end="502" id="V3139955" lisp="(ONT::EVENT ONT::V3139955 ONT::SIGNALING :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph243" rule="-RULE5_1_AGENT_AFFECTED-NONE" start="395" uttnum="270"><type>ONT::SIGNALING</type><force>ONT::TRUE</force><predicate end="502" id="V3139955" start="395"><type>ONT::SIGNALING</type><text>signals to activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response [31]</text></predicate><text>signals to activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response [31]</text></EVENT>

<EVENT end="502" id="V3139986" lisp="(ONT::EVENT ONT::V3139986 ONT::ACTIVATE :AFFECTED ONT::V3140052 :FORCE ONT::TRUE)" paragraph="paragraph243" rule="-RULE40_2_AGENT_AFFECTED-AFFECTED" start="406" uttnum="270"><type>ONT::ACTIVATE</type><force>ONT::TRUE</force><predicate end="502" id="V3139986" start="406"><type>ONT::ACTIVATE</type><text>activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response [31]</text></predicate><arg2 end="432" id="V3140052" role=":AFFECTED" start="415"><type>ONT::GENE-PROTEIN</type><text normalization="">p70S6K and 4EBP1</text></arg2><text>activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response [31]</text></EVENT>
Argument:V3140052

<EVENT end="502" id="V3140109" lisp="(ONT::EVENT ONT::V3140109 ONT::INCREASE :AFFECTED ONT::V3140134 :FORCE ONT::TRUE)" paragraph="paragraph243" rule="-RULE20_1_AGENT_AFFECTED-AFFECTED" start="435" uttnum="270"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="502" id="V3140109" start="435"><type>ONT::INCREASE</type><text>increase protein translation as part of a cell growth response [31]</text></predicate><arg2 end="464" id="V3140134" role=":AFFECTED" start="444"><type>ONT::TRANSLATE</type><text normalization="">protein translation</text></arg2><text>increase protein translation as part of a cell growth response [31]</text></EVENT>
Argument:V3140134
NESTED EVENT!!!

<EVENT end="464" id="V3140134" lisp="(ONT::EVENT ONT::V3140134 ONT::TRANSLATE :DRUM ((:DRUM (TERM :ID GO::|0006412| :NAME &quot;translation&quot; :SCORE 0.70732 :MATCHES ((MATCH :SCORE 0.70732 :MATCHED &quot;protein translation&quot; :STATUS &quot;EXACT synonym&quot; :EXACT 2)) :ONT-TYPES (ONT::GENE-TRANSLATION)))))" paragraph="paragraph243" rule="-RULE50_4_AGENT_AFFECTED-NONE" start="444" uttnum="270"><type>ONT::TRANSLATE</type><predicate end="464" id="V3140134" start="444"><type>ONT::TRANSLATE</type><text>protein translation</text></predicate><drum-terms><drum-term dbid="GO:0006412" match-score="0.70732" matched-name="protein translation" name="translation"><types><type>ONT::GENE-TRANSLATION</type></types></drum-term></drum-terms><text>protein translation</text></EVENT>

SENTENCES EXTRACTED:
Current knowledge suggests that B-Raf and mTOR protein kinases operate in separate signaling pathways.The B-Raf kinase is activated by GTP-Ras in response to growth factors and phosphorylates MEK, which in turn activates ERK to phosphorylate downstream targets such as kinases and transcription factors that promote cell division [30] .The mTOR kinase responds to both nutrient and growth factor signals to activate p70S6K and 4EBP1 to increase protein translation as part of a cell growth response [31].
1289294P26.txt

EVENTS EXTRACTED:
<EVENT end="22" id="V3045614" lisp="(ONT::EVENT ONT::V3045614 ONT::MODULATE :AFFECTED ONT::V3045611)" paragraph="paragraph241" rule="-RULE10_1_AGENT_AFFECTED-AFFECTED" start="0" uttnum="268"><type>ONT::MODULATE</type><predicate end="22" id="V3045614" start="0"><type>ONT::MODULATE</type><text>New cancer treatments</text></predicate><arg2 end="11" id="V3045611" role=":AFFECTED" start="4"><type>ONT::CANCER</type><text normalization="">cancer</text></arg2><text>New cancer treatments</text></EVENT>
Argument:V3045611

<EVENT end="110" id="V3045628" lisp="(ONT::EVENT ONT::V3045628 ONT::TRANSLOCATE :AGENT ONT::V3045637 :FORCE ONT::TRUE :DEGREE (ONT::DEGREE-MODIFIER W::DIRECTLY))" paragraph="paragraph241" rule="-RULE10_4_AGENT_AFFECTED-AGENT" start="30" uttnum="268"><type>ONT::TRANSLOCATE</type><force>ONT::TRUE</force><mods><degree><type>ONT::DEGREE-MODIFIER</type><value>DIRECTLY</value></degree></mods><predicate end="110" id="V3045628" start="30"><type>ONT::TRANSLOCATE</type><text>directly targeting enzymes essential for the growth and proliferation of cancer</text></predicate><arg1 end="110" id="V3045637" role=":AGENT" start="30"><type>ONT::PROTEIN</type><text normalization="">directly targeting enzymes essential for the growth and proliferation of cancer</text></arg1><text>directly targeting enzymes essential for the growth and proliferation of cancer</text></EVENT>
Argument:V3045637

<EVENT end="154" id="V3045777" lisp="(ONT::EVENT ONT::V3045777 ONT::MODULATE :AGENT ONT::V3045773 :AFFECTED ONT::V3045805 :FORCE ONT::TRUE :TENSE W::PRES)" paragraph="paragraph241" rule="-RULE10_1_AGENT_AFFECTED" start="110" uttnum="268"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="154" id="V3045777" start="110"><type>ONT::MODULATE</type><text>cells.The mTOR pathway regulates cell growth</text></predicate><arg1 end="133" id="V3045773" role=":AGENT" start="110"><type>ONT::SIGNALING-PATHWAY</type><text normalization="">cells.The mTOR pathway</text></arg1><arg2 end="154" id="V3045805" role=":AFFECTED" start="143"><type>ONT::BIOLOGICAL-PROCESS</type><text normalization="">cell growth</text></arg2><text>cells.The mTOR pathway regulates cell growth</text></EVENT>
Argument:V3045773
Argument:V3045805

<EVENT end="346" id="V3059367" lisp="(ONT::EVENT ONT::V3059367 ONT::TRANSFORM :AFFECTED ONT::V3059415)" paragraph="paragraph241" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="295" uttnum="268"><type>ONT::TRANSFORM</type><predicate end="346" id="V3059367" start="295"><type>ONT::TRANSFORM</type><text>making B-Raf a potential target for small molecule</text></predicate><arg2 end="308" id="V3059415" role=":AFFECTED" start="302"><type>ONT::GENE-PROTEIN</type><text normalization="">B-Raf</text></arg2><text>making B-Raf a potential target for small molecule</text></EVENT>
Argument:V3059415

<EVENT end="379" id="V3059504" lisp="(ONT::EVENT ONT::V3059504 ONT::INHIBIT)" paragraph="paragraph241" rule="-RULE30_1_AGENT_FORMAL-NONE" start="346" uttnum="268"><type>ONT::INHIBIT</type><predicate end="379" id="V3059504" start="346"><type>ONT::INHIBIT</type><text>inhibitors as therapy [3,4,11,28]</text></predicate><text>inhibitors as therapy [3,4,11,28]</text></EVENT>

<EVENT end="417" id="V3071234" lisp="(ONT::EVENT ONT::V3071234 ONT::PRODUCE :AGENT ONT::V3071128 :FORCE ONT::TRUE :AFFECTED ONT::V3072230 :TENSE W::PRES)" paragraph="paragraph241" rule="-RULE40_2_AGENT_AFFECTED-RESULT-AGENT" start="380" uttnum="268"><type>ONT::PRODUCE</type><force>ONT::TRUE</force><predicate end="417" id="V3071234" start="380"><type>ONT::PRODUCE</type><text>Indeed, new drugs such as BAY43-9006</text></predicate><arg1 end="398" id="V3071128" role=":AGENT" start="388"><type>ONT::MEDICATION</type><text normalization="">new drugs</text></arg1><arg2 end="417" id="V3072230" role=":AFFECTED" start="408"><type>ONT::NUMBER</type><text normalization="">Y43-9006</text></arg2><text>Indeed, new drugs such as BAY43-9006</text></EVENT>
Argument:V3071128
Argument:V3072230

<EVENT end="488" id="V3071304" lisp="(ONT::EVENT ONT::V3071304 ONT::PRODUCE :FORCE ONT::TRUE)" paragraph="paragraph241" rule="-RULE40_2_AGENT_AFFECTED-RESULT-NONE" start="417" uttnum="268"><type>ONT::PRODUCE</type><force>ONT::TRUE</force><predicate end="488" id="V3071304" start="417"><type>ONT::PRODUCE</type><text>have been developed as selective inhibitors of B-Raf and are currently</text></predicate><text>have been developed as selective inhibitors of B-Raf and are currently</text></EVENT>

<EVENT end="470" id="V3071347" lisp="(ONT::EVENT ONT::V3071347 ONT::INHIBIT :AFFECTED ONT::V3071398)" paragraph="paragraph241" rule="-RULE30_1_AGENT_AFFECTED-AFFECTED" start="440" uttnum="268"><type>ONT::INHIBIT</type><predicate end="470" id="V3071347" start="440"><type>ONT::INHIBIT</type><text>selective inhibitors of B-Raf</text></predicate><arg2 end="470" id="V3071398" role=":AFFECTED" start="461"><type>ONT::GENE-PROTEIN</type><text normalization="">of B-Raf</text></arg2><text>selective inhibitors of B-Raf</text></EVENT>
Argument:V3071398

SENTENCES EXTRACTED:
New cancer treatments involve directly targeting enzymes essential for the growth and proliferation of cancer cells.The mTOR pathway regulates cell growth, and the Raf/MEK/ERK pathway is critical for cell proliferation.Activating mutations in B-Raf have been found in 60â€“70% of human melanomas, making B-Raf a potential target for small molecule inhibitors as therapy [3,4,11,28] .Indeed, new drugs such as BAY43-9006 have been developed as selective inhibitors of B-Raf and are currently in Phase II clinical trials [6].
1289294P10.txt

EVENTS EXTRACTED:
<EVENT end="155" id="V1905774" lisp="(ONT::EVENT ONT::V1905774 ONT::TRANSFORM :FORCE ONT::TRUE)" paragraph="paragraph208" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="113" uttnum="235"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="155" id="V1905774" start="113"><type>ONT::TRANSFORM</type><text>and incubated for 24 hours in either RPMI</text></predicate><text>and incubated for 24 hours in either RPMI</text></EVENT>

<EVENT end="227" id="V1919566" lisp="(ONT::EVENT ONT::V1919566 ONT::BIND :AFFECTED ONT::V1919541 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph208" rule="-RULE40_4_AGENT_AFFECTED-AFFECTED" start="202" uttnum="235"><type>ONT::BIND</type><force>ONT::TRUE</force><predicate end="227" id="V1919566" start="202"><type>ONT::BIND</type><text>the cells were harvested</text></predicate><arg2 end="212" id="V1919541" role=":AFFECTED" start="202"><type>ONT::CELL</type><text normalization="">the cells</text></arg2><text>the cells were harvested</text></EVENT>
Argument:V1919541

<EVENT end="441" id="V1931875" lisp="(ONT::EVENT ONT::V1931875 ONT::MODULATE :FORCE ONT::TRUE)" paragraph="paragraph208" rule="-NEUTRALTOAGENT,-RULE10_1_AGENT_AFFECTED-NONE" start="393" uttnum="235"><type>ONT::MODULATE</type><force>ONT::TRUE</force><predicate end="441" id="V1931875" start="393"><type>ONT::MODULATE</type><text>treated with drugs or not for one hour, washed,</text></predicate><text>treated with drugs or not for one hour, washed,</text></EVENT>

<EVENT end="551" id="V1946757" lisp="(ONT::EVENT ONT::V1946757 ONT::TRANSFORM :AFFECTED ONT::V1946733 :FORCE ONT::TRUE :TENSE W::PAST :PASSIVE +)" paragraph="paragraph208" rule="-RULE5_1_AFFECTED_AFFECTED1-AFFECTED" start="506" uttnum="235"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="551" id="V1946757" start="506"><type>ONT::TRANSFORM</type><text>cells were rinsed with room temperature PBS,</text></predicate><arg2 end="512" id="V1946733" role=":AFFECTED" start="506"><type>ONT::CELL</type><text normalization="">cells</text></arg2><text>cells were rinsed with room temperature PBS,</text></EVENT>
Argument:V1946733

<EVENT end="613" id="V1946798" lisp="(ONT::EVENT ONT::V1946798 ONT::TRANSFORM :FORCE ONT::TRUE)" paragraph="paragraph208" rule="-RULE5_1_AFFECTED_AFFECTED1-NONE" start="551" uttnum="235"><type>ONT::TRANSFORM</type><force>ONT::TRUE</force><predicate end="613" id="V1946798" start="551"><type>ONT::TRANSFORM</type><text>frozen by placing the dish on a mixture of acetone and dry ice</text></predicate><text>frozen by placing the dish on a mixture of acetone and dry ice</text></EVENT>

SENTENCES EXTRACTED:
For analysis of proteins in Figure 1B and 1C, VMM5A, VMM18, and VMM39 melanoma cells were plated in Petri dishes and incubated for 24 hours in either RPMI medium plus 5% FBS or 0.5% FBS.After 24 hours, the cells were harvested and lysed as described for analysis of proteins in Figures 4 and 5.For analysis of the proteins in Figures 4 and 5, VMM18 melanoma cells were plated in petri dishes, treated with drugs or not for one hour, washed, and incubated overnight in RPMI medium plus 5% FBS.The next day, cells were rinsed with room temperature PBS, frozen by placing the dish on a mixture of acetone and dry ice.
1289294P30.txt

EVENTS EXTRACTED:
<EVENT end="208" id="V3318697" lisp="(ONT::EVENT ONT::V3318697 ONT::INCREASE :AGENT ONT::V3318637 :FORCE ONT::TRUE :TENSE W::PAST)" paragraph="paragraph249" rule="-RULE20_1_AGENT_AFFECTED-AGENT" start="134" uttnum="276"><type>ONT::INCREASE</type><force>ONT::TRUE</force><predicate end="208" id="V3318697" start="134"><type>ONT::INCREASE</type><text>the addition of serum to the medium doubled the rate of proliferation.Thus</text></predicate><arg1 end="170" id="V3318637" role=":AGENT" start="134"><type>ONT::ADD-INCLUDE</type><text normalization="ADDITION">the addition of serum to the medium</text></arg1><text>the addition of serum to the medium doubled the rate of proliferation.Thus</text></EVENT>
Argument:V3318637

SENTENCES EXTRACTED:
We found that multiple human melanoma cell lines proliferated in culture at different relative rates in the absence of serum and that the addition of serum to the medium doubled the rate of proliferation.Thus, we could use the consistent serum response to compare cell growth and proliferation with a variety of melanoma cell lines.At concentrations in the nanomolar range, we observed dose-dependent inhibition of cell proliferation by either rapamycin or BAY43-9006.In every cell line examined, combination of BAY43-9006 and rapamycin produced synergistic inhibition of cell proliferation compared to either drug alone.

The final nested event count is: 31
The final event count is: 274
The final sentence count is: 69
